<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10459860</article-id><article-id pub-id-type="doi">10.3390/ph16081174</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-16-01174</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Quinoxaline 1,4-Dioxides: Advances in Chemistry and Chemotherapeutic Drug Development</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4940-9686</contrib-id><name><surname>Buravchenko</surname><given-names>Galina I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shchekotikhin</surname><given-names>Andrey E.</given-names></name><xref rid="c1-pharmaceuticals-16-01174" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>El Bakri</surname><given-names>Youness</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-16-01174">Gause Institute of New Antibiotics, 119021 Moscow, Russia; <email>buravchenkogi@gmail.com</email></aff><author-notes><corresp id="c1-pharmaceuticals-16-01174"><label>*</label>Correspondence: <email>shchekotikhin@gause-inst.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>16</volume><issue>8</issue><elocation-id>1174</elocation-id><history><date date-type="received"><day>16</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>08</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic toggle="yes">N</italic>-Oxides of heterocyclic compounds are the focus of medical chemistry due to their diverse biological properties. The high reactivity and tendency to undergo various rearrangements have piqued the interest of synthetic chemists in heterocycles with <italic toggle="yes">N</italic>-oxide fragments. Quinoxaline 1,4-dioxides are an example of an important class of heterocyclic <italic toggle="yes">N</italic>-oxides, whose wide range of biological activity determines the prospects of their practical use in the development of drugs of various pharmaceutical groups. Derivatives from this series have found application in the clinic as antibacterial drugs and are used in agriculture. Quinoxaline 1,4-dioxides present a promising class for the development of new drugs targeting bacterial infections, oncological diseases, malaria, trypanosomiasis, leishmaniasis, and amoebiasis. The review considers the most important methods for the synthesis and key directions in the chemical modification of quinoxaline 1,4-dioxide derivatives, analyzes their biological properties, and evaluates the prospects for the practical application of the most interesting compounds.</p></abstract><kwd-group><kwd>heterocyclic <italic toggle="yes">N</italic>-oxides</kwd><kwd>quinoxaline 1,4-dioxides</kwd><kwd>methods of synthesis</kwd><kwd>biological and pharmaceutical activity</kwd><kwd>SAR-analysis</kwd><kwd>therapeutic application</kwd></kwd-group><funding-group><award-group><funding-source>Russian Science Foundation</funding-source><award-id>21-45-00018</award-id></award-group><funding-statement>The study was partially financially supported by the Russian Science Foundation (RSF grant number 21-45-00018).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-16-01174"><title>1. Introduction</title><p>It is well known that nitrogen-containing heterocycles are privileged structures in medicinal chemistry because their derivatives have various biological properties [<xref rid="B1-pharmaceuticals-16-01174" ref-type="bibr">1</xref>]. The importance of nitrogen heterocycles as key pharmacophoric moieties lies in the synthesis of novel anticancer compounds [<xref rid="B2-pharmaceuticals-16-01174" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-16-01174" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-16-01174" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-16-01174" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-16-01174" ref-type="bibr">6</xref>]. Indeed, the presence of different nitrogen electron-donor atoms in the structure improves the interaction with target proteins, enzymes, and receptors through the formation of several types of interactions, such as hydrogen bonds, dipole-dipole, hydrophobic interactions, van der Waals forces, and &#x003c0;-stacking interactions. The chemistry of <italic toggle="yes">N</italic>-oxides of heterocyclic compounds is one of the dynamically developing areas of organic synthesis. Aliphatic and aromatic <italic toggle="yes">N</italic>-oxides are known as prodrugs due to their ability to be reduced by various oxidoreductases expressed in bacterial and tumor cells [<xref rid="B7-pharmaceuticals-16-01174" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-16-01174" ref-type="bibr">8</xref>]. Quinoxaline 1,4-dioxides attract close attention due to their wide spectrum of biological activity. The presence of two <italic toggle="yes">N</italic>-oxide groups determines the pharmaceutical properties of quinoxaline-1,4-dioxides, such as antibacterial, antitumor, antifungal, insecticidal, herbicidal, and antiparasitic. The synthetic availability and biological potential of quinoxaline 1,4-dioxides define the prospects for their use in the targeted design of compounds with practical and valuable properties.</p><p>Moreover, the interest in heterocyclic <italic toggle="yes">N</italic>-oxides is explained by the presence of such structures in certain biologically active compounds found in natural sources. An example of a natural compound based on quinoxaline 1,4-dioxide is 6-chloro-2-quinoxalinecarboxylic acid 1,4-dioxide (<bold>1</bold>, <xref rid="pharmaceuticals-16-01174-f001" ref-type="fig">Figure 1</xref>) produced by <italic toggle="yes">Streptomyces ambofaciens</italic>, which can inhibit the growth of gram-positive bacteria. It has been noted that esters and amides of this acid also have antibacterial activity [<xref rid="B9-pharmaceuticals-16-01174" ref-type="bibr">9</xref>]. Iodinin (<bold>2</bold>, <xref rid="pharmaceuticals-16-01174-f001" ref-type="fig">Figure 1</xref>) is another example of a derivative of natural origin with a related structure to quinoxaline 1,4-dioxide [<xref rid="B10-pharmaceuticals-16-01174" ref-type="bibr">10</xref>]. Iodinin (<bold>2</bold>) was first identified and isolated from the bacterial culture <italic toggle="yes">Chromobacterium iodinum</italic> [<xref rid="B11-pharmaceuticals-16-01174" ref-type="bibr">11</xref>], and its antimicrobial properties were described in 1943 by H. McIlwain [<xref rid="B12-pharmaceuticals-16-01174" ref-type="bibr">12</xref>]. The results of recent studies have shown that iodinin (<bold>2</bold>) exhibits high cytotoxicity and selectivity for acute myeloid leukemia and promyelocytic leukemia cells (EC<sub>50</sub> values for apoptotic cell death were 40 times lower than for non-tumor cells). Notably, iodinin (<bold>2</bold>) induced apoptosis in tumor cell isolates from patients with a poor survival prognosis [<xref rid="B13-pharmaceuticals-16-01174" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-16-01174" ref-type="bibr">14</xref>].</p><p>Since the second half of the twentieth century, many researchers have observed the pronounced antibacterial activity of synthetic quinoxaline 1,4-dioxides. Some derivatives have been patented as antimicrobial agents and have found application in husbandry as promoters that increase animal weight gain [<xref rid="B15-pharmaceuticals-16-01174" ref-type="bibr">15</xref>].</p><p>Certain quinoxaline derivatives have also been patented and used in clinical practice as antibacterial drugs. For example, quinoxidine (<bold>3</bold>; 2,3-bis(acetoxymethyl)quinoxaline 1,4-dioxide, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) and dioxidine (<bold>4</bold>; 2,3-bis(hydroxymethyl)quinoxaline 1,4-dioxide, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) have been used in the clinic since the 1970s as broad-spectrum antibacterial agents [<xref rid="B16-pharmaceuticals-16-01174" ref-type="bibr">16</xref>].</p><p>Further studies have shown that quinoxaline 1,4-dioxides are a promising scaffold for the development of new drugs for the treatment of tuberculosis and parasitic infections such as malaria, trypanosomiasis, leishmaniasis, amoebiasis, and trichomoniasis [<xref rid="B17-pharmaceuticals-16-01174" ref-type="bibr">17</xref>]. For instance, derivative <bold>5</bold> (<xref rid="pharmaceuticals-16-01174-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B18-pharmaceuticals-16-01174" ref-type="bibr">18</xref>] has demonstrated promising antituberculosis activity, while compounds <bold>6</bold> and <bold>7</bold> exhibited high fungicidal [<xref rid="B19-pharmaceuticals-16-01174" ref-type="bibr">19</xref>] and antiviral [<xref rid="B20-pharmaceuticals-16-01174" ref-type="bibr">20</xref>] effects, respectively (<xref rid="pharmaceuticals-16-01174-f003" ref-type="fig">Figure 3</xref>). Derivatives of quinoxaline-2-carbonitrile 1,4-dioxide, such as compound <bold>8</bold> (<xref rid="pharmaceuticals-16-01174-f003" ref-type="fig">Figure 3</xref>), exhibit selective cytotoxicity against solid tumor cells under hypoxic conditions [<xref rid="B21-pharmaceuticals-16-01174" ref-type="bibr">21</xref>].</p><p>However, despite the high biological activity of quinoxaline 1,4-dioxides, the derivatives described in the literature have several disadvantages associated with low solubility, mutagenicity [<xref rid="B22-pharmaceuticals-16-01174" ref-type="bibr">22</xref>], photoallergic reactions [<xref rid="B23-pharmaceuticals-16-01174" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-16-01174" ref-type="bibr">24</xref>], and the development of bacterial resistance [<xref rid="B25-pharmaceuticals-16-01174" ref-type="bibr">25</xref>].</p><p>Methods for the synthesis and biological activity of quinoxaline 1,4-dioxides have been previously discussed in several papers [<xref rid="B26-pharmaceuticals-16-01174" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-16-01174" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-16-01174" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-16-01174" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-16-01174" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-16-01174" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-16-01174" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-16-01174" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-16-01174" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-16-01174" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-16-01174" ref-type="bibr">36</xref>]. However, the reviews published in the last twenty years have primarily focused on the biological aspects of quinoxaline 1,4-dioxides, providing limited consideration of their chemical properties and structure-activity relationships. In addition, the current reviews on the chemistry and biology of quinoxaline 1,4-dioxides do not contain up-to-date information published since 2016. Moreover, the information regarding the synthesis methods and chemical modifications of this class of compounds has not been systematized yet. Therefore, there is an interest in the general analysis and summarization of the data in the field of synthesis, modification, and biological properties of quinoxaline 1,4-dioxides, as well as the coverage of emerging trends in their study in medicinal chemistry and pharmaceuticals.</p></sec><sec sec-type="methods" id="sec2-pharmaceuticals-16-01174"><title>2. Methods of the Synthesis of Quinoxaline 1,4-Dioxides</title><p>Synthetic approaches to the formation of quinoxaline 1,4-dioxides are significantly limited (<xref rid="pharmaceuticals-16-01174-f004" ref-type="fig">Figure 4</xref>). Prior to 1965, the primary method for their synthesis was the direct oxidation of quinoxaline derivatives. Additionally, benzene-unsubstituted quinoxaline 1,4-dioxides can be obtained by the condensation of <italic toggle="yes">o</italic>-benzoquinone dioxime with 1,2-dicarbonyl derivatives. However, currently, a more efficient method for obtaining quinoxaline 1,4-dioxide derivatives has become the heterocyclization of benzofuroxans with enols or enamines by the Beirut reaction.</p><p>The oxidation of quinoxalines with peroxy acids or hydrogen peroxide does not result in a preparative yield of the desired quinoxaline 1,4-dioxides. This limitation arises from the deactivation of the heterocyclic core, preventing further electrophilic attack due to the formation of an <italic toggle="yes">N</italic>-oxide fragment following the oxidation of one of the nitrogen atoms [<xref rid="B37-pharmaceuticals-16-01174" ref-type="bibr">37</xref>]. In 2006, M. Carmeli and S. Rozen developed a method based on the application of a complex of hypofluorous acid with acetonitrile. This approach allows oxidizing of quinoxalines to quinoxaline 1,4-dioxides with quantitative yields, even for derivatives with electron-withdrawing substituents and sterically hindered 5-substituted derivatives. For instance, quinoxaline <bold>9</bold> can be oxidized to derivative <bold>10</bold> with a substituent at position 5, which is otherwise challenging to access using alternative methods (<xref rid="pharmaceuticals-16-01174-sch001" ref-type="fig">Scheme 1</xref>) [<xref rid="B37-pharmaceuticals-16-01174" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-16-01174" ref-type="bibr">38</xref>].</p><p>Several examples of the formation of a fragment of quinoxaline 1,4-dioxide via cyclization of <italic toggle="yes">o</italic>-benzoquinone dioxime with 1,2-dicarbonyl compounds are known. In 1970, E. Abushanab [<xref rid="B39-pharmaceuticals-16-01174" ref-type="bibr">39</xref>] described the interaction of 1,2-diketones with <italic toggle="yes">o</italic>-benzoquinone dioxime (<bold>11</bold>), leading to 2,3-disubstituted derivatives (compound <bold>12</bold>, <xref rid="pharmaceuticals-16-01174-sch002" ref-type="fig">Scheme 2</xref>) in low yields. However, the formation of 2-hydroxyquinoxaline 1,4-dioxides as the main products, such as compound <bold>13</bold>, was observed in good yields when <italic toggle="yes">&#x003b1;</italic>-ketoaldehydes were used for this condensation (<xref rid="pharmaceuticals-16-01174-sch002" ref-type="fig">Scheme 2</xref>) [<xref rid="B39-pharmaceuticals-16-01174" ref-type="bibr">39</xref>].</p><p>The most significant preparative method for the synthesis of quinoxaline 1,4-dioxides is the cyclization of benzofuroxans by the Beirut reaction, developed by M.J. Haddadin and C.H. Issidorides in 1965 [<xref rid="B40-pharmaceuticals-16-01174" ref-type="bibr">40</xref>].</p><p>Initially, quinoxaline 1,4-dioxides were obtained by the condensation of benzofuroxans with enamines. Thus, the interaction of benzofuroxan (<bold>14a</bold>) with morpholinylcyclohexene gives 2,3-tetramethylenequinoxaline 1,4-dioxide (<bold>15</bold>) in moderate yield (<xref rid="pharmaceuticals-16-01174-sch003" ref-type="fig">Scheme 3</xref>) [<xref rid="B41-pharmaceuticals-16-01174" ref-type="bibr">41</xref>]. Later, the synthetic possibilities of the Beirut reaction were expanded by using a large number of starting substrates. In 1972, M.J. Haddadin and C.H. Issidorides used this method to synthesize phenazine 5,10-dioxides, analogs of the antibiotic Iodinin. The authors found that cyclization of benzofuroxan (<bold>14a</bold>) with hydroquinone in the presence of a base gives 2-hydroxyphenazine 5,10-dioxide (<bold>16</bold>) (<xref rid="pharmaceuticals-16-01174-sch003" ref-type="fig">Scheme 3</xref>) [<xref rid="B42-pharmaceuticals-16-01174" ref-type="bibr">42</xref>]. In the same year, A. Tanaka et al. showed the possibility of using alkynes in the Beirut reaction for the synthesis of 2,3-disubstituted quinoxaline 1,4-dioxides. Thus, the derivative <bold>17</bold> was obtained from benzofuroxan (<bold>14a</bold>) and 2-(furan-2-ylethynyl)-5-nitrofuran in the presence of methylamine, although in low yield (<xref rid="pharmaceuticals-16-01174-sch003" ref-type="fig">Scheme 3</xref>) [<xref rid="B43-pharmaceuticals-16-01174" ref-type="bibr">43</xref>]. Cyclization of benzofuroxan (<bold>14a</bold>) with aryl- and heteroaryl ethylenes (<xref rid="pharmaceuticals-16-01174-sch003" ref-type="fig">Scheme 3</xref>) was proposed for the synthesis of 2-substituted quinoxaline 1,4-dioxides (for example, derivative <bold>18</bold>) by J. Li et al. [<xref rid="B44-pharmaceuticals-16-01174" ref-type="bibr">44</xref>].</p><p>Several possible variants of the Beirut reaction mechanism have been described [<xref rid="B27-pharmaceuticals-16-01174" ref-type="bibr">27</xref>,<xref rid="B41-pharmaceuticals-16-01174" ref-type="bibr">41</xref>,<xref rid="B45-pharmaceuticals-16-01174" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-16-01174" ref-type="bibr">46</xref>]. The first stage of the proposed mechanism includes the nucleophilic attack of the formed enolate ion on the electrophilic nitrogen atom of benzofuroxan <bold>14a</bold>, leading to intermediate <bold>a</bold> [<xref rid="B27-pharmaceuticals-16-01174" ref-type="bibr">27</xref>]. Based on the mechanism of the Beirut reaction (<xref rid="pharmaceuticals-16-01174-f005" ref-type="fig">Figure 5</xref>), the opening of benzofuroxan <bold>14a</bold> in one of the transition states is accompanied by an attack of the oxime nitrogen atom on the electrophilic carbonyl group of intermediate <bold>b</bold>, which causes the formation of dihydroxyquinoxaline <bold>c</bold>. Further elimination of water from intermediate <bold>c</bold> leads to the formation of the quinoxaline 1,4-dioxide (<bold>d</bold>).</p><p>In 1995, A. Monge et al. described the synthesis of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxide <bold>19a</bold> by the Beirut reaction from malononitrile and benzofuroxan <bold>14a</bold> (<xref rid="pharmaceuticals-16-01174-sch004" ref-type="fig">Scheme 4</xref>) when developing antiparasitic agents [<xref rid="B47-pharmaceuticals-16-01174" ref-type="bibr">47</xref>]. A similar cyclization with malonic ester in the presence of sodium hydride leading to 2-hydroxyquinoxaline 1,4-dioxide <bold>20</bold> in high yield was reported by Y. Xu et al. (<xref rid="pharmaceuticals-16-01174-sch004" ref-type="fig">Scheme 4</xref>) [<xref rid="B48-pharmaceuticals-16-01174" ref-type="bibr">48</xref>].</p><p>Cyclization of benzofuroxans with 1,3-diketones, <italic toggle="yes">&#x003b2;</italic>-ketoesters, or <italic toggle="yes">&#x003b2;</italic>-ketoamides has been proposed to obtain 2-acyl derivatives of quinoxaline 1,4-dioxide [<xref rid="B49-pharmaceuticals-16-01174" ref-type="bibr">49</xref>]. Thus, the interaction of 5,6-difluorobenzofuroxan (<bold>14b</bold>) with acetylacetone, acetoacetic ester, or <italic toggle="yes">N</italic>-phenylacetoacetamide in triethylamine at 0&#x02013;10 &#x000b0;C gives 6,7-difluoroquinoxaline 1,4-dioxides <bold>21</bold>&#x02013;<bold>22a</bold>, <bold>23</bold>, respectively, with yields of 65&#x02013;83% (<xref rid="pharmaceuticals-16-01174-sch005" ref-type="fig">Scheme 5</xref>) [<xref rid="B50-pharmaceuticals-16-01174" ref-type="bibr">50</xref>].</p><p>T. Lima et al. evaluated the effect of acid-base catalysts in the Beirut reaction on the yield of 2-carboethoxyquinoxaline 1,4-dioxide during the study of the condensation of benzofuroxan (<bold>14a</bold>) with benzoylacetic esters [<xref rid="B51-pharmaceuticals-16-01174" ref-type="bibr">51</xref>]. Thus, the target products were obtained in the presence of organic bases in less than 7% yields. In the case of acid catalysis, the key derivatives formed slightly higher yields (~13%). Catalysis with potassium fluoride on alumina in the absence of an organic solvent leads to the formation of desired products in acceptable yields (31&#x02013;40%). A higher yield (50&#x02013;64%) of derivatives of 3-phenylquinoxaline-2-carboxylic acid 1,4-dioxide was achieved using K<sub>2</sub>CO<sub>3</sub> as a catalyst in acetone or DMF.</p><p>T. Sun et al. carried out the heterocyclization of benzofuroxan <bold>14a</bold> and carbonyl compounds to substituted quinoxaline 1,4-dioxides via supramolecular catalysis by <italic toggle="yes">&#x003b2;</italic>-cyclodextrin in water [<xref rid="B52-pharmaceuticals-16-01174" ref-type="bibr">52</xref>]. A similar procedure was used to obtain conjugates of 6(7)-haloquinoxaline 1,4-dioxides with primaquine [<xref rid="B53-pharmaceuticals-16-01174" ref-type="bibr">53</xref>] or with <italic toggle="yes">N</italic>-aryl-substituted 1,2,3-triazoles [<xref rid="B54-pharmaceuticals-16-01174" ref-type="bibr">54</xref>], which have antimalarial and antimycobacterial activity.</p><p>In some cases, the Beirut reaction between monosubstituted benzofuroxans and CH-acids leads to a mixture of 7- and 6-substituted quinoxaline 1,4-dioxides [<xref rid="B55-pharmaceuticals-16-01174" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-16-01174" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceuticals-16-01174" ref-type="bibr">57</xref>], which is explained by the presence of tautomeric equilibrium in benzofuroxans [<xref rid="B58-pharmaceuticals-16-01174" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-16-01174" ref-type="bibr">59</xref>]. A study of the regioselectivity of the Beirut reaction between monosubstituted benzofuroxans <bold>14c</bold>&#x02013;<bold>i</bold> and benzoylacetonitrile revealed that, along with the 7-isomers <bold>24a</bold>&#x02013;<bold>g</bold>, their 6-substituted analogs <bold>25c</bold>&#x02013;<bold>g</bold> [<xref rid="B60-pharmaceuticals-16-01174" ref-type="bibr">60</xref>] are formed in the reaction (<xref rid="pharmaceuticals-16-01174-sch006" ref-type="fig">Scheme 6</xref>). It is shown that the yield of the 6-isomer increases with the growth of electron-withdrawing properties of the substituent in the starting benzofuroxan and correlates well with the Hammett constant. Thus, the 6-isomer is not formed in the case of derivatives with electron-donating groups, while the 6-substituted compounds <bold>25f</bold>,<bold>g</bold> with CO<sub>2</sub>Me- and CF<sub>3</sub>-groups are the main products of the reaction. The structure of the isomers was accurately confirmed by NMR spectroscopy and X-ray analysis. Compounds <bold>24a</bold>&#x02013;<bold>g</bold> and <bold>25f</bold>,<bold>g</bold> showed high antiproliferative activity against breast adenocarcinoma cells (MCF-7, MDA-MB-231) under hypoxic conditions. Moreover, the structural isomers <bold>24c</bold>&#x02013;<bold>g</bold> and <bold>25c</bold>&#x02013;<bold>g</bold> had considerable differences in properties.</p><p>The reaction of aminobenzofuroxans <bold>14j</bold>,<bold>k</bold> with benzoylacetonitrile in chloroform in the presence of Et<sub>3</sub>N also yields 7-amino-substituted quinoxaline-2-carbonitrile 1,4-dioxides <bold>26a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-sch007" ref-type="fig">Scheme 7</xref>) [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>]. This method of heterocyclization was later used to synthesize 7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-dioxide <bold>27a</bold> (<xref rid="pharmaceuticals-16-01174-sch007" ref-type="fig">Scheme 7</xref>) [<xref rid="B62-pharmaceuticals-16-01174" ref-type="bibr">62</xref>]. The 7-amino derivatives of <bold>26a</bold>,<bold>b</bold> have high aqueous solubility and downregulate the expression of HIF1&#x003b1;, BCL2, and ER&#x003b1; and induce apoptosis in MCF-7 cells at submicromolar concentrations.</p><p>In summary, the Beirut cyclization is currently the main preparative method for the synthesis of quinoxaline 1,4-dioxides with various substituents at positions 2, 3, 6, and 7. Ongoing research is focused on studying regioselectivity and exploring the possibilities of varying starting compounds, catalysts, and conditions to increase the yield of target quinoxaline 1,4-dioxides.</p></sec><sec id="sec3-pharmaceuticals-16-01174"><title>3. Chemical Properties of Quinoxaline 1,4-Dioxides</title><p>The reactivity of quinoxaline 1,4-dioxides is generally similar to the properties of heteroaromatic <italic toggle="yes">N</italic>-oxides. As a result, most of the reactions of quinoxaline 1,4-dioxides described in the literature involve the modification of the <italic toggle="yes">N</italic>-oxide fragment or are related to the transformation of the functional groups of the side chains and the benzene ring of quinoxaline.</p><p>Since the <italic toggle="yes">N</italic>-oxide fragment in the quinoxaline 1,4-dioxide facilitates many reactions, its reduction holds important synthetic value for the preparation of quinoxaline derivatives. Deoxygenation of heteroaromatic <italic toggle="yes">N</italic>-oxides can proceed in the presence of various reducing agents, such as catalytic hydrogenation, complex metal hydrides, sodium hypophosphite, titanium (III) chloride, dissolving metals, ascorbic acid, trivalent phosphorus compounds, and a number of sulfur-containing compounds [<xref rid="B63-pharmaceuticals-16-01174" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceuticals-16-01174" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-16-01174" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-16-01174" ref-type="bibr">66</xref>]. However, not all reagents are suitable for the preparative reduction of quinoxaline 1,4-dioxides to quinoxalines due to the tendency of these substrates to undergo deoxygenation to mono-<italic toggle="yes">N</italic>-oxides or the formation of dihydro- and tetrahydroquinoxalines [<xref rid="B67-pharmaceuticals-16-01174" ref-type="bibr">67</xref>].</p><p>Quinoxaline 1,4-dioxides are sensitive to UV irradiation and, as a result of photoinduced rearrangement, can yield various products that depend on the structure of the starting compound. In particular, 2-substituted quinoxaline 1,4-dioxides <bold>28a</bold>,<bold>b</bold> isomerize to 3-oxoquinoxaline 1-<italic toggle="yes">N</italic>-oxides <bold>30a</bold> and <bold>30b</bold> in high yield through the intermediate oxaziridines <bold>29</bold> under photolysis of their aqueous solutions (<xref rid="pharmaceuticals-16-01174-sch008" ref-type="fig">Scheme 8</xref>) [<xref rid="B68-pharmaceuticals-16-01174" ref-type="bibr">68</xref>].</p><p>Reduction and rearrangements occurring in the 1,4-dioxide core are often observed under basic conditions [<xref rid="B69-pharmaceuticals-16-01174" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-16-01174" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceuticals-16-01174" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-16-01174" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceuticals-16-01174" ref-type="bibr">73</xref>], by treatment of nucleophiles [<xref rid="B74-pharmaceuticals-16-01174" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceuticals-16-01174" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-16-01174" ref-type="bibr">76</xref>] or acid halides [<xref rid="B77-pharmaceuticals-16-01174" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceuticals-16-01174" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceuticals-16-01174" ref-type="bibr">79</xref>], which frequently reduce the yield of the target products and limit the possibility of transforming the functional groups of quinoxaline 1,4-dioxides. At the same time, the electron-withdrawing nature of the <italic toggle="yes">N</italic>-oxide fragments in the quinoxaline nucleus makes it possible to carry out a nucleophilic substitution of the leaving groups in positions 2, 3 and 6, 7 of the heterocyclic core under relatively mild conditions.</p><sec id="sec3dot1-pharmaceuticals-16-01174"><title>3.1. Transformations of Alkyl and Acyl Groups</title><p>Transformations of alkyl groups in the quinoxaline core are one of the most important approaches for obtaining a wide range of derivatives. For example, the synthesis of the original antibacterial drugs quinoxidine and dioxidine (compounds <bold>3</bold> and <bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) is based on the modification of the methyl groups of the heterocycle. Bromination of 2,3-dimethylquinoxaline 1,4-dioxide (<bold>12</bold>) yields 2,3-bis(bromomethyl)quinoxaline 1,4-dioxide (<bold>31</bold>), which, upon treatment with acetic acid in the presence of triethylamine, gives quinoxidine (<bold>3</bold>). Hydrolysis of the di-<italic toggle="yes">O</italic>-acetyl derivative <bold>3</bold> in aqueous methanol leads to dioxidine (<bold>4</bold>) in good yield (<xref rid="pharmaceuticals-16-01174-sch009" ref-type="fig">Scheme 9</xref>) [<xref rid="B80-pharmaceuticals-16-01174" ref-type="bibr">80</xref>].</p><p>The CH-groups in the methyl attached to the pyrazine ring of quinoxaline 1,4-dioxides have high acidity, which explains the facilitation of the condensation of 2-benzoyl-3-methylquinoxaline 1,4-dioxides <bold>32a</bold>,<bold>b</bold> with dimethylacetal of <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylformamide (DMADMF) in <italic toggle="yes">o</italic>-xylene, which gives high yields of enamines <bold>33a</bold>,<bold>b</bold>, respectively (<xref rid="pharmaceuticals-16-01174-sch010" ref-type="fig">Scheme 10</xref>) [<xref rid="B81-pharmaceuticals-16-01174" ref-type="bibr">81</xref>].</p><p>Similarly, enamine <bold>34</bold> was obtained from 2-carboethoxy-7-chloro-3-methylquinoxaline 1,4-dioxide and DMADMF [<xref rid="B82-pharmaceuticals-16-01174" ref-type="bibr">82</xref>]. The transamination of this derivative with morpholine gives enamine <bold>35</bold>, while the reaction with anilines is accompanied by cyclization to pyridin-2-ones, leading to the formation of derivatives <bold>36a</bold>&#x02013;<bold>c</bold> in good yields (<xref rid="pharmaceuticals-16-01174-sch011" ref-type="fig">Scheme 11</xref>).</p><p>The synthesis of aldehyde-derived quinoxaline 1,4-dioxides by the Beirut reaction is limited by the accessibility of the starting reagents. M. Quiliano et al. described the preparation of 2-formylquinoxaline 1,4-dioxides, developed for obtaining analogs of isoniazid [<xref rid="B83-pharmaceuticals-16-01174" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceuticals-16-01174" ref-type="bibr">84</xref>]. Oxidation of 2,3-dimethylquinoxaline <bold>12</bold> by treatment with SeO<sub>2</sub> under microwave irradiation gave 2-formylquinoxaline <bold>37a</bold>, which upon condensation with a derivative of hydrazine, resulted in hydrazones <bold>38a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-sch012" ref-type="fig">Scheme 12</xref>). Compounds <bold>38a</bold>,<bold>b</bold> showed high antitubercular activity against <italic toggle="yes">M. tuberculosis</italic> H37Rv with low cytotoxicity for non-tumor cells (Vero cells).</p><p>Another example of the use of 2-formylquinoxaline 1,4-dioxide for the synthesis of antimycobacterial agents was presented by Zhang H. et al. [<xref rid="B85-pharmaceuticals-16-01174" ref-type="bibr">85</xref>]. The condensation of carbaldehydes <bold>39a</bold>,<bold>b</bold> with amines formed the corresponding <italic toggle="yes">N</italic>-substituted 2-thiazolidinonequinoxaline 1,4-dioxides, which further underwent intramolecular cyclization with thioglycolic acid to give 2-thiazolidinone-substituted quinoxalines <bold>40a</bold>,<bold>b</bold> in good yield (<xref rid="pharmaceuticals-16-01174-sch013" ref-type="fig">Scheme 13</xref>). Derivative <bold>40b</bold> demonstrated high antimycobacterial activity (MIC = 1.6 &#x003bc;g/mL, <italic toggle="yes">M. tuberculosis</italic> H37Rv), as well as significant antifungal activity (MIC = 2&#x02013;4 &#x003bc;g/mL) against a panel of pathogenic fungi (<italic toggle="yes">Candida</italic> spp., <italic toggle="yes">Aspergillus</italic> spp., <italic toggle="yes">Cryptococcus</italic> spp.) comparable to the reference drug amphotericin B (MIC = 0.5&#x02013;2 &#x003bc;g/mL).</p><p>In addition, 2-formylquinoxaline 1,4-dioxide <bold>37a</bold> was applied for the synthesis of nitrones <bold>41a</bold>,<bold>b</bold> via its condensation with <italic toggle="yes">N</italic>-substituted hydroxylamines (<xref rid="pharmaceuticals-16-01174-sch014" ref-type="fig">Scheme 14</xref>) [<xref rid="B86-pharmaceuticals-16-01174" ref-type="bibr">86</xref>]. Derivatives <bold>41a</bold>,<bold>b</bold> exhibited high antibacterial activity against Gram-positive and Gram-negative bacteria, including resistant strains, both in vitro and in vivo. It has been shown that the introduction of an additional <italic toggle="yes">N</italic>-oxide fragment into position 3 leads to an increase in the selectivity of the antibacterial effect of these derivatives against Gram-negative bacteria.</p><p>An alternative synthesis of quinoxalinylnitrones based on the condensation of 2-methylquinoxaline 1,4-dioxide (<bold>28b</bold>) with <italic toggle="yes">p</italic>-nitrosodimethylaniline, resulted in a high yield of nitrone <bold>42</bold> (<xref rid="pharmaceuticals-16-01174-sch015" ref-type="fig">Scheme 15</xref>) [<xref rid="B87-pharmaceuticals-16-01174" ref-type="bibr">87</xref>].</p><p>B.B. Michniak et al. described the conversion of 2-formylquinoxaline 1,4-dioxide (<bold>39a</bold>) to quinoxaline-2-carbonitrile 1,4-dioxide (<bold>44</bold>) via <italic toggle="yes">O</italic>-acyloxime <bold>43</bold> (<xref rid="pharmaceuticals-16-01174-sch016" ref-type="fig">Scheme 16</xref>) [<xref rid="B88-pharmaceuticals-16-01174" ref-type="bibr">88</xref>].</p><p>Y. Pan et al. used the modification of the acetyl residue for the diversification of quinoxaline 1,4-dioxides and increasing the solubility of compounds in aqueous solutions [<xref rid="B89-pharmaceuticals-16-01174" ref-type="bibr">89</xref>]. Bromination of ketone <bold>21b</bold> and subsequent substitution of the halogen in <italic toggle="yes">&#x003b1;</italic>-bromoketone <bold>45</bold> with amines gave <italic toggle="yes">&#x003b1;</italic>-aminoketones <bold>46a</bold>,<bold>b</bold> in high yield (<xref rid="pharmaceuticals-16-01174-sch017" ref-type="fig">Scheme 17</xref>). Treatment of the bromo derivative <bold>45</bold> with thiols yielded <italic toggle="yes">&#x003b2;</italic>-mercaptoketones <bold>47a</bold>,<bold>b</bold>. The obtained compounds demonstrated high antimycobacterial activity against the <italic toggle="yes">M. tuberculosis</italic> H37Rv strain without cytotoxic effects on non-tumor cells (Vero cells).</p><p>The condensation of 2-acetyl-3-methylquinoxaline 1,4-dioxide <bold>21c</bold> with <italic toggle="yes">p</italic>-chlorobenzaldehyde in NaOH solution leading to chalcone <bold>48</bold> with high yield (<xref rid="pharmaceuticals-16-01174-sch018" ref-type="fig">Scheme 18</xref>) is described in several papers [<xref rid="B81-pharmaceuticals-16-01174" ref-type="bibr">81</xref>,<xref rid="B90-pharmaceuticals-16-01174" ref-type="bibr">90</xref>]. An example of the modification of chalcones based on quinoxaline 1,4-dioxide is the heterocyclization of compound <bold>48</bold> with thiourea and hydrazine, resulting in derivatives of thiopyrimidine <bold>49</bold> and pyrazole <bold>50</bold>, respectively (<xref rid="pharmaceuticals-16-01174-sch018" ref-type="fig">Scheme 18</xref>) [<xref rid="B81-pharmaceuticals-16-01174" ref-type="bibr">81</xref>]. The obtained compounds <bold>49</bold>, <bold>50</bold> exhibit high antitumor activity against hepatocellular carcinoma HepG2 and are two orders of magnitude more active than the reference agent tirapazamine under hypoxic conditions.</p><p>An alternative method for the synthesis of chalcones based on quinoxaline 1,4-dioxide was developed by Burguete A. et al. [<xref rid="B91-pharmaceuticals-16-01174" ref-type="bibr">91</xref>]. The Wittig reaction of 2-acetyl-3-methylquinoxaline 1,4-dioxide <bold>37b</bold> under microwave irradiation yielded enone <bold>51</bold>, which has high antioxidant and anti-inflammatory activity (<xref rid="pharmaceuticals-16-01174-sch019" ref-type="fig">Scheme 19</xref>) [<xref rid="B92-pharmaceuticals-16-01174" ref-type="bibr">92</xref>].</p><p>A. Monge&#x02019;s group carried out cyclopropanation of the conjugated double bonds of chalcones based on quinoxaline 1,4-dioxide using the Corey-Tchaikovsky reaction [<xref rid="B90-pharmaceuticals-16-01174" ref-type="bibr">90</xref>]. Thus, the reaction of enone <bold>51</bold> with sulfoxonium methylide generated from trimethyloxosulfonium iodide (TMSOI) gave the cyclopropyl derivative <bold>52</bold> in low yield (<xref rid="pharmaceuticals-16-01174-sch020" ref-type="fig">Scheme 20</xref>).</p><p>Compound <bold>52</bold> demonstrated good antimalarial activity against the <italic toggle="yes">P. falciparum</italic> FCR-3 strain.</p></sec><sec id="sec3dot2-pharmaceuticals-16-01174"><title>3.2. Reactions of Amino Derivatives of Quinoxaline 1,4-Dioxides</title><p>A. Monge et al. demonstrated that 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides <bold>19b</bold>&#x02013;<bold>d</bold> can be acylated using acid chlorides, resulting in the formation of the corresponding amides <bold>53a</bold>&#x02013;<bold>d</bold> (<xref rid="pharmaceuticals-16-01174-sch021" ref-type="fig">Scheme 21</xref>) [<xref rid="B93-pharmaceuticals-16-01174" ref-type="bibr">93</xref>]. Condensation of 5-nitrofuran- and 5-nitrothiophene-2-carboxylic acids <bold>53a</bold>&#x02013;<bold>d</bold> in the presence of carbodiimide (EDCI) and DMAP was used for the synthesis of the corresponding amides (<xref rid="pharmaceuticals-16-01174-sch021" ref-type="fig">Scheme 21</xref>). Derivative <bold>53a</bold> exhibits MIC values close to the reference rifampicin against <italic toggle="yes">M. tuberculosis</italic> H37Rv. Compounds <bold>53b</bold> and <bold>53c</bold> have comparable activity with the anti-Chagas drug nifurtimox for the <italic toggle="yes">T. cruzi</italic> Tulahuen 2 strain.</p><p>The reaction of 2-aminoquinoxaline 1,4-dioxides <bold>19a</bold>,<bold>b</bold> with isocyanates leads to cyclic carbamates <bold>54a</bold>,<bold>b</bold>. The ring opening of these carbamates with alcohols results in the formation of alkylcarbamates of quinoxaline 1,4-dioxides <bold>55a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-sch022" ref-type="fig">Scheme 22</xref>) [<xref rid="B94-pharmaceuticals-16-01174" ref-type="bibr">94</xref>].</p><p>Soliman D.H. et al. described an interesting modification of the amino group in the pyrazine ring of quinoxaline, allowing the obtainment of tricyclic diazaphosphorins <bold>57a</bold>,<bold>b</bold> as a result of cyclization of 3-aminoquinoxaline 1,4-dioxides <bold>19a</bold> and <bold>56</bold> by treatment with phosphorus(V) sulfide in pyridine. Further methylation of diazaphosphorins <bold>57a</bold>,<bold>b</bold> yielded <italic toggle="yes">N</italic>,<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>-trimethyl derivatives <bold>58a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-sch023" ref-type="fig">Scheme 23</xref>). These compounds demonstrated high activity against the prostate cancer cells (PC3), comparable to doxorubicin [<xref rid="B95-pharmaceuticals-16-01174" ref-type="bibr">95</xref>]. In addition, compound <bold>58b</bold> was able to inhibit VEGFR-2 and SRC kinases (IC<sub>50</sub> = 18 &#x003bc;M).</p></sec><sec id="sec3dot3-pharmaceuticals-16-01174"><title>3.3. Metal-Containing Chelates of Quinoxaline 1,4-Dioxides</title><p>One of the promising strategies in the search for new antitumor agents is the development of metal-containing chelates [<xref rid="B96-pharmaceuticals-16-01174" ref-type="bibr">96</xref>]. For example, copper(II) complexes with amino acids [<xref rid="B97-pharmaceuticals-16-01174" ref-type="bibr">97</xref>], casiopeins [<xref rid="B98-pharmaceuticals-16-01174" ref-type="bibr">98</xref>], oligopeptides [<xref rid="B99-pharmaceuticals-16-01174" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceuticals-16-01174" ref-type="bibr">100</xref>], and mono- and bis-thiosemicarbazones [<xref rid="B101-pharmaceuticals-16-01174" ref-type="bibr">101</xref>,<xref rid="B102-pharmaceuticals-16-01174" ref-type="bibr">102</xref>] have demonstrated significant antitumor activity in human tumor models in vivo. The study of complexes with transition metals showed that quinoxaline-2-carboxilic acid 1,4-dioxide could act as a mono- or bidentate ligand for different coordination ions (Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Ce(III), Nd(III), V(IV)) [<xref rid="B103-pharmaceuticals-16-01174" ref-type="bibr">103</xref>].</p><p>Another example of a ligand for chelates is 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides <bold>19e</bold>,<bold>f</bold>, which forms complexes with Cu(II) (<bold>59</bold>) [<xref rid="B104-pharmaceuticals-16-01174" ref-type="bibr">104</xref>] or V(IV) (<bold>60</bold>), respectively (<xref rid="pharmaceuticals-16-01174-sch024" ref-type="fig">Scheme 24</xref>) [<xref rid="B105-pharmaceuticals-16-01174" ref-type="bibr">105</xref>].</p><p>Derivative <bold>60</bold> has caused hypoglycemic and antihyperlipidemic effects using in vitro models, while the copper complex <bold>59</bold> demonstrated promising antiproliferative potency and selectivity under hypoxic conditions.</p></sec><sec id="sec3dot4-pharmaceuticals-16-01174"><title>3.4. Nucleophilic Substitution of Halogen Atoms</title><p>Despite the high biological activity of some quinoxaline 1,4-dioxide derivatives, their study is complicated by low solubility in pharmacologically acceptable aqueous media [<xref rid="B106-pharmaceuticals-16-01174" ref-type="bibr">106</xref>]. One way to increase the bioavailability of organic compounds is by introducing substituents containing salt-forming groups, such as amino groups. The presence of a di-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02032;-oxide fragment in the quinoxaline core increases the reactivity of quinoxalines in nucleophilic substitution reactions. Therefore, the most important methods of diversification of quinoxaline 1,4-dioxides are based on the modification of halogen atoms, alkoxy- or alkylthio-groups in the activated positions of the heterocycle.</p><p>M.A. Ortega et al. demonstrated that 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides <bold>19b</bold> and <bold>19e</bold> do not undergo diazotization reactions under classical conditions due to the low basicity of the amino group and the low solubility of such compounds. However, it was possible to produce a diazonium salt and replace the diazo group with a halogen by the Sandmeyer reaction. Thus, treatment of amines <bold>19b</bold> and <bold>19e</bold> with <italic toggle="yes">tert</italic>-butyl nitrite, heating in acetonitrile in the presence of CuCl<sub>2</sub> in an inert atmosphere gave 3-chloro derivatives <bold>61a</bold>,<bold>b</bold>, although in low yield (<xref rid="pharmaceuticals-16-01174-sch025" ref-type="fig">Scheme 25</xref>) [<xref rid="B107-pharmaceuticals-16-01174" ref-type="bibr">107</xref>]. Further nucleophilic substitution of the chlorine atom in compounds <bold>61a</bold>,<bold>b</bold> by diamines in chloroform in the presence of K<sub>2</sub>CO<sub>3</sub> led to 3-amino derivatives, such as piperazines <bold>62a</bold>,<bold>b</bold>, in low yields (<xref rid="pharmaceuticals-16-01174-sch025" ref-type="fig">Scheme 25</xref>). An alternative method for introducing amine residues into position 3 of quinoxaline 1,4-dioxides is based on the substitution of alkylthio-, aryloxy-, and sulfonyl-groups, which gives 3-amino derivatives in high yields [<xref rid="B108-pharmaceuticals-16-01174" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceuticals-16-01174" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceuticals-16-01174" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceuticals-16-01174" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-16-01174" ref-type="bibr">112</xref>].</p><p>The substitution of halogen atoms in the benzene ring activated by electron-withdrawing groups in the pyrazine nucleus of quinoxalines proceeds more efficiently. Thus, a series of amino derivatives <bold>64a</bold>&#x02013;<bold>c</bold> was synthesized by treating an excess of diamines with halogen derivatives of 3-phenylquinoxaline-2-carbonitrile 1,4-dioxides <bold>24c</bold> and <bold>63a</bold>,<bold>b</bold> in DMF, yielding moderate-to-good yields (40&#x02013;85%) (<xref rid="pharmaceuticals-16-01174-sch026" ref-type="fig">Scheme 26</xref>). It should be noted that for 6,7-dihalogen derivatives, the reaction proceeds regioselectively, leading to 6-amino-substituted <bold>64b</bold>,<bold>c</bold>, which is explained by the electron-withdrawing effect of the CN group in position 2 of the heterocycle [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B113-pharmaceuticals-16-01174" ref-type="bibr">113</xref>]. The structure of these compounds was confirmed by the <sup>13</sup>C NMR spectra, as well as X-ray analysis. Amino derivatives <bold>64a</bold>&#x02013;<bold>c</bold> at low micromolar concentrations inhibited the proliferation of a panel of tumor cell lines of various tissue origins and also showed outstanding selectivity for malignant cells under hypoxia.</p><p>In 2021, a similar approach was used by N. Zhang et al. to modify 2-acyl-6,7-difluoro-3-methylquinoxaline 1,4-dioxides <bold>21</bold>&#x02013;<bold>22a</bold>. The treatment of derivatives <bold>21</bold>&#x02013;<bold>22a</bold> with piperazine or azoles in ethanol in the presence of K<sub>2</sub>CO<sub>3</sub> yielded 6-amino derivatives <bold>65a</bold>&#x02013;<bold>c</bold> (<xref rid="pharmaceuticals-16-01174-sch027" ref-type="fig">Scheme 27</xref>), which exhibit promising antituberculosis potency [<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>].</p><p>A similar method for modifying 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides was used for the development of new antibacterial agents [<xref rid="B62-pharmaceuticals-16-01174" ref-type="bibr">62</xref>,<xref rid="B115-pharmaceuticals-16-01174" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-16-01174" ref-type="bibr">116</xref>]. However, derivatives with two electron-withdrawing groups in positions 2 and 3 have a high tendency for deoxygenation of the 1,4-dioxide moiety [<xref rid="B116-pharmaceuticals-16-01174" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceuticals-16-01174" ref-type="bibr">117</xref>]. The substitution of the halogen atom in derivatives <bold>66a</bold>&#x02013;<bold>c</bold> proceeds more efficiently when using Boc-piperazine to give amino derivatives <bold>67a</bold>&#x02013;<bold>f</bold> (<xref rid="pharmaceuticals-16-01174-sch028" ref-type="fig">Scheme 28</xref>).</p><p>In the case of 6,7-dihalogen derivatives, the reaction also proceeds retrospectively but leads to 7-amino derivatives <bold>67b</bold>&#x02013;<bold>f</bold>, the structure of which was confirmed by analysis of the <sup>13</sup>C NMR spectra [<xref rid="B62-pharmaceuticals-16-01174" ref-type="bibr">62</xref>].</p></sec><sec id="sec3dot5-pharmaceuticals-16-01174"><title>3.5. Transformations of Carboxylic Acids and Their Derivatives</title><p>1,4-Dioxides of quinoxaline-2-carboxylic acids and their derivatives have high biological activity and a wide range of pharmacological properties. Therefore, it is important to analyze their chemical properties and the most valuable methods of their transformations. The 1,4-dioxides of quinoxaline-2-carboxylic acids are unstable and easily decarboxylated. Thus, quinoxaline 1,4-dioxide <bold>28a</bold> is formed from acid <bold>68</bold> when heated in propanol (<xref rid="pharmaceuticals-16-01174-sch029" ref-type="fig">Scheme 29</xref>) [<xref rid="B56-pharmaceuticals-16-01174" ref-type="bibr">56</xref>].</p><p>The hydrolysis of ester <bold>22b</bold> to acid <bold>70</bold> was successfully carried out by heating in aqueous ethanol in the presence of triethylamine and catalytic amounts of calcium chloride (<xref rid="pharmaceuticals-16-01174-sch030" ref-type="fig">Scheme 30</xref>). It has been shown that calcium ions accelerate the hydrolysis of esters of 1,4-dioxides of quinoxaline-2-carboxylic acids due to the formation of complex <bold>69</bold> [<xref rid="B118-pharmaceuticals-16-01174" ref-type="bibr">118</xref>].</p><p>The direct alkaline hydrolysis of 2-carboethoxy-7-fluoroquinoxaline 1,4-dioxide <bold>65b</bold> proceeds in low yield and gives acid <bold>71</bold>, as described in [<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>]. This is apparently explained by the instability of quinoxaline 1,4-dioxides in the presence of bases (<xref rid="pharmaceuticals-16-01174-sch031" ref-type="fig">Scheme 31</xref>).</p><p>S.S. Sabri et al. synthesized amides from quinoxaline-2-carboxylic acid <bold>70</bold> using diphenylphospharylazide (DPPA) as an activating agent. Carboxamides <bold>72a</bold>&#x02013;<bold>e</bold> were obtained in good yields from acid <bold>70</bold> and primary amines in the presence of DPPA and triethylamine in DMF (<xref rid="pharmaceuticals-16-01174-sch032" ref-type="fig">Scheme 32</xref>) [<xref rid="B119-pharmaceuticals-16-01174" ref-type="bibr">119</xref>].</p><p>The Curtius rearrangement can be used for the synthesis of some 2-amino derivatives of quinoxaline 1,4-dioxide from azides of 1,4-dioxides of quinoxaline-2-carboxylic acids. Hydrazinolysis and subsequent nitrosation of ester <bold>22c</bold> gave the azide of 3-methylquinoxaline-2-carboxylic acid <bold>73</bold>. Azide <bold>73</bold> rearranges into 2-alkyl carbamates <bold>74a</bold>&#x02013;<bold>c</bold> or substituted ureas <bold>75a</bold>&#x02013;<bold>c</bold> when boiled in an alcohol or amine solution, respectively (<xref rid="pharmaceuticals-16-01174-sch033" ref-type="fig">Scheme 33</xref>) [<xref rid="B120-pharmaceuticals-16-01174" ref-type="bibr">120</xref>].</p><p>The transformations of the hydrazide of 3-methylquinoxaline-2-carboxylic acid <bold>76</bold>, obtained from the corresponding ethyl ester and hydrazine, are applied to the functionalization of the quinoxaline 1,4-dioxide scaffold at position 2 [<xref rid="B82-pharmaceuticals-16-01174" ref-type="bibr">82</xref>]. Condensation of hydrazide <bold>76</bold> with benzaldehydes in the presence of acetic acid in ethanol gave hydrazones <bold>77a</bold> and <bold>77b</bold> (<xref rid="pharmaceuticals-16-01174-sch034" ref-type="fig">Scheme 34</xref>).</p><p>Treatment of hydrazide <bold>76</bold> with carbon disulfide leads to the cyclization of 2-(1,3,4-oxadiazol-2-thione) <bold>78</bold> (<xref rid="pharmaceuticals-16-01174-sch034" ref-type="fig">Scheme 34</xref>). Boiling hydrazide <bold>76</bold> with <italic toggle="yes">p</italic>-nitrobenzoic acid in the presence of phosphoryl chloride gave 2-(1,3,4-oxadiazolyl)quinoxaline 1,4-dioxide <bold>79</bold>.</p></sec></sec><sec id="sec4-pharmaceuticals-16-01174"><title>4. Chemotherapeutic Properties of Quinoxaline 1,4-Dioxides</title><p>The unique biological properties of quinoxaline 1,4-dioxides have attracted significant interest from scientists for their use as an important scaffold for drug development. As mentioned earlier, aliphatic and aromatic <italic toggle="yes">N</italic>-oxides are known as prodrugs due to their ability to be reduced by various oxidoreductases expressed in bacterial and tumor cells. Moreover, the attention given to heterocyclic <italic toggle="yes">N</italic>-oxides, particularly quinoxaline derivatives, can be explained by the presence of this scaffold in natural bioactive compounds, such as iodinin, its analog myxin, echinomycin, and aspergilic acid [<xref rid="B121-pharmaceuticals-16-01174" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-16-01174" ref-type="bibr">122</xref>].</p><sec id="sec4dot1-pharmaceuticals-16-01174"><title>4.1. Antibacterial and Antifungal Activity of Quinoxaline 1,4-Dioxides</title><p>In 1938, the investigation of the biological properties of quinoxaline 1,4-dioxides started with the discovery of the antibacterial activity of its closest analog, iodinin [<xref rid="B123-pharmaceuticals-16-01174" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceuticals-16-01174" ref-type="bibr">124</xref>]. Subsequent studies have revealed that the mechanism of the antibacterial action of quinoxaline 1,4-dioxides is associated with the ability of heterocyclic <italic toggle="yes">N</italic>-oxides to reduction by oxidoreductases, leading to the generation of ROS, DNA damage, inhibition of DNA and RNA synthesis, morphological changes in the bacterial cell wall, as well as suppression of extracellular bacterial nuclease and &#x003b1;-toxin action [<xref rid="B125-pharmaceuticals-16-01174" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceuticals-16-01174" ref-type="bibr">126</xref>,<xref rid="B127-pharmaceuticals-16-01174" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceuticals-16-01174" ref-type="bibr">128</xref>]. Thus, the single-electron reduction of NADPH-dependent monooxygenases (P450) of quinoxaline 1,4-dioxide (<bold>28a</bold>, <xref rid="pharmaceuticals-16-01174-sch008" ref-type="fig">Scheme 8</xref>) leads to the formation of an oxygen-sensitive intermediate radical <bold>80</bold>, generating reactive hydroxyl radical and metabolite <bold>81</bold> (<xref rid="pharmaceuticals-16-01174-sch035" ref-type="fig">Scheme 35</xref>) [<xref rid="B129-pharmaceuticals-16-01174" ref-type="bibr">129</xref>].</p><p>The medicinal drugs in this class of heterocycles include quinoxidine and dioxidine (compounds <bold>3</bold> and <bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>), which were discovered in the 1970s and are still used in parenteral forms and in various topical drug formulations. Dioxidine (<bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) is a reserve drug for the treatment of purulent infections. Washing of burning and purulent-necrotic wounds with dioxidine promotes faster wound surface cleansing, stimulates wound regeneration, and enhances epithelization [<xref rid="B130-pharmaceuticals-16-01174" ref-type="bibr">130</xref>]. Quinoxidine (<bold>3</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) acts on both Gram-positive organisms (including <italic toggle="yes">Staphylococcus</italic> spp., resistant to other antimicrobial drugs) and Gram-negative bacteria (<italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. aeruginos</italic>, <italic toggle="yes">Proteus</italic> spp.). Dioxidine (<bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) causes loosening of the cell wall and agglomeration of DNA fibrils in <italic toggle="yes">Staphylococcus aureus</italic> cells [<xref rid="B113-pharmaceuticals-16-01174" ref-type="bibr">113</xref>]. In anaerobic conditions, the antibacterial activity of this drug increases by 8&#x02013;128 times, depending on the type of pathogen [<xref rid="B113-pharmaceuticals-16-01174" ref-type="bibr">113</xref>]. Dioxidine (<bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>) does not exhibit cross-resistance with other antimicrobial drugs. Recent studies have confirmed the low toxicity of dioxidine, including the absence of cardiotoxicity, immunotoxicity, and toxic effects on the adrenal glands and other organs, which makes it suitable for use as a new dosage form for the treatment of pharyngitis and tonsillitis [<xref rid="B131-pharmaceuticals-16-01174" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceuticals-16-01174" ref-type="bibr">132</xref>].</p><p>In the pursuit of quinoxaline 1,4-dioxides with antibacterial and antifungal activity, it has been shown that 2-phenylsulfonyl-substituted quinoxaline 1,4-dioxides hold promise for the development of new antimicrobial agents. Among the synthesized series, derivatives <bold>82a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-f006" ref-type="fig">Figure 6</xref>) demonstrated the highest activity against <italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">Enterococcus faecium</italic> strains, with MIC values ranging from 0.4 to 1.9 &#x003bc;g/mL [<xref rid="B133-pharmaceuticals-16-01174" ref-type="bibr">133</xref>].</p><p>A. Carta et al. have discovered promising derivatives with high anti-candida activity against <italic toggle="yes">Candida</italic> spp. The authors have demonstrated that the 2-chlorinated derivatives <bold>83a</bold>,<bold>b</bold> exhibit the highest antifungal activity (MIC = 0.39&#x02013;0.78 &#x003bc;g/mL, <xref rid="pharmaceuticals-16-01174-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B134-pharmaceuticals-16-01174" ref-type="bibr">134</xref>]. Furthermore, the water-soluble 3-trifluoromethyl derivatives <bold>27a</bold> and <bold>67c</bold> (<xref rid="pharmaceuticals-16-01174-f006" ref-type="fig">Figure 6</xref>) have shown antimicrobial activity against Gram-positive and Gram-negative bacteria and mycobacteria, comparable to reference drugs ciprofloxacin and rifampicin, with MIC values ranging from 0.25 to 10 &#x003bc;g/mL [<xref rid="B62-pharmaceuticals-16-01174" ref-type="bibr">62</xref>]. Additionally, compounds <bold>27a</bold> and <bold>67c</bold> demonstrated high antifungal activity comparable to amphotericin B against fungal cultures of <italic toggle="yes">C. albicans</italic> ATCC 10,231 and <italic toggle="yes">M. canis</italic> B-200. An analysis of the structure-activity relationship of the 3-trifluoromethylquinoxaline 1,4-dioxide series (for example, derivatives <bold>27a</bold> and <bold>67c</bold>, <xref rid="pharmaceuticals-16-01174-f006" ref-type="fig">Figure 6</xref>) revealed that the introduction of an additional piperazine residue negatively affects the antimicrobial properties of these compounds. Furthermore, substituents in position 2 of the quinoxaline core do not significantly influence the antimicrobial activity of such derivatives. In particular, 7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-dioxides demonstrated high activity against Gram-positive bacteria, while their effect on Gram-negative bacteria and fungi was noticeably lower.</p><p>The study of the mechanism of antibacterial action on the dual reporter test system pDualrep2 revealed that the 3-trifluoromethyl derivatives <bold>27a</bold>, <bold>67c</bold> (<xref rid="pharmaceuticals-16-01174-f006" ref-type="fig">Figure 6</xref>), as well as the reference dioxidine (<bold>4</bold>, <xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>), induced a bacterial SOS-response in the strain <italic toggle="yes">E. coli</italic> BW25513 [<xref rid="B62-pharmaceuticals-16-01174" ref-type="bibr">62</xref>].</p></sec><sec id="sec4dot2-pharmaceuticals-16-01174"><title>4.2. Antimycobacterial Activity of Quinoxaline 1,4-Dioxides</title><p>Previously, based on the structural similarity of quinoxaline 1,4-dioxides with vitamin K, which plays an important role in the metabolism of <italic toggle="yes">M. tuberculosis</italic> [<xref rid="B135-pharmaceuticals-16-01174" ref-type="bibr">135</xref>], A. Monge et al. tested a series of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides (<bold>62a</bold>, <bold>84</bold>, <bold>85</bold>, <xref rid="pharmaceuticals-16-01174-f007" ref-type="fig">Figure 7</xref>, <xref rid="pharmaceuticals-16-01174-sch025" ref-type="fig">Scheme 25</xref>) against clinical isolates of <italic toggle="yes">M. tuberculosis</italic> with MDR [<xref rid="B136-pharmaceuticals-16-01174" ref-type="bibr">136</xref>]. The screening results for antimycobacterial properties demonstrated high activity of some derivatives of this type (for example, compounds <bold>62a</bold>, <bold>84</bold>, <bold>85</bold>, <xref rid="pharmaceuticals-16-01174-f007" ref-type="fig">Figure 7</xref>) against <italic toggle="yes">M. tuberculosis</italic> H37Rv strain, highlighting the significant role of <italic toggle="yes">N</italic>-oxide fragments in their ability to inhibit the growth of the mycobacterium [<xref rid="B137-pharmaceuticals-16-01174" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceuticals-16-01174" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceuticals-16-01174" ref-type="bibr">139</xref>]. Moreover, compound <bold>62a</bold> exhibited a high selectivity index (SI) (SI = IC<sub>50,Vero</sub>/MIC &#x0003e; 124).</p><p>The replacement of the nitrile group at position 2 of quinoxaline with a carboxamide moiety, acyl, or carboxyl groups increased the inhibitory potency and, more importantly, reduced the cytotoxicity of such derivatives by an order of magnitude (<bold>21b</bold>&#x02013;<bold>e</bold>, <bold>22b</bold>&#x02013;<bold>d</bold>, <bold>86</bold>&#x02013;<bold>87a</bold>&#x02013;<bold>c</bold>, <xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>) [<xref rid="B140-pharmaceuticals-16-01174" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceuticals-16-01174" ref-type="bibr">141</xref>]. Among the 2-carboxamide derivatives, compounds <bold>62a</bold> and <bold>84</bold>, <bold>85</bold> were the most active (<xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>), with MIC values of 0.89, 0.42, and 0.14 &#x003bc;g/mL, respectively. In the series of 2-acyl derivatives, 2-acetylquinoxaline 1,4-dioxides <bold>21b</bold>&#x02013;<bold>e</bold> showed the highest activity (<xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>), although these derivatives had slightly higher MIC values (0.87, 3.13, 0.8, and 4.3 &#x003bc;g/mL, respectively) compared to their analogs with carboxamide (compounds <bold>62a</bold>, <bold>84</bold>, <bold>85</bold>) and ester (compounds <bold>22b</bold>&#x02013;<bold>d</bold>, <bold>87a</bold>&#x02013;<bold>c</bold>) groups. The quinoxaline-2-carboxylates <bold>22b</bold>&#x02013;<bold>d</bold> and <bold>87a</bold>&#x02013;<bold>c</bold> exhibited the highest activity against <italic toggle="yes">M. tuberculosis</italic> H37Rv among all tested derivatives (MIC = 0.56, 2.30, 1.50, and 0.01 &#x003bc;g/mL, respectively), surpassing the reference drug rifampicin in activity. Notably, compounds <bold>87b</bold> and <bold>87c</bold> showed activity against the majority of tested strains of <italic toggle="yes">M. tuberculosis</italic> with MDR.</p><p>Some studies have demonstrated that 3-alkylquinoxaline 1,4-dioxides with carboxamide (compounds <bold>86a</bold>&#x02013;<bold>c</bold>), acyl (compounds <bold>21b</bold>&#x02013;<bold>e</bold>), alkoxycarbonyl (compounds <bold>22b</bold>&#x02013;<bold>d</bold>, <bold>87a</bold>&#x02013;<bold>c</bold>), or thioaryl (compound <bold>88a</bold>) substituents at position 2 also possess high antituberculosis activity (<xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>) [<xref rid="B142-pharmaceuticals-16-01174" ref-type="bibr">142</xref>]. Compound <bold>88a</bold> exhibited moderate MIC values (30&#x02013;60 &#x003bc;g/mL); however, in bacteriostatic concentrations, it acted synergistically with isoniazid, reducing its MIC by more than two orders of magnitude [<xref rid="B143-pharmaceuticals-16-01174" ref-type="bibr">143</xref>]. </p><p>Compounds <bold>65b</bold>&#x02013;<bold>d</bold> (<xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>) demonstrated high antimycobacterial activity against <italic toggle="yes">M. tuberculosis</italic> H37Rv, as well as low cytotoxicity for non-tumor cells (MIC &#x02264; 0.25 &#x003bc;g/mL, SI<sub>(Vero)</sub> = 169&#x02013;412) [<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>]. The 6-(1,3,4-triazol-1-yl) substituted derivative <bold>65d</bold> showed the highest antitubercular activity in a model of macrophages infected with <italic toggle="yes">M. tuberculosis</italic>. Additionally, compound <bold>65d</bold> disrupted the integrity of membranes and energy homeostasis of <italic toggle="yes">M. tuberculosis</italic> and significantly increased the level of ROS in eukaryotic cells. Consequently, it induced autophagy in infected macrophages, suggesting an indirect blockage of intracellular replication of <italic toggle="yes">M. tuberculosis</italic>. Pharmacological studies in vivo demonstrated that compound <bold>65d</bold> was reasonably safe and possessed favorable pharmacokinetic properties.</p><p>The analysis of the obtained data for 2-carbonyl-containing quinoxaline 1,4-dioxides (for example, compounds <bold>21a</bold>&#x02013;<bold>e</bold>; <bold>22b</bold>&#x02013;<bold>d</bold>; <bold>87a</bold>&#x02013;<bold>c</bold> and <bold>65b</bold>&#x02013;<bold>d</bold>, <xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>) revealed that the acetyl group at position 2 of the quinoxaline led to moderate to good antimycobacterial activity. Replacement of this moiety with a butyryl or isovaleryl group dramatically reduced the activity. However, the ethoxycarbonyl group at the C<sub>2</sub> carbon atom of the quinoxaline ring generally enhanced antimycobacterial activity. In contrast, a benzyl analog did not alter the activity of such derivatives. Nevertheless, the introduction of an isopropyl ester group at the 2 position leads to a significant decrease in antimycobacterial activity. Moreover, the presence of a piperidine, morpholine, or pyrrolidine group in the structure of derivatives containing a 2-carbonyl fragment negatively affected the activity against the <italic toggle="yes">M. tuberculosis</italic> strain. Interestingly, the introduction of an imidazole or a 1,2,4-triazole group at position 6 of the heterocyclic ring resulted in a significant increase in the anti-TB potency of the corresponding compounds (derivatives <bold>65b</bold>&#x02013;<bold>d</bold>, <xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>). This indicates that an aromatic nitrogen heterocyclic group attached to the C6 carbon atom may be beneficial for activity.</p><p>Compound <bold>40b</bold> (<xref rid="pharmaceuticals-16-01174-f008" ref-type="fig">Figure 8</xref>) exhibited high antituberculosis activity (IC<sub>50</sub> = 1.6 &#x003bc;g/mL) against <italic toggle="yes">M. tuberculosis</italic> H37Rv and showed high selectivity with weak cytotoxic effect (SI = 60.6) on non-tumor cells (Vero cells) [<xref rid="B85-pharmaceuticals-16-01174" ref-type="bibr">85</xref>].</p></sec><sec id="sec4dot3-pharmaceuticals-16-01174"><title>4.3. Antiparasitic Activity of Quinoxaline 1,4-Dioxides</title><p>The resistance of parasites belonging to the <italic toggle="yes">Plasmodium</italic> genus, including <italic toggle="yes">Plasmodium falciparum</italic>, to antimalarial drugs such as chloroquine, mefloquine, and artemisin-based combination therapy, poses a significant challenge in the treatment and control of malaria [<xref rid="B144-pharmaceuticals-16-01174" ref-type="bibr">144</xref>]. A. Monge et al. have developed a series of quinoxaline 1,4-dioxides that exhibit activity against <italic toggle="yes">P. falciparum</italic>, both in vitro and in vivo [<xref rid="B145-pharmaceuticals-16-01174" ref-type="bibr">145</xref>]. Based on the SAR analysis, the authors have several derivatives with high activity against chloroquine-resistant <italic toggle="yes">P. falciparum</italic> FcB1 strain, including compounds <bold>32c</bold>, <bold>62c</bold>&#x02013;<bold>d</bold>, <bold>88b</bold>&#x02013;<bold>d</bold>, and <bold>89a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>) [<xref rid="B146-pharmaceuticals-16-01174" ref-type="bibr">146</xref>]. Among these, the 2-carbonitrile derivatives <bold>89a</bold> and <bold>89b</bold> (<xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>) showed the highest activity, with an IC<sub>50</sub> of 5&#x02013;6 &#x003bc;M against <italic toggle="yes">P. falciparum</italic>. In an in vivo experiment using Rj:SWISS (IOPs Orl) mice infected with a resistant strain of <italic toggle="yes">Plasmodium berghei</italic> NK65 Vincke and Lips 1948 was shown that at four times administration of 20 mg/kg of derivatives <bold>89a</bold> and <bold>89b</bold> led to a suppression of parasitemia by 70% and 88% on the fifth day, respectively. However, increasing the dosage of the tested substances resulted in the toxic death of animals.</p><p>Mechanistic studies have shown that quinoxaline 1,4-dioxide derivatives act as irreversible inhibitors of peroxiredoxin-2 and exhibit strong lytic activity against <italic toggle="yes">Plasmodium</italic> spp. [<xref rid="B147-pharmaceuticals-16-01174" ref-type="bibr">147</xref>].</p><p>A. Monge et al. have recently disclosed the antileishmaniasis activity of 3-acylaminoquinoxaline-2-carbonitrile 1,4-dioxides (for example, derivatives <bold>90</bold>, <bold>91</bold>) [<xref rid="B148-pharmaceuticals-16-01174" ref-type="bibr">148</xref>,<xref rid="B149-pharmaceuticals-16-01174" ref-type="bibr">149</xref>]. Among tested compounds, <bold>90</bold>, <bold>91</bold> (<xref rid="pharmaceuticals-16-01174-f010" ref-type="fig">Figure 10</xref>) exhibited the most activity against both amastigote and promastigote forms of <italic toggle="yes">Leishmania amazonensis</italic> while showing relatively low cytotoxicity for mammalian cells. In vitro and in silico studies revealed some structure-activity relationship correlations. First of all, the presence of a halogen atom at position 7 of quinoxaline was found to be critical for anti-leishmaniasis activity. Additionally, electron-donating substituents at position 7 were shown to reduce the potency of such derivatives by an order of magnitude. K.F. Chac&#x000f3;n-Vargas et al. described a series of 7-isopropoxycarbonyl-substituted derivatives that inhibit the growth of amastigotes of <italic toggle="yes">Leishmania mexicana</italic>, with compounds <bold>92</bold>, <bold>93</bold> demonstrating the highest activity and selectivity against this parasite [<xref rid="B150-pharmaceuticals-16-01174" ref-type="bibr">150</xref>].</p><p>Further studies have revealed high activity against the causative agent of amoebiasis, Entamoeba histolytica, for certain quinoxaline 1,4-dioxides [<xref rid="B151-pharmaceuticals-16-01174" ref-type="bibr">151</xref>,<xref rid="B152-pharmaceuticals-16-01174" ref-type="bibr">152</xref>]. The A. Monge group designed and synthesized a library of 2-acyl-3-methylquinoxaline 1,4-dioxides. Notably, compounds containing the thienyl fragment at position 2, as well as electron-withdrawing groups in the benzene ring of quinoxaline, exhibited the highest antiamoebic potency [<xref rid="B151-pharmaceuticals-16-01174" ref-type="bibr">151</xref>]. The most active compound was 3-trifluoromethyl quinoxaline 1,4-dioxide <bold>94</bold> (<xref rid="pharmaceuticals-16-01174-f011" ref-type="fig">Figure 11</xref>) with an IC<sub>50</sub> value of 0.35 &#x003bc;M, although it showed relatively low selectivity for mammalian cells (SI [IC<sub>50(Vero cells)</sub>/IC<sub>50(<italic toggle="yes">E. histolytica</italic>)</sub>] = 16.7). The 3-methyl analog (compound <bold>95</bold>, <xref rid="pharmaceuticals-16-01174-f011" ref-type="fig">Figure 11</xref>) was four times less active than the 3-trifluoromethyl derivative <bold>94</bold> (IC<sub>50</sub> = 1.4 &#x003bc;M, <italic toggle="yes">E. histolytica</italic>), but it displayed a higher selectivity index (SI &#x0003e; 60).</p><p>A. Carta et al. also observed the antitrichomonas activity of 6,7-difluoro-3-methylquinoxaline 1,4-dioxides, including compounds <bold>90b</bold> and <bold>96</bold> (<xref rid="pharmaceuticals-16-01174-f012" ref-type="fig">Figure 12</xref>) [<xref rid="B142-pharmaceuticals-16-01174" ref-type="bibr">142</xref>]. It was found that 2-phenylthio derivatives of 3-methylquinoxaline 1,4-dioxide exhibited 20&#x02013;30 times higher activity than the reference drug metronidazole against the protist parasite <italic toggle="yes">Trichomonas vaginalis</italic> SS22. For instance, the derivative <bold>90b</bold> suppressed the growth of the protozoan at submicromolar concentrations (IC<sub>50</sub> = 0.4 &#x003bc;M). Interestingly, sulfone <bold>96</bold> (<xref rid="pharmaceuticals-16-01174-f012" ref-type="fig">Figure 12</xref>) [<xref rid="B153-pharmaceuticals-16-01174" ref-type="bibr">153</xref>] displayed four times lower activity (IC<sub>50</sub> = 1.6 &#x003bc;M) than the non-oxidized analog <bold>90b</bold>, but it more effectively blocked the growth of <italic toggle="yes">T. vaginalis</italic> compared to the reference drug metronidazole (IC<sub>50</sub> = 12.5 &#x003bc;M).</p><p>E. Torres and co-authors developed a series of quinoxaline 1,4-dioxides with activity against <italic toggle="yes">Trypanosoma cruzi</italic>, the causative agent of trypanosomiasis (Chagas disease), contained at position 2, the carbonitrile fragment, carboxyl or ester groups [<xref rid="B154-pharmaceuticals-16-01174" ref-type="bibr">154</xref>]. The evaluation of the biological properties of the synthesized compounds revealed promising derivatives (for example, compounds <bold>53c</bold>, <bold>97</bold>, <xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>, [<xref rid="B155-pharmaceuticals-16-01174" ref-type="bibr">155</xref>]) with high activity against <italic toggle="yes">T. cruzi</italic>. It is shown that derivatives <bold>53c</bold>, <bold>97</bold> (<xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>) exhibited IC<sub>50</sub> values similar to the reference drug nifurtimox with a selectivity index SI &#x0003e; 10. The authors conducted a SAR analysis, revealing that electron-withdrawing substituents at position 3 and, more critically, at position 6 and/or 7 of quinoxaline play a key role in the inhibitory ability of these derivatives. Conversely, the introduction of electron-donating groups into the heterocyclic nucleus led to a decrease in the trypanosomicidal activity of quinoxaline 1,4-dioxides. The proposed mechanism of antitrypanosomal activity of the lead compounds <bold>53c</bold> and <bold>97</bold> (<xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>) is based on the inhibition of mitochondrial dehydrogenases in <italic toggle="yes">T. cruzi</italic> cells.</p><p>Derivatives <bold>67d</bold>&#x02013;<bold>f</bold> (<xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>) also exhibited high antiparasitic activity against epimastigotes of <italic toggle="yes">T. cruzi</italic>, with IC<sub>50</sub> &#x0003c; 1.5 &#x003bc;M, surpassing the activity of reference drugs nifurtimox and benznidazole [<xref rid="B116-pharmaceuticals-16-01174" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceuticals-16-01174" ref-type="bibr">117</xref>].</p><p>The study of the relationship between structure and antiparasitic activity revealed the key role of the nitrile group at position 2 of quinoxaline 1,4-dioxide (for example, derivatives <bold>53c</bold>; <bold>89a</bold>,<bold>b</bold>; <bold>62c</bold>,<bold>d</bold>; <bold>90</bold>; <bold>91</bold>, <xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>, <xref rid="pharmaceuticals-16-01174-f010" ref-type="fig">Figure 10</xref> and <xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>). It should be noted that similar to the antitumor activity of such derivatives, replacing the carbonitrile group with carboxyl and carboxamide groups, which have close electronic influences, leads to a partial or complete loss of the activity of the compounds. It was found that the substituents at position 3 of the heterocycle also play an important role in the antiparasitic properties of quinoxaline 1,4-dioxides. In general, the presence of an aromatic fragment at the C<sub>3</sub> carbon atom of quinoxaline 1,4-dioxides significantly increases the activity of such derivatives. Furthermore, electron-donating substituents at position 3 of the heterocycle positively affect the ability of the compounds to block the growth of protozoa and enhance the selectivity indexes of such derivatives against parasites. Additionally, the introduction of a halogen atom into the benzene ring of quinoxaline leads to an increased ability of the compounds to suppress the growth of parasites.</p></sec><sec id="sec4dot4-pharmaceuticals-16-01174"><title>4.4. Anticancer Properties of Quinoxaline 1,4-Dioxides</title><p>It is known that quinoxaline-2-carbonitrile 1,4-dioxides have high antiproliferative activity against tumor cells of various histogenesis, and their activity increases in hypoxia. A voltammetric study of the electrochemical properties of series derivatives has shown that the introduction of electron-withdrawing groups into the benzene ring of quinoxaline is accompanied by a significant shift of the redox potential to the positive region. This shift correlates with an increase in the cytotoxicity of such compounds under hypoxia [<xref rid="B156-pharmaceuticals-16-01174" ref-type="bibr">156</xref>]. Taking into account the results of electrochemical studies, U. Das et al. synthesized 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides <bold>19a</bold>&#x02013;<bold>f</bold> (<xref rid="pharmaceuticals-16-01174-f014" ref-type="fig">Figure 14</xref>), which selectively induced tumor cells death under hypoxic conditions with low cytotoxicity against non-malignant cells [<xref rid="B157-pharmaceuticals-16-01174" ref-type="bibr">157</xref>]. Further optimization of the structure of quinoxalines <bold>19a</bold>&#x02013;<bold>f</bold> by introducing aminoalkylamino-groups into position 3 of quinoxaline (compounds <bold>98a</bold>&#x02013;<bold>d</bold>, <xref rid="pharmaceuticals-16-01174-f013" ref-type="fig">Figure 13</xref>) leads to an increase in the water solubility of such derivatives while retaining the high antitumor activity of the compounds [<xref rid="B158-pharmaceuticals-16-01174" ref-type="bibr">158</xref>]. It should also be noted that the coordination complexes of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides <bold>59</bold> and <bold>60</bold> with metals (<xref rid="pharmaceuticals-16-01174-sch024" ref-type="fig">Scheme 24</xref>) exhibit high antiproliferative activity against solid tumor cells, with improved bioavailability and toxicity properties [<xref rid="B159-pharmaceuticals-16-01174" ref-type="bibr">159</xref>].</p><p>H.U. Gali-Muhtasib et al. [<xref rid="B160-pharmaceuticals-16-01174" ref-type="bibr">160</xref>] have shown that compounds <bold>21f</bold>, <bold>99a</bold>,<bold>b</bold> (<xref rid="pharmaceuticals-16-01174-f015" ref-type="fig">Figure 15</xref>) induce apoptosis and inhibit the growth of colon carcinoma cells T-84 at micromolar concentrations, as well as inhibit the cell cycle in both normoxia and hypoxia. Compounds <bold>21f</bold>, <bold>99a</bold>,<bold>b</bold> were found to increase transcript levels of apoptotic transforming growth factor &#x003b2;1 (TGF-&#x003b2;1) and decrease the level of TGF-&#x003b1; mRNA. In addition, derivatives <bold>21f</bold>, <bold>99a</bold>,<bold>b</bold> suppress the expression of the antiapoptotic protein gene Bcl-2a and increase the expression level of proapoptotic proteins p53 and p21, which are key mediators that cause apoptosis and cell cycle blocking.</p><p>H.U. Gali-Muhtasib et al. observed the effect of quinoxaline 1,4-dioxides on the expression of mRNA transcription factor HIF-1<italic toggle="yes">&#x003b1;</italic> in T-cell leukemia [<xref rid="B161-pharmaceuticals-16-01174" ref-type="bibr">161</xref>]. It is known that the 1&#x003b1; subunit of the heterodimeric transcription factor HIF regulates a metabolic adaptation to oxygen deficiency and plays an important role in the transcriptional activation of genes involved in angiogenesis. The screening results showed that compounds <bold>99a</bold> and <bold>99b</bold> (<xref rid="pharmaceuticals-16-01174-f015" ref-type="fig">Figure 15</xref>) effectively reduce the expression of HIF-1a mRNA, while their non-chlorinated analog <bold>21f</bold> does not affect the expression of the HIF-1<italic toggle="yes">&#x003b1;</italic> gene [<xref rid="B162-pharmaceuticals-16-01174" ref-type="bibr">162</xref>]. It was also found that compound <bold>99a</bold> induces the arrest of the cells in G2/M-phases and inhibits the expression of cyclin B, causing apoptosis of tumor cells. The derivative <bold>99a</bold> reduces the level of expression of the Bcl-2<italic toggle="yes">&#x003b1;</italic> gene encoding the antiapoptotic Bcl-2<italic toggle="yes">&#x003b1;</italic> protein and increases the expression of the proapoptotic BAX protein [<xref rid="B163-pharmaceuticals-16-01174" ref-type="bibr">163</xref>]. </p><p>In 2008, Weng Q. et al. [<xref rid="B164-pharmaceuticals-16-01174" ref-type="bibr">164</xref>] found a highly active derivative <bold>100</bold> (<xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) capable of inhibiting the growth of a wide panel of tumor cell lines at low concentrations (IC<sub>50</sub> = 0.2&#x02013;8.9 &#x000b5;M) under hypoxic conditions. Recent studies, including virtual screening, the synthesis of polysubstituted derivatives, and the evaluation of their biological activity, have led to the discovery of a series of 3-phenylquinoxaline-2-carbonitrile 1,4-dioxides (compounds <bold>26c</bold>, <bold>63a</bold>, <bold>64a</bold> and <bold>64d</bold>, <xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>,<xref rid="B165-pharmaceuticals-16-01174" ref-type="bibr">165</xref>], which exhibit remarkable cytotoxicity. It was shown that compound <bold>63a</bold> (<xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) induces apoptosis in human tumor cells of various histogenesis. Moreover, lead compounds <bold>26c</bold> and <bold>64a</bold>,<bold>d</bold> (<xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) have in one order highest activity and selectivity under hypoxic conditions than the reference antitumor hypoxic cytotoxin tirapazamine [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>].</p><p>Analysis of the structure-activity relationship in a series of antitumor agents based on quinoxaline 1,4-dioxide reveals an essential role for the carbonitrile group at position 2 of the heterocyclic ring (for example, derivatives <bold>19a</bold>&#x02013;<bold>f</bold>; <bold>26c</bold>; <bold>63a</bold>; <bold>64a</bold>,<bold>d</bold>; <bold>98a</bold>&#x02013;<bold>d</bold>, <xref rid="pharmaceuticals-16-01174-f014" ref-type="fig">Figure 14</xref> and <xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>). Additionally, substituents at position 3 of the heterocycle are equally important for the antiproliferative properties of quinoxaline 1,4-dioxides. Among these compounds, congeners with a benzene ring at position 3 of the quinoxaline (such as compounds <bold>21f</bold>; <bold>26c</bold>; <bold>63a</bold>; <bold>64a</bold>,<bold>d</bold>; <bold>99a</bold>,<bold>b</bold>; <bold>100</bold>, <xref rid="pharmaceuticals-16-01174-f015" ref-type="fig">Figure 15</xref> and <xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) exhibit the highest activity, whereas compounds with different substituents in this position (for example, compounds <bold>19a</bold>&#x02013;<bold>f</bold>; <bold>98a</bold>&#x02013;<bold>d</bold>, <xref rid="pharmaceuticals-16-01174-f014" ref-type="fig">Figure 14</xref>) show lower levels of activity. Another crucial factor for the ability of compounds to inhibit tumor cell growth under both normoxic and hypoxic conditions is the nature and location of substituents at positions 6 and 7 of quinoxaline 1,4-dioxide. Introduction of linear diamines into the benzene ring of quinoxaline results in a complete loss of antiproliferative activity, whereas the presence of cyclic diamines significantly increases activity, particularly under hypoxic conditions. Notably, derivatives containing substituents at position 7 of quinoxaline exhibit noticeably higher activity compared to their corresponding regioisomeric analogs with substituents at position 6. Furthermore, the introduction of a halogen atom into the quinoxaline structure positively affects the ability of compounds to inhibit tumor cell growth. Remarkably, the addition of a chlorine atom proves to be the most crucial modification for enhancing the hypoxic cytotoxicity of quinoxaline 1,4-dioxide derivatives.</p><p>Compounds <bold>26c</bold> and <bold>64a</bold>,<bold>d</bold> are also able to induce apoptosis in the myelogenous leukemia cell line and its doxorubicin-resistant subline K562/4 cell with the expression of P-glycoprotein (P-gp) [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>].</p></sec></sec><sec id="sec5-pharmaceuticals-16-01174"><title>5. Targeting Signaling Pathways in Cells by Quinoxaline 1,4-Dioxide Derivatives</title><p>The search for ways to selectively induce tumor cell death is one of the key goals in the development of new anticancer drugs. Therefore, the discovery of the hypoxia-selective cytotoxic mode of action of quinoxaline 1,4-dioxides stimulated further study of the mechanisms of their antitumor activity. It has been shown that, similarly to the antibacterial action, the antitumor potency of quinoxaline 1,4-dioxides is associated with their bioreduction in tumor cells by reductases expressed under hypoxic conditions, leading to the generation of ROS and the damage of DNA in malignant cells [<xref rid="B166-pharmaceuticals-16-01174" ref-type="bibr">166</xref>,<xref rid="B167-pharmaceuticals-16-01174" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceuticals-16-01174" ref-type="bibr">168</xref>].</p><p>As noted above, quinoxaline 1,4-dioxide derivatives are able to trigger a cascade of various proapoptotic processes and suppress the mechanisms of cell resistance to xenobiotics [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>,<xref rid="B165-pharmaceuticals-16-01174" ref-type="bibr">165</xref>]. It has been shown that quinoxaline derivatives induce tumor cell death via apoptosis [<xref rid="B169-pharmaceuticals-16-01174" ref-type="bibr">169</xref>,<xref rid="B170-pharmaceuticals-16-01174" ref-type="bibr">170</xref>,<xref rid="B171-pharmaceuticals-16-01174" ref-type="bibr">171</xref>]. Additionally, due to the outstanding hypoxic selectivity of several quinoxaline 1,4-dioxides, this class has a high potential for the development of drugs for the targeted treatment of solid tumors. Thus, previous works [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B114-pharmaceuticals-16-01174" ref-type="bibr">114</xref>,<xref rid="B165-pharmaceuticals-16-01174" ref-type="bibr">165</xref>] have shown that the hypoxic selectivity of compounds <bold>26c</bold>, <bold>64a</bold>,<bold>d</bold>, and <bold>99b</bold> (<xref rid="pharmaceuticals-16-01174-sch012" ref-type="fig">Scheme 12</xref>, <xref rid="pharmaceuticals-16-01174-f015" ref-type="fig">Figure 15</xref> and <xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) is associated with the inhibition of expression and activity of the hypoxia-induced factor HIF-1&#x003b1; in tumor cells. At the same time, amino derivatives <bold>26c</bold> and <bold>64a</bold>,<bold>d</bold> have a significant effect on the signaling pathways of the estrogen receptor ER&#x003b1;, which supports the growth of hormone-dependent tumor cells MCF-7 and can be considered as double blockers of HIF-1&#x003b1;/ER&#x003b1;, modulating the activity of the HIF-1&#x003b1; and ERK1/2 signaling pathways. In addition, the induction of apoptosis in HCT-116p53KO tumor cells with a deletion of the tumor suppressor p53, observed for derivative <bold>63a</bold> [<xref rid="B60-pharmaceuticals-16-01174" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>], is evidence that tumor cell death induced by quinoxaline 1,4-dioxides can proceed via a p53-independent mechanism [<xref rid="B165-pharmaceuticals-16-01174" ref-type="bibr">165</xref>,<xref rid="B171-pharmaceuticals-16-01174" ref-type="bibr">171</xref>].</p><p>The compounds <bold>100</bold> (<xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) and <bold>99b</bold> (<xref rid="pharmaceuticals-16-01174-f015" ref-type="fig">Figure 15</xref>) could reduce the expression of vascular endothelial growth factor (VEGF) under hypoxic conditions. Quincetone (<bold>104</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) and derivative <bold>100</bold> (<xref rid="pharmaceuticals-16-01174-f016" ref-type="fig">Figure 16</xref>) also down-regulated the expression of mitogen-activated protein kinases (MAPKs) involved in the mitochondrial apoptosis pathway. When studying the molecular mechanisms of action of olaquindox, D. Li and co-workers found that it can induce DNA damage and S-phase arrest, contributing to an increase in the expression of GADD45a, cyclin A, Cdk2, p21, and p53, a decrease in cyclin D1, as well as activation of phosphorylation of c-Jun <italic toggle="yes">N</italic>-terminal kinases (p-JNK), p38 (p-p38), and extracellular signal-regulated kinases (p-ERK) [<xref rid="B172-pharmaceuticals-16-01174" ref-type="bibr">172</xref>].</p><p>The A. Monge group found that the leishmanicidal activity of compound <bold>92</bold> (<xref rid="pharmaceuticals-16-01174-f010" ref-type="fig">Figure 10</xref>) is associated with the induction of necrosis of <italic toggle="yes">L. mexicana</italic> caused by ROS production, leading to damage to the cell membrane, phosphatidylserine flip-flop, disruption of the mitochondrial membrane potential, and subsequent fragmentation of the parasite DNA [<xref rid="B173-pharmaceuticals-16-01174" ref-type="bibr">173</xref>]. The study of the mechanism of antiparasitic action showed that thioredoxin reductase (EhTrxR) is the main biological target of quinoxaline 1,4-dioxides in the cells of <italic toggle="yes">E. histolytica</italic> [<xref rid="B174-pharmaceuticals-16-01174" ref-type="bibr">174</xref>]. Compound <bold>95</bold> (<xref rid="pharmaceuticals-16-01174-f011" ref-type="fig">Figure 11</xref>) acts as a substrate that disrupts the electron transfer in the active site of the EhTrxR enzyme, which leads to an increase in ROS levels and induces oxidative stress, causing changes in chromatin, cell granularity, and the redistribution of vacuoles.</p></sec><sec id="sec6-pharmaceuticals-16-01174"><title>6. Agricultural Use of Quinoxaline 1,4-Dioxide Derivatives</title><p>Quinoxaline 1,4-dioxide derivatives have been used for over 50 years as animal growth promoters, significantly improving feed efficiency in animal husbandry [<xref rid="B175-pharmaceuticals-16-01174" ref-type="bibr">175</xref>]. The most well-known compounds (<bold>101</bold>&#x02013;<bold>104</bold>) are shown in <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref> [<xref rid="B176-pharmaceuticals-16-01174" ref-type="bibr">176</xref>,<xref rid="B177-pharmaceuticals-16-01174" ref-type="bibr">177</xref>].</p><p>Carbadox (CARB, <bold>101</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) acts on Gram-positive bacteria but is inactive against Gram-negative bacteria. It was patented by Pfizer in 1968. As a feed additive, it stimulates the growth of pigs and is also used to control swine dysentery (caused by <italic toggle="yes">Serpulina hyodysenteriae</italic>), bacterial enteritis (caused by <italic toggle="yes">Salmonella</italic> spp.), and nasal infections (caused by <italic toggle="yes">Bordetella bronchiseptica</italic>) [<xref rid="B178-pharmaceuticals-16-01174" ref-type="bibr">178</xref>]. Carbadox improves the retention of dietary proteins [<xref rid="B23-pharmaceuticals-16-01174" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-16-01174" ref-type="bibr">24</xref>] and increases the ratio of RNA to DNA and protein to DNA in the lean muscles of young pigs [<xref rid="B179-pharmaceuticals-16-01174" ref-type="bibr">179</xref>]. Additionally, it reduces the energy requirement of the gastrointestinal tract, spleen, and pancreas in pigs [<xref rid="B180-pharmaceuticals-16-01174" ref-type="bibr">180</xref>]. However, the use of carbadox as a feed additive for livestock has been banned in Canada and the EU since 2004 due to the experimental evidence showing its carcinogenic and genotoxic properties [<xref rid="B181-pharmaceuticals-16-01174" ref-type="bibr">181</xref>]. Nonetheless, it is still used as a therapeutic and preventive agent in the treatment of bacterial enteritis of pigs and porcine dysentery caused by <italic toggle="yes">B. hyodysenteriae</italic> in the United States, Canada, and some other countries.</p><p>Olaquindox (OLAQ, <bold>102</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>), developed by Bayer in 1967, is used to stimulate the growth of pigs. The drug improves the functioning of the gastrointestinal tract in animals, suppressing pathogenic Gram-positive and Gram-negative microflora. It is also used to prevent swine dysentery caused by <italic toggle="yes">B. hyodysenteriae</italic> [<xref rid="B182-pharmaceuticals-16-01174" ref-type="bibr">182</xref>]. Carbadox (<bold>101</bold>) and olaquindox (<bold>102</bold>) can irritate mucous membranes and cause superficial dermatitis and photoallergic reactions in animals [<xref rid="B183-pharmaceuticals-16-01174" ref-type="bibr">183</xref>].</p><p>Studies have shown that quinoxaline 1,4-dioxide derivatives are not present in meat after 10 days of keeping pigs before slaughter. Furthermore, carbadox and olaquindox exhibit low acute toxicity [<xref rid="B183-pharmaceuticals-16-01174" ref-type="bibr">183</xref>]. The LD<sub>50</sub> for administration of carbadox peros in rats is 850 mg/kg, and in mice, it is 2810 mg/kg. Olaquindox (<bold>102</bold>) is somewhat less toxic, with an oral LD<sub>50</sub> for rabbits ranging from 1000 to 2000 mg/kg and about 1600 mg/kg for rats. The subcutaneous LD<sub>50</sub> of olaquindox in rats is 1275 mg/kg. However, both carbadox and olaquindox have shown genotoxicity using in vitro and in vivo studies. Carbadox (<bold>101</bold>) induced chromosome damage in human lymphocytes, and olaquindox damaged DNA in Chinese hamster cell culture. Additionally, carbadox (<bold>101</bold>) and olaquindox (<bold>102</bold>) caused an increase in the number of micronuclear polychromatic erythrocytes in the bone marrow of rats, indicating their genotoxicity in animals. The metabolites of carbadox (<bold>101</bold>) and olaquindox (<bold>102</bold>) could potentially be carcinogenic, thus requiring careful monitoring of their content in the meat and animal fat.</p><p>Mequindox (MEQ, <bold>21b</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>), created by Pfizer, exhibits high antibacterial activity against Gram-negative bacteria, particularly <italic toggle="yes">Salmonella</italic> spp., and is widely used in China as a feed additive for animals and as a veterinary drug for dysentery and white diarrhea in pigs [<xref rid="B184-pharmaceuticals-16-01174" ref-type="bibr">184</xref>].</p><p>Quincetone (QUIN, <bold>103</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>), developed by the Lanzhou Institute of Animal Husbandry and Veterinary Drugs (Chinese Academy of Agricultural Sciences, Lanzhou, China), is active against <italic toggle="yes">B. hyodysenteriae</italic>, <italic toggle="yes">Salmonella</italic> spp., <italic toggle="yes">E. coli</italic>, and other Gram-negative bacilli. Quincetone (<bold>103</bold>) is approved as an animal growth promoter in China and has been used in swine, poultry, and aquaculture since 2003 [<xref rid="B185-pharmaceuticals-16-01174" ref-type="bibr">185</xref>].</p><p>Cyadox (CYAD, <bold>104</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>), described by Chemapol Benelux, exhibits antibacterial activity against <italic toggle="yes">Staphylococcus hyicus</italic>, <italic toggle="yes">Pasteurella multocida</italic>, <italic toggle="yes">E. coli</italic> and also shows a beneficial effect as a growth promoter in broiler chickens and pigs. Cyadox (<bold>104</bold>) has low toxicity and high safety, making it a potential substituent for olaquindox (<bold>102</bold>) and carbadox (<bold>101</bold>) in animal husbandry [<xref rid="B186-pharmaceuticals-16-01174" ref-type="bibr">186</xref>].</p><p>Several quinoxaline 1,4-dioxide derivatives, such as compounds <bold>105</bold> and <bold>106</bold> (<xref rid="pharmaceuticals-16-01174-f018" ref-type="fig">Figure 18</xref>), have shown herbicidal activity against dicotyledonous and cereal plants by disrupting the functioning of photosystem I [<xref rid="B187-pharmaceuticals-16-01174" ref-type="bibr">187</xref>]. Due to the presence of two <italic toggle="yes">N</italic>-oxide groups, compounds <bold>105</bold> and <bold>106</bold> compete with NADP<sup>+</sup> in the active site of ferredoxin-NADP<sup>+</sup> reductase, initiating numerous oxidative transformations in plant cells, leading to their death.</p><p>In conclusion, the synthetic availability and the ability to modulate desired pharmacological properties make quinoxaline 1,4-dioxide derivatives as a promising class of heterocyclic compounds for the development of new agrochemical agents.</p></sec><sec id="sec7-pharmaceuticals-16-01174"><title>7. Toxicological Properties of Quinoxaline 1,4-Dioxides</title><p>The ability of quinoxaline 1,4-dioxides to generate ROS in cells, thereby inducing DNA single- or double-stranded breaks, also underlies their mutagenic action. For example, T. Negishi and co-workers proved the mutagenicity of compounds <bold>101</bold>&#x02013;<bold>104</bold> (<xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) and <bold>3</bold> (<xref rid="pharmaceuticals-16-01174-f002" ref-type="fig">Figure 2</xref>), as well as some other quinoxaline 1,4-dioxides, on <italic toggle="yes">Salmonella typhimurium</italic> TA 98 and TA 100 strains [<xref rid="B188-pharmaceuticals-16-01174" ref-type="bibr">188</xref>]. It was shown that the mutagenicity of quinoxaline 1,4-dioxides is associated with the presence of two <italic toggle="yes">N</italic>-oxide groups since quinoxaline and quinoxaline 1-<italic toggle="yes">N</italic>-oxide did not exhibit mutagenic activity under the same conditions. In addition, using in vivo experiments (a micronuclear test in mice) additionally confirmed the clastogenicity of quinoxaline 1,4-dioxides [<xref rid="B22-pharmaceuticals-16-01174" ref-type="bibr">22</xref>]. Thus, olaquindox (<bold>102</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) induces chromosome aberrations when administered orally at a dose of 100 mg/kg, while carbadox (<bold>101</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) exhibits the same effect at a dose of 800 mg/kg [<xref rid="B189-pharmaceuticals-16-01174" ref-type="bibr">189</xref>]. Nevertheless, in contrast to the derivatives <bold>101</bold> and <bold>102</bold>, the agricultural agent cyadox (<bold>104</bold>, <xref rid="pharmaceuticals-16-01174-f017" ref-type="fig">Figure 17</xref>) did not show a damaging effect on chromosomes, even at a dose of 1200 mg/kg. It was found that derivative <bold>101</bold> has a teratogenic effect and leads to intrauterine malformation of the fetus and death of the embryo using in vivo experiments on rats [<xref rid="B190-pharmaceuticals-16-01174" ref-type="bibr">190</xref>]. Teratogenic, embryotoxic, and mutagenic effects have been shown for the clinically used dioxidine, which limits its use [<xref rid="B191-pharmaceuticals-16-01174" ref-type="bibr">191</xref>].</p><p>The phototoxicity of some derivatives of quinoxaline 1,4-dioxide was observed in [<xref rid="B192-pharmaceuticals-16-01174" ref-type="bibr">192</xref>], indicating the ability of quinoxaline 1,4-dioxides used in agriculture and veterinary practice to cause photoallergic reactions in animals. It was found that the reactive oxaziridine intermediate <bold>29</bold> and its 2,3-disubstituted derivatives, as well as its dioxaziridine analogs (<xref rid="pharmaceuticals-16-01174-sch008" ref-type="fig">Scheme 8</xref>) generated under UV irradiation, engage in the chemical interaction with proteins. In particular, irradiation of 3-phenylquinoxaline-2-carbonitrile 1,4-dioxide (<bold>89b</bold>, <xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>) by the long-wavelength part of the visible spectrum leads to selective cleavage of the bond at the 2&#x02019;-position of deoxyguanosine [<xref rid="B193-pharmaceuticals-16-01174" ref-type="bibr">193</xref>]. An enhancement of photoinduced bond breaking in pBR322 plasmid DNA caused by compound <bold>89b</bold> (<xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>) occurs with the further participation of NADPH-dependent enzymes under anaerobic conditions. Notably, in contrast to derivative <bold>89b</bold> (<xref rid="pharmaceuticals-16-01174-f009" ref-type="fig">Figure 9</xref>), DNA damage induced by quinoxaline 1,4-dioxide (<bold>28a</bold>, <xref rid="pharmaceuticals-16-01174-sch008" ref-type="fig">Scheme 8</xref>) was independent of NADPH-dependent enzymes.</p></sec><sec sec-type="conclusions" id="sec8-pharmaceuticals-16-01174"><title>8. Conclusions</title><p>The search for new possibilities to functionalize quinoxaline 1,4-dioxides has attracted special attention from chemists due to the unique biological properties and high pharmacological activity of this class of compounds. Over the past decade, several effective methods for their synthesis have been developed, and classical methods for the preparation and modification of quinoxaline 1,4-dioxides have been improved. Progress in the chemistry of this class has allowed the evaluation of bioactivities for a wide range of functionalized derivatives. Recent experimental works demonstrate the continued scientific and practical interest in quinoxaline 1,4-dioxides. Therefore, a systematization of preparation methods of quinoxaline 1,4-dioxides are in demand to develop new schemes for the synthesis of these compounds and contribute to further evaluations of this class of heterocycles.</p><p>In recent years, there has been a high priority placed on modifying the structure of quinoxaline 1,4-dioxide to develop drugs with greater selectivity or improved therapeutic properties. However, analyzing the relationship between biological activity and the structure of quinoxaline 1,4-dioxides, considering multiple types of activity simultaneously, and evaluating specific structural features, is a challenging task. General observations include the following:
<list list-type="simple"><list-item><label>-</label><p>the introduction of electron-withdrawing substituents at positions 3 and 6/7 of the quinoxaline moiety promotes more readily reduction by bacterial or eukaryotic reductases, resulting in increased cytotoxicity and antimicrobial activity of such derivatives;</p></list-item><list-item><label>-</label><p>the presence of a carbonitrile moiety at position 2 of the pyrazine ring enhances antiproliferative activity, while ester or carboxamide fragments at this position improve the antibacterial properties of quinoxaline 1,4-dioxides;</p></list-item><list-item><label>-</label><p>overall, the presence of a halogen atom in the quinoxaline core enhances the biological activity of the compounds, with chlorine being the most significant;</p></list-item><list-item><label>-</label><p>the introduction of electron-donating groups at C3 or C7 carbon atoms of the heterocycle increases the hypoxic cytotoxicity of quinoxaline-2-carbonitrile 1,4-dioxide derivatives.</p></list-item></list></p><p>However, the activity of such compounds strongly depends on the structure of the substituents. The presence of linear alkylamino groups at these positions had a negative effect, resulting in a complete loss of antiproliferative properties and selectivity under hypoxic conditions. [<xref rid="B61-pharmaceuticals-16-01174" ref-type="bibr">61</xref>,<xref rid="B108-pharmaceuticals-16-01174" ref-type="bibr">108</xref>]. On the other hand, the presence of cyclic amino groups at positions 3 or 7 leads to a significant increase in the hypoxic selectivity of quinoxaline-2-carbonitrile 1,4-dioxides. Additionally:
<list list-type="simple"><list-item><label>-</label><p>lipophilic substituents at positions 2, 6, or 7 improve the antituberculous potential of the derivatives;</p></list-item><list-item><label>-</label><p>acylamino groups at position 3 of the quinoxaline ring have a positive effect on suppressing the growth of protozoa (<italic toggle="yes">Leishmania</italic> spp. and <italic toggle="yes">Plasmodium</italic> spp);</p></list-item><list-item><label>-</label><p>the introduction of salt-forming fragments leads to water-soluble derivatives while retaining their biological potency.</p></list-item></list>
</p><p>However, due to the limited available data on target proteins and the necessity for further searches for intracellular reductases involved in the activation of quinoxaline 1,4-dioxides, a comprehensive understanding of the mechanism of action remains essential. H. Zhang et al. conducted QSAR analysis for antimycobacterial activity using CoMFA and CoMSIA models [<xref rid="B89-pharmaceuticals-16-01174" ref-type="bibr">89</xref>]. The results of 3D-QSAR modeling identified several critical requirements for the structure of quinoxaline 1,4-dioxides for their antituberculosis properties. This indicates the specificity of the binding of this class of compounds to intracellular targets important for inhibiting pathogen growth. Electron-withdrawing and sterically bulky substituents, particularly halogen atoms, at position 7 of the quinoxaline are preferred for increasing antimycobacterial activity. Furthermore, the introduction of hydrogen bond donors at the C<sub>2</sub> carbon atom of the pyrazine ring enhances activity against <italic toggle="yes">Mycobacterium</italic> spp.</p><p>Despite the observed progress, the further development of methods for preparing new quinoxaline 1,4-dioxides and the study of their mode of action remains an urgent task. Addressing these tasks could broaden the practical applications for this unique class of heterocyclic compounds.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank A.A. Vatlin and D.A. Maslov for supervision of the project RSF 21-45-00018.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization and formal analysis A.E.S. and G.I.B.; writing&#x02014;original draft preparation, G.I.B.; writing&#x02014;review and editing, A.E.S. and G.I.B.; supervision, A.E.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data sharing not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-16-01174"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vitaku</surname><given-names>E.</given-names></name>
<name><surname>Smith</surname><given-names>D.T.</given-names></name>
<name><surname>Njardarson</surname><given-names>J.T.</given-names></name>
</person-group><article-title>Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA Approved Pharmaceuticals</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><fpage>10257</fpage><lpage>10274</lpage><pub-id pub-id-type="doi">10.1021/jm501100b</pub-id><?supplied-pmid 25255204?><pub-id pub-id-type="pmid">25255204</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-16-01174"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohan</surname><given-names>C.D.</given-names></name>
<name><surname>Anilkumar</surname><given-names>N.C.</given-names></name>
<name><surname>Rangappa</surname><given-names>S.</given-names></name>
<name><surname>Shanmugam</surname><given-names>M.K.</given-names></name>
<name><surname>Mishra</surname><given-names>S.</given-names></name>
<name><surname>Chinnathambi</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>S.A.</given-names></name>
<name><surname>Bhattacharjee</surname><given-names>A.</given-names></name>
<name><surname>Sethi</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>A.P.</given-names></name>
<etal/>
</person-group><article-title>Novel 1,3,4-oxadiazole induces anticancer activity by targeting NF-&#x003ba;B in hepatocellular carcinoma cells</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00042</pub-id><?supplied-pmid 29616186?><pub-id pub-id-type="pmid">29616186</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-16-01174"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pecoraro</surname><given-names>C.</given-names></name>
<name><surname>De Franco</surname><given-names>M.</given-names></name>
<name><surname>Carbone</surname><given-names>D.</given-names></name>
<name><surname>Bassani</surname><given-names>D.</given-names></name>
<name><surname>Pavan</surname><given-names>M.</given-names></name>
<name><surname>Cascioferro</surname><given-names>S.</given-names></name>
<name><surname>Parrino</surname><given-names>B.</given-names></name>
<name><surname>Cirrincione</surname><given-names>G.</given-names></name>
<name><surname>Dall&#x02019;Acqua</surname><given-names>S.</given-names></name>
<name><surname>Moro</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>1,2,4-Amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: Synthesis and pharmacological evaluation</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>249</volume><fpage>115134</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115134</pub-id><pub-id pub-id-type="pmid">36709650</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-16-01174"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moniot</surname><given-names>S.</given-names></name>
<name><surname>Forgione</surname><given-names>M.</given-names></name>
<name><surname>Lucidi</surname><given-names>A.</given-names></name>
<name><surname>Hailu</surname><given-names>G.S.</given-names></name>
<name><surname>Nebbioso</surname><given-names>A.</given-names></name>
<name><surname>Carafa</surname><given-names>V.</given-names></name>
<name><surname>Baratta</surname><given-names>F.</given-names></name>
<name><surname>Altucci</surname><given-names>L.</given-names></name>
<name><surname>Giacch&#x000e9;</surname><given-names>N.</given-names></name>
<name><surname>Passeri</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Development of 1,2,4-oxadiazoles as potent and selective inhibitors of the human deacetylase sirtuin 2: Structure-activity relationship, X-ray crystal ctructure, and anticancer activity</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>2344</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01609</pub-id><?supplied-pmid 28240897?><pub-id pub-id-type="pmid">28240897</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-16-01174"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carbone</surname><given-names>D.</given-names></name>
<name><surname>De Franco</surname><given-names>M.</given-names></name>
<name><surname>Pecoraro</surname><given-names>C.</given-names></name>
<name><surname>Bassani</surname><given-names>D.</given-names></name>
<name><surname>Pavan</surname><given-names>M.</given-names></name>
<name><surname>Cascioferro</surname><given-names>S.</given-names></name>
<name><surname>Parrino</surname><given-names>B.</given-names></name>
<name><surname>Cirrincione</surname><given-names>G.</given-names></name>
<name><surname>Dall&#x02019;Acqua</surname><given-names>S.</given-names></name>
<name><surname>Moro</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Discovery of the 3-amino-1,2,4-triazine-based library as selective PDK1 inhibitors with therapeutic potential in highly aggressive pancreatic ductal adenocarcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>3679</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24043679</pub-id><pub-id pub-id-type="pmid">36835086</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-16-01174"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdel-Aziz</surname><given-names>A.K.</given-names></name>
<name><surname>Dokla</surname><given-names>E.M.E.</given-names></name>
<name><surname>Abouzid</surname><given-names>K.A.M.</given-names></name>
<name><surname>Minucci</surname><given-names>S.</given-names></name>
</person-group><article-title>Discovery of EMD37, a 1,2,4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity</article-title><source>Biochem. Pharmacol.</source><year>2022</year><volume>206</volume><fpage>115316</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2022.115316</pub-id><pub-id pub-id-type="pmid">36283444</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-16-01174"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patterson</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Rationale for the use of aliphatic <italic toggle="yes">N</italic>-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent</article-title><source>Cancer Metastasis Rev.</source><year>1993</year><volume>12</volume><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/BF00689805</pub-id><pub-id pub-id-type="pmid">8375016</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-16-01174"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Gates</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Enzyme-activated generation of reactive oxygen species from heterocyclic <italic toggle="yes">N</italic>-oxides under aerobic and anaerobic conditions and its relevance to hypoxia-selective prodrugs</article-title><source>Chem. Res. Toxicol.</source><year>2019</year><volume>32</volume><fpage>348</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.9b00036</pub-id><pub-id pub-id-type="pmid">30817135</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-16-01174"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicola</surname><given-names>O.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Revisiting unexploited antibiotics in search of new antibacterial drug candidates: The case of MSD-819 (6-chloro-2-quinoxalinecarboxylic acid 1,4-dioxide)</article-title><source>J. Antibiot.</source><year>2017</year><volume>70</volume><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.140</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-16-01174"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>J.M.</given-names></name>
<name><surname>Messenger</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Occurrence, biochemistry and physiology of phenazine pigment production</article-title><source>Adv. Microb. Physiol.</source><year>1986</year><volume>27</volume><fpage>211</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/S0065-2911(08)60306-9</pub-id><pub-id pub-id-type="pmid">3532716</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-16-01174"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cimmino</surname><given-names>A.</given-names></name>
<name><surname>Evidente</surname><given-names>A.</given-names></name>
<name><surname>Mathieu</surname><given-names>V.</given-names></name>
<name><surname>Andolfi</surname><given-names>A.</given-names></name>
<name><surname>Lefranc</surname><given-names>F.</given-names></name>
<name><surname>Kornienko</surname><given-names>A.</given-names></name>
<name><surname>Kiss</surname><given-names>R.</given-names></name>
</person-group><article-title>Phenazines and cancer</article-title><source>Nat. Prod. Rep.</source><year>2012</year><volume>29</volume><fpage>487</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1039/c2np00079b</pub-id><pub-id pub-id-type="pmid">22337153</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-16-01174"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McIlwain</surname><given-names>H.</given-names></name>
</person-group><article-title>Bacterial inhibition by metabolite analogues. Part V. Reactions and antibacterial properties of <italic toggle="yes">p</italic>-diazine di-<italic toggle="yes">N</italic>-oxides</article-title><source>J. Chem. Soc.</source><year>1943</year><volume>88</volume><fpage>322</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1039/jr9430000322</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-16-01174"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viktorsson</surname><given-names>E.&#x000d6;.</given-names></name>
<name><surname>Melling Gr&#x000f8;the</surname><given-names>B.</given-names></name>
<name><surname>Aesoy</surname><given-names>R.</given-names></name>
<name><surname>Sabir</surname><given-names>M.</given-names></name>
<name><surname>Snellingen</surname><given-names>S.</given-names></name>
<name><surname>Prandina</surname><given-names>A.</given-names></name>
<name><surname>&#x000c5;strand</surname><given-names>O.A.H.</given-names></name>
<name><surname>Bonge-Hansen</surname><given-names>T.</given-names></name>
<name><surname>D&#x000f8;skeland</surname><given-names>S.O.</given-names></name>
<name><surname>Herfindal</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives</article-title><source>Bioorg. Med. Chem.</source><year>2017</year><volume>25</volume><fpage>2285</fpage><lpage>2293</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.02.058</pub-id><pub-id pub-id-type="pmid">28284865</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-16-01174"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Myhren</surname><given-names>L.</given-names></name>
<name><surname>Nygaard</surname><given-names>G.</given-names></name>
<name><surname>Gausdal</surname><given-names>G.</given-names></name>
<name><surname>Sletta</surname><given-names>H.</given-names></name>
<name><surname>Teigen</surname><given-names>K.</given-names></name>
<name><surname>Degnes</surname><given-names>K.</given-names></name>
<name><surname>Zahlsen</surname><given-names>K.</given-names></name>
<name><surname>Brunsvik</surname><given-names>A.</given-names></name>
<name><surname>Bruserud</surname><given-names>&#x000d8;.</given-names></name>
<name><surname>D&#x000f8;skeland</surname><given-names>S.O.</given-names></name>
<etal/>
</person-group><article-title>Iodinin (1,6-Dihydroxyphenazine 5,10-dioxide) from <italic toggle="yes">Streptosporangium</italic> sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells</article-title><source>Mar. Drugs</source><year>2013</year><volume>11</volume><fpage>332</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.3390/md11020332</pub-id><?supplied-pmid 23364682?><pub-id pub-id-type="pmid">23364682</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-16-01174"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>B.S.</given-names></name>
<name><surname>Pollak</surname><given-names>J.</given-names></name>
<name><surname>Bailey-Davis</surname><given-names>L.</given-names></name>
<name><surname>Hirsch</surname><given-names>A.G.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Nau</surname><given-names>C.</given-names></name>
<name><surname>Kress</surname><given-names>A.M.</given-names></name>
<name><surname>Glass</surname><given-names>T.A.</given-names></name>
<name><surname>Bandeen-Roche</surname><given-names>K.</given-names></name>
</person-group><article-title>Antibiotic use and childhood body mass index trajectory</article-title><source>Int. J. Obes.</source><year>2016</year><volume>40</volume><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1038/ijo.2015.218</pub-id><?supplied-pmid 26486756?><pub-id pub-id-type="pmid">26486756</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-16-01174"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dvoryantseva</surname><given-names>G.G.</given-names></name>
<name><surname>Lindeman</surname><given-names>S.V.</given-names></name>
<name><surname>Aleksanyan</surname><given-names>M.S.</given-names></name>
<name><surname>Struehkov</surname><given-names>Y.T.</given-names></name>
<name><surname>Teten&#x02019;ehuk</surname><given-names>K.P.</given-names></name>
<name><surname>Khabarova</surname><given-names>L.S.</given-names></name>
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Connection between the structure and the antibacterial activity of the <italic toggle="yes">N</italic>-oxides of quinoxalines. Molecular structure of dioxidine and quinoxidine</article-title><source>Pharm. Chem. J.</source><year>1990</year><volume>24</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1007/BF00767037</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-16-01174"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>Bongard</surname><given-names>E.</given-names></name>
<name><surname>Charnaud</surname><given-names>S.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>Perez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Vivas</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as antimalarial agents</article-title><source>Eur. J. Med. Chem.</source><year>2008</year><volume>43</volume><fpage>1903</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2007.11.024</pub-id><pub-id pub-id-type="pmid">18215443</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-16-01174"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>J. Med. Chem.</source><year>2003</year><volume>11</volume><fpage>2149</fpage><lpage>2156</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(03)00119-6</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-16-01174"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>M.L.</given-names></name>
<name><surname>Bambury</surname><given-names>R.E.</given-names></name>
<name><surname>Ritter</surname><given-names>H.W.</given-names></name>
</person-group><article-title>3-Substituted 2-formylquinoxaline 1,4-dioxides</article-title><source>J. Med. Chem.</source><year>1975</year><volume>18</volume><fpage>637</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1021/jm00240a027</pub-id><?supplied-pmid 239234?><pub-id pub-id-type="pmid">239234</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-16-01174"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleim</surname><given-names>J.P.</given-names></name>
<name><surname>Bender</surname><given-names>R.</given-names></name>
<name><surname>Billhardt</surname><given-names>U.M.</given-names></name>
<name><surname>Meichsner</surname><given-names>C.</given-names></name>
<name><surname>Riess</surname><given-names>G.</given-names></name>
<name><surname>R&#x000f6;sner</surname><given-names>M.</given-names></name>
<name><surname>Winkler</surname><given-names>I.</given-names></name>
<name><surname>Paessens</surname><given-names>A.</given-names></name>
</person-group><article-title>Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>1659</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.8.1659</pub-id><pub-id pub-id-type="pmid">7692812</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-16-01174"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Palop</surname><given-names>J.A.</given-names></name>
<name><surname>Cerain</surname><given-names>A.L.</given-names></name>
<name><surname>Senador</surname><given-names>V.</given-names></name>
<name><surname>Martinez-Crespo</surname><given-names>F.J.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Narro</surname><given-names>S.</given-names></name>
<name><surname>Garcia</surname><given-names>E.</given-names></name>
<name><surname>de Miguel</surname><given-names>C.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Greenhow hypoxia-selective agents derived from quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides</article-title><source>J. Med. Chem.</source><year>1995</year><volume>38</volume><fpage>1786</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1021/jm00010a023</pub-id><pub-id pub-id-type="pmid">7752202</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-16-01174"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tucker</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Carcinogenic action of quinoxaline 1,4-dioxide in rats</article-title><source>J. Natl. Cancer Inst.</source><year>1975</year><volume>55</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1093/jnci/55.1.137</pub-id><pub-id pub-id-type="pmid">1159806</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-16-01174"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaynoun</surname><given-names>S.</given-names></name>
<name><surname>Johnson</surname><given-names>B.</given-names></name>
<name><surname>Frain-Bell</surname><given-names>W.</given-names></name>
</person-group><article-title>The investigation of Quindoxin photosensitivity</article-title><source>Contact Derm.</source><year>1976</year><volume>2</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0536.1976.tb03073.x</pub-id><?supplied-pmid 1032128?><pub-id pub-id-type="pmid">1032128</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-16-01174"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Vries</surname><given-names>H.</given-names></name>
<name><surname>Bojarski</surname><given-names>J.</given-names></name>
<name><surname>Donker</surname><given-names>A.A.</given-names></name>
<name><surname>Bakri</surname><given-names>A.</given-names></name>
<name><surname>Beyersbergen van Henegouwen</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Photochemical reactions of Quindoxin, Olaquindox, Carbadox and Cyadox with protein, indicating photoallergic properties</article-title><source>Toxicology</source><year>1990</year><volume>63</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0300-483X(90)90071-N</pub-id><?supplied-pmid 2382272?><pub-id pub-id-type="pmid">2382272</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-16-01174"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vieira</surname><given-names>M.</given-names></name>
<name><surname>Pinheiro</surname><given-names>C.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.</given-names></name>
<name><surname>Noronha</surname><given-names>J.P.</given-names></name>
<name><surname>Prudencio</surname><given-names>C.</given-names></name>
</person-group><article-title>Antimicrobial activity of quinoxaline 1,4-dioxide with 2-and 3-substituted derivatives</article-title><source>Microbiol. Res.</source><year>2014</year><volume>169</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2013.06.015</pub-id><pub-id pub-id-type="pmid">23928379</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-16-01174"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carta</surname><given-names>A.</given-names></name>
<name><surname>Corona</surname><given-names>P.</given-names></name>
<name><surname>Loriga</surname><given-names>M.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxide: A versatile scaffold endowed with manifold activities</article-title><source>Curr. Med. Chem.</source><year>2005</year><volume>12</volume><fpage>2259</fpage><lpage>2272</lpage><pub-id pub-id-type="doi">10.2174/0929867054864831</pub-id><?supplied-pmid 16178784?><pub-id pub-id-type="pmid">16178784</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-16-01174"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>do Amaral</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Beirut reaction and its application in the synthesis of quinoxaline-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02032;-dioxides bioactive compounds</article-title><source>Rev. Virtual Quim.</source><year>2013</year><volume>5</volume><fpage>1075</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.5935/1984-6835.20130079</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-16-01174"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>N.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>A.</given-names></name>
</person-group><article-title>An appraisal on synthetic and pharmaceutical perspectives of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide scaffold</article-title><source>Chem. Biol. Drug Des.</source><year>2022</year><volume>100</volume><fpage>346</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/cbdd.14094</pub-id><pub-id pub-id-type="pmid">35610776</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-16-01174"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivera</surname><given-names>G.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives: Are they unselective or selective inhibitors?</article-title><source>Mini Rev. Med. Chem.</source><year>2022</year><volume>22</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2174/1389557521666210126142541</pub-id><pub-id pub-id-type="pmid">33573542</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-16-01174"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dos Santos Fernandes</surname><given-names>G.F.</given-names></name>
<name><surname>Pavan</surname><given-names>A.R.</given-names></name>
<name><surname>dos Santos</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Heterocyclic <italic toggle="yes">N</italic>-oxides&#x02014;A promising class of agents against tuberculosis, malaria and neglected tropical diseases</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>1325</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.2174/1381612824666180417122625</pub-id><pub-id pub-id-type="pmid">29663875</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-16-01174"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamama</surname><given-names>W.S.</given-names></name>
<name><surname>Waly</surname><given-names>S.M.</given-names></name>
<name><surname>Said</surname><given-names>S.B.</given-names></name>
<name><surname>Zoorob</surname><given-names>H.H.</given-names></name>
</person-group><article-title>Highlights on the chemistry of 2-amino-3-cyano-quinoxaline 1,4-dioxides and their derivatives</article-title><source>Synth. Commun.</source><year>2020</year><volume>50</volume><fpage>1737</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1080/00397911.2017.1342843</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-16-01174"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Sa</surname><given-names>W.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Guo</surname><given-names>L.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-di-<italic toggle="yes">N</italic>-Oxides: Biological activities and mechanisms of actions</article-title><source>Front. Pharmacol.</source><year>2016</year><volume>7</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00064</pub-id><?supplied-pmid 27047380?><pub-id pub-id-type="pmid">27047380</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-16-01174"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxide and phenazine 5,10-dioxide</article-title><source>Bioact. Heterocycl. V</source><year>2007</year><volume>11</volume><fpage>179</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1007/7081_2007_066</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-16-01174"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Goldman</surname><given-names>R.C.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide and the potential for treating tuberculosis infectious disorders</article-title><source>Curr. Drug Targets</source><year>2011</year><volume>11</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.2174/187152611795589735</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-16-01174"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keri</surname><given-names>R.S.</given-names></name>
<name><surname>Pandule</surname><given-names>S.S.</given-names></name>
<name><surname>Budagumpi</surname><given-names>S.</given-names></name>
<name><surname>Nagaraja</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Quinoxaline and quinoxaline-1,4-di-<italic toggle="yes">N</italic>-oxides: An emerging class of antimycobacterials</article-title><source>Arch. Pharm.</source><year>2018</year><volume>351</volume><fpage>e1700325</fpage><pub-id pub-id-type="doi">10.1002/ardp.201700325</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-16-01174"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montana</surname><given-names>M.</given-names></name>
<name><surname>Montero</surname><given-names>V.</given-names></name>
<name><surname>Khoumeri</surname><given-names>O.</given-names></name>
<name><surname>Vanelle</surname><given-names>P.</given-names></name>
</person-group><article-title>Quinoxaline moiety: A potential scaffold against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>4742</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26164742</pub-id><pub-id pub-id-type="pmid">34443334</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-16-01174"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carmeli</surname><given-names>M.</given-names></name>
<name><surname>Rozen</surname><given-names>S.</given-names></name>
</person-group><article-title>A new efficient route for the formation of quinoxaline <italic toggle="yes">N</italic>-oxides and <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02032;-dioxides using HOF-CH<sub>3</sub>CN</article-title><source>J. Org. Chem.</source><year>2006</year><volume>71</volume><fpage>5761</fpage><lpage>5765</lpage><pub-id pub-id-type="doi">10.1021/jo0608016</pub-id><pub-id pub-id-type="pmid">16839160</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-16-01174"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Synthesis, crystal structure and calculation of oxides of 2-methylamino-3-methyl quinoxaline</article-title><source>J. Mol. Struct.</source><year>2020</year><volume>1222</volume><fpage>128826</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128826</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-16-01174"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abushanab</surname><given-names>E.</given-names></name>
</person-group><article-title>One-step synthesis of quinoxaline 1,4-dioxides and related compounds</article-title><source>J. Org. Chem.</source><year>1970</year><volume>35</volume><fpage>4279</fpage><lpage>4280</lpage><pub-id pub-id-type="doi">10.1021/jo00837a646</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-16-01174"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Enamines with isobenzofuroxan: A novel synthesis of quinoxaline-di-<italic toggle="yes">N</italic>-oxides</article-title><source>Tetrahedron Lett.</source><year>1965</year><volume>6</volume><fpage>3253</fpage><lpage>3256</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(01)89222-4</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-16-01174"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Jie</surname><given-names>J.L.</given-names></name>
</person-group><source>Name Reactions: A Collection of Detailed Reaction Mechanisms</source><edition>3rd ed.</edition><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2006</year><volume>Volume 1</volume><fpage>504</fpage></element-citation></ref><ref id="B42-pharmaceuticals-16-01174"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Haj</surname><given-names>M.J.A.</given-names></name>
<name><surname>Dominy</surname><given-names>B.W.</given-names></name>
<name><surname>Johnston</surname><given-names>J.D.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>New route to phenazine 5,10-dioxides and related compounds</article-title><source>J. Org. Chem.</source><year>1972</year><volume>37</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1021/jo00969a015</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-16-01174"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>A.A.</given-names></name>
<name><surname>Usui</surname><given-names>T.</given-names></name>
</person-group><article-title>Studies on furan derivatives. Preparation of 2-substituted 3-(5-nitro-2-furyl) quinoxaline 1,4-dioxides and determination of their antibacterial activity</article-title><source>Chem. Pharm. Bull.</source><year>1981</year><volume>29</volume><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1248/cpb.29.110</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-16-01174"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Ji</surname><given-names>M.</given-names></name>
<name><surname>Hua</surname><given-names>W.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
</person-group><article-title>Synthesis of 2-substituted-quinoxaline 1,4-dioxides</article-title><source>Ind. J. Chem. B</source><year>2001</year><volume>40</volume><fpage>1230</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1002/chin.200213166</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-16-01174"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McFarland</surname><given-names>J.W.</given-names></name>
</person-group><article-title>2,3-Dihydroquinoxaline 1,4-dioxides as intermediates in the reaction between benzofurazan 1-oxide and enamines</article-title><source>J. Org. Chem.</source><year>1971</year><volume>36</volume><fpage>1842</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1021/jo00812a031</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-16-01174"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atfah</surname><given-names>A.</given-names></name>
<name><surname>Hill</surname><given-names>J.</given-names></name>
</person-group><article-title>Reaction of 2,1,3-benzoxadiazole 1-oxide with ethyl 2,4-dioxo-4-phenylbutyrate. A route to 2-benzoylquinoxaline, its 1,4-dioxide, and related compounds</article-title><source>J. Chem. Soc. Perkin Trans. 1</source><year>1989</year><volume>2</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1039/p19890000221</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-16-01174"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Palop</surname><given-names>J.A.</given-names></name>
<name><surname>Urbasos</surname><given-names>I.</given-names></name>
<name><surname>Fernandez-Alvarez</surname><given-names>E.</given-names></name>
</person-group><article-title>New quinoxaline and pyrimido [4,5-b]quinoxaline derivatives</article-title><source>Potential antihypertensive and blood platelet antiaggregating agents J. Heterocycl. Chem.</source><year>1989</year><volume>26</volume><fpage>1623</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570260621</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-16-01174"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>F.</given-names></name>
<name><surname>Yao</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
</person-group><article-title>Synthesis of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide analogues and crystal structure of 2-carbomethoxy-3-hydroxyquinoxaline-di-<italic toggle="yes">N</italic>-oxide</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>6894</fpage><lpage>6901</lpage><pub-id pub-id-type="doi">10.3390/molecules16086894</pub-id><pub-id pub-id-type="pmid">21841728</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-16-01174"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>R.F.</given-names></name>
<name><surname>Yadav</surname><given-names>P.</given-names></name>
<name><surname>Shinde</surname><given-names>S.S.</given-names></name>
<name><surname>Hong</surname><given-names>C.R.</given-names></name>
<name><surname>Pullen</surname><given-names>S.M.</given-names></name>
<name><surname>Reynisson</surname><given-names>J.</given-names></name>
<name><surname>Wilso</surname><given-names>W.R.</given-names></name>
<name><surname>Hay</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Radical chemistry and cytotoxicity of bioreductive 3-substituted quinoxaline di-<italic toggle="yes">N</italic>-oxides</article-title><source>Chem. Res. Toxicol.</source><year>2016</year><volume>29</volume><fpage>1310</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00133</pub-id><?supplied-pmid 27380897?><pub-id pub-id-type="pmid">27380897</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-16-01174"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chupakhin</surname><given-names>O.N.</given-names></name>
<name><surname>Kotovskaya</surname><given-names>S.K.</given-names></name>
<name><surname>Perova</surname><given-names>N.M.</given-names></name>
<name><surname>Baskakova</surname><given-names>Z.M.</given-names></name>
<name><surname>Charushin</surname><given-names>V.N.</given-names></name>
</person-group><article-title>Synthesis of new fluorine-containing derivatives of quinoxaline 1,4-dioxides and condensed systems derived from them</article-title><source>Chem. Heterocycl. Compd.</source><year>1999</year><volume>35</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1007/BF02319335</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-16-01174"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Marin</surname><given-names>A.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Perez Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Comparative use of solvent-free KF-Al<sub>2</sub>O<sub>3</sub> and K<sub>2</sub>CO<sub>3</sub> in acetone in the synthesis of quinoxaline 1,4-dioxide derivatives designed as antimalarial drug candidates</article-title><source>J. Heterocycl. Chem.</source><year>2005</year><volume>42</volume><fpage>1381</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570420718</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-16-01174"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>T.</given-names></name>
<name><surname>Zhao</surname><given-names>W.-J.</given-names></name>
<name><surname>Hao</surname><given-names>A.-Y.</given-names></name>
<name><surname>Sun</surname><given-names>L.-Z.</given-names></name>
</person-group><article-title>Effective promotion of Beirut reaction by &#x003b2;-cyclodextrin in water</article-title><source>Synth. Commun.</source><year>2011</year><volume>41</volume><fpage>3097</fpage><lpage>3105</lpage><pub-id pub-id-type="doi">10.1080/00397911.2010.517371</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-16-01174"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonilla-Ram&#x000ed;rez</surname><given-names>L.</given-names></name>
<name><surname>Rios</surname><given-names>A.</given-names></name>
<name><surname>Quiliano</surname><given-names>M.</given-names></name>
<name><surname>Ram&#x000ed;rez-Calderon</surname><given-names>G.</given-names></name>
<name><surname>Beltr&#x000e1;n-Hortelano</surname><given-names>I.</given-names></name>
<name><surname>Franetich</surname><given-names>J.F.</given-names></name>
<name><surname>Corcuera</surname><given-names>L.</given-names></name>
<name><surname>Bordessoulles</surname><given-names>M.</given-names></name>
<name><surname>Vettorazzi</surname><given-names>A.</given-names></name>
<name><surname>L&#x000f3;pez de Cerain</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide hybrids: Design, synthesis, <italic toggle="yes">Plasmodium</italic> life cycle stage profile, and preliminary toxicity studies</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>158</volume><fpage>68</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.08.063</pub-id><?supplied-pmid 30199706?><pub-id pub-id-type="pmid">30199706</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-16-01174"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srinivasarao</surname><given-names>S.</given-names></name>
<name><surname>Nandikolla</surname><given-names>A.</given-names></name>
<name><surname>Suresh</surname><given-names>A.</given-names></name>
<name><surname>Ewa</surname><given-names>A.-K.</given-names></name>
<name><surname>G&#x00142;ogowska</surname><given-names>A.</given-names></name>
<name><surname>Ghosh</surname><given-names>B.</given-names></name>
<name><surname>Kumar</surname><given-names>B.K.</given-names></name>
<name><surname>Murugesan</surname><given-names>S.</given-names></name>
<name><surname>Pulya</surname><given-names>S.</given-names></name>
<name><surname>Aggrawal</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Discovery of 1,2,3-triazole based quinoxaline-1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as potential anti-tubercular agents</article-title><source>Bioorg. Chem.</source><year>2020</year><volume>100</volume><fpage>103955</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103955</pub-id><pub-id pub-id-type="pmid">32464405</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-16-01174"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gasco</surname><given-names>A.M.</given-names></name>
<name><surname>Ermondi</surname><given-names>G.</given-names></name>
<name><surname>Fruttero</surname><given-names>R.</given-names></name>
<name><surname>Gasco</surname><given-names>A.</given-names></name>
</person-group><article-title>Benzofurazanyl- and benzofuroxanyl-1,4-dihydropyridines: Synthesis, structure and calcium entry blocker activity</article-title><source>Eur. J. Med. Chem.</source><year>1996</year><volume>31</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0223-5234(96)80001-8</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-16-01174"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Taha</surname><given-names>M.U.</given-names></name>
<name><surname>Jarrar</surname><given-names>A.A.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Reaction of benzofurazan oxide with unsymmetrical 1,3-diketones; steric and polar effects</article-title><source>Tetrahedron</source><year>1976</year><volume>32</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(01)93796-2</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-16-01174"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>The Beirut reaction</article-title><source>Heterocycles</source><year>1993</year><volume>3</volume><fpage>1503</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.3987/REV-92-SR(T)8</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-16-01174"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Lavaggi</surname><given-names>M.L.</given-names></name>
<name><surname>Porcal</surname><given-names>W.</given-names></name>
</person-group><article-title>Preparation of phenazine <italic toggle="yes">N<sup>5</sup>,N<sup>10</sup></italic>-dioxides. Effects of benzofuroxan substituents in the outcome of their expansion reaction with phenolates</article-title><source>J. Braz. Chem. Soc.</source><year>2005</year><volume>16</volume><fpage>1290</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1590/S0103-50532005000700030</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-16-01174"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ermondi</surname><given-names>G.</given-names></name>
<name><surname>Visentin</surname><given-names>S.</given-names></name>
<name><surname>Boschi</surname><given-names>D.</given-names></name>
<name><surname>Fruttero</surname><given-names>R.</given-names></name>
<name><surname>Gasco</surname><given-names>A.</given-names></name>
</person-group><article-title>Structural investigation of Ca<sup>2+</sup> antagonists benzofurazanyl and benzofuraxanyl-1,4-dihydropiridines</article-title><source>J. Mol. Struct.</source><year>2000</year><volume>523</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S0022-2860(99)00386-5</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-16-01174"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buravchenko</surname><given-names>G.I.</given-names></name>
<name><surname>Scherbakov</surname><given-names>A.M.</given-names></name>
<name><surname>Korlukov</surname><given-names>A.D.</given-names></name>
<name><surname>Dorovatovskii</surname><given-names>P.V.</given-names></name>
<name><surname>Shchekotikhin</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Revision of the regioselectivity of the Beirut reaction of monosubstituted benzofuroxans with benzoylacetonitrile. 6-Substituted quinoxaline-2-carbonitrile 1,4-dioxides: Structural characterization and estimation of anticancer activity and hypoxia selectivity</article-title><source>Curr. Org. Chem.</source><year>2020</year><volume>17</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.2174/1570179416666191210100754</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-16-01174"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buravchenko</surname><given-names>G.I.</given-names></name>
<name><surname>Scherbakov</surname><given-names>A.M.</given-names></name>
<name><surname>Dezhenkova</surname><given-names>L.G.</given-names></name>
<name><surname>Monzote</surname><given-names>L.</given-names></name>
<name><surname>Shchekotikhin</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Synthesis of 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: A way forward for targeting hypoxia and drug resistance of cancer cells</article-title><source>RSC Adv.</source><year>2021</year><volume>11</volume><fpage>38782</fpage><lpage>38795</lpage><pub-id pub-id-type="doi">10.1039/D1RA07978F</pub-id><pub-id pub-id-type="pmid">35493230</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-16-01174"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buravchenko</surname><given-names>G.I.</given-names></name>
<name><surname>Maslov</surname><given-names>D.A.</given-names></name>
<name><surname>Alam</surname><given-names>M.S.</given-names></name>
<name><surname>Grammatikova</surname><given-names>N.E.</given-names></name>
<name><surname>Frolova</surname><given-names>S.G.</given-names></name>
<name><surname>Vatlin</surname><given-names>A.A.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>Ivanov</surname><given-names>I.V.</given-names></name>
<name><surname>Bekker</surname><given-names>O.B.</given-names></name>
<name><surname>Kryakvin</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and characterization of novel 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides as potential antimicrobial agents</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.3390/ph15020155</pub-id><pub-id pub-id-type="pmid">35215268</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-16-01174"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dirlam</surname><given-names>J.P.</given-names></name>
<name><surname>McFarland</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Selective monodeoxygenation of certain quinoxaline 1,4-dioxides with trimethyl phosphite</article-title><source>J. Org. Chem.</source><year>1977</year><volume>42</volume><fpage>1360</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1021/jo00428a020</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-16-01174"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kluge</surname><given-names>A.F.</given-names></name>
<name><surname>Maddox</surname><given-names>M.L.</given-names></name>
<name><surname>Lewis</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Formation of quinoxaline monoxides from reaction of benzofurazan oxide with enones and carbon-13 NMR correlations of quinoxaline <italic toggle="yes">N</italic>-oxides</article-title><source>J. Org. Chem.</source><year>1980</year><volume>45</volume><fpage>1909</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1021/jo01298a030</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-16-01174"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demirdji</surname><given-names>S.H.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Deoxygenation of quinoxaline and phenazine <italic toggle="yes">N</italic>-oxides by catalytic transfer reduction and by iodide in the presence of pyridine/sulfur trioxide complex</article-title><source>J. Heterocycl. Chem.</source><year>1983</year><volume>20</volume><fpage>1735</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570200661</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-16-01174"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novacek</surname><given-names>L.</given-names></name>
<name><surname>Nechvatal</surname><given-names>M.</given-names></name>
</person-group><article-title>Partial reduction of quinoxaline 1,4-dioxide derivatives with <italic toggle="yes">L</italic>-ascorbic acid</article-title><source>Collect. Czech. Chem. Commun.</source><year>1988</year><volume>53</volume><fpage>1302</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1135/cccc19881302</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-16-01174"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Homaidan</surname><given-names>F.R.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Deoxygenation of 2,3-disubstituted quinoxaline 1,4-dioxides</article-title><source>Heterocycles</source><year>1981</year><volume>16</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.3987/R-1981-03-0411</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-16-01174"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarrar</surname><given-names>A.A.</given-names></name>
<name><surname>Fataftah</surname><given-names>Z.A.</given-names></name>
</person-group><article-title>Photolysis of some quinoxaline-1,4-di-oxides</article-title><source>Tetrahedron</source><year>1977</year><volume>33</volume><fpage>2127</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1016/0040-4020(77)80326-8</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-16-01174"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirota</surname><given-names>T.</given-names></name>
<name><surname>Namba</surname><given-names>T.</given-names></name>
<name><surname>Sasaki</surname><given-names>K.</given-names></name>
</person-group><article-title>Polycyclic <italic toggle="yes">N</italic>-hetero compounds. XXII Reaction of pyridine <italic toggle="yes">N</italic>-oxides and pyrazine di-<italic toggle="yes">N</italic>-oxides with formamide</article-title><source>J. Heterocycl. Chem.</source><year>1987</year><volume>24</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570240412</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-16-01174"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koyama</surname><given-names>T.</given-names></name>
<name><surname>Nanba</surname><given-names>T.</given-names></name>
<name><surname>Hirota</surname><given-names>T.</given-names></name>
<name><surname>Ohmori</surname><given-names>S.</given-names></name>
<name><surname>Yamato</surname><given-names>M.</given-names></name>
</person-group><article-title>Polycyclic <italic toggle="yes">N</italic>-hetero compounds. XIII. Reactions of pyridine <italic toggle="yes">N</italic>-oxides with formamide</article-title><source>Chem. Pharm. Bull.</source><year>1977</year><volume>25</volume><fpage>964</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1248/cpb.25.964</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-16-01174"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
<name><surname>Musatova</surname><given-names>I.S.</given-names></name>
<name><surname>Titkova</surname><given-names>R.M.</given-names></name>
<name><surname>Dubinskii</surname><given-names>R.A.</given-names></name>
<name><surname>Goizman</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Redox transformations of 2-formylquinoxaline hydrate and diethylacetal <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02032;-dioxides</article-title><source>Chem. Heterocycl. Compd.</source><year>1980</year><volume>16</volume><fpage>861</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1007/BF00513172</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-16-01174"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Epstein</surname><given-names>W.W.</given-names></name>
<name><surname>Sweat</surname><given-names>F.W.</given-names></name>
</person-group><article-title>Dimethyl sulfoxide oxidations</article-title><source>Chem. Rev.</source><year>1967</year><volume>67</volume><fpage>247</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1021/cr60247a001</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-16-01174"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
<name><surname>Tsyrul&#x02019;nikova</surname><given-names>L.G.</given-names></name>
<name><surname>Syrova</surname><given-names>G.P.</given-names></name>
</person-group><article-title>N-oxides of the quinoxaline series. XVI. Redox reactions in the <italic toggle="yes">N</italic>-oxides of &#x003b1;-hydroxymethyl derivatives of quinoxaline</article-title><source>Chem. Heterocycl. Compd.</source><year>1969</year><volume>5</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/BF01031786</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-16-01174"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarrar</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Photochemistry of some quinoxaline 1,4-dioxides</article-title><source>J. Heterocycl. Chem.</source><year>1978</year><volume>15</volume><fpage>177</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570150201</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-16-01174"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vega</surname><given-names>A.O.</given-names></name>
<name><surname>Gil</surname><given-names>M.J.</given-names></name>
<name><surname>Fernandez-Alvarez</surname><given-names>E.</given-names></name>
</person-group><article-title>Synthesis of 1-hydrazinopyridazino [4,5-b]quinoxaline and related compounds</article-title><source>J. Heterocycl. Chem.</source><year>1984</year><volume>21</volume><fpage>1271</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570210505</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-16-01174"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Perez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Unexpected reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives by amines</article-title><source>Molecules</source><year>2008</year><volume>13</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.3390/molecules13010078</pub-id><pub-id pub-id-type="pmid">18259131</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-16-01174"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>Y.</given-names></name>
<name><surname>Qureshi</surname><given-names>M.I.</given-names></name>
<name><surname>Habib</surname><given-names>M.S.</given-names></name>
<name><surname>Farooqi</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Quinoxaline derivatives. XII. The reactions of quinoxaline 1,4-dioxides with acetic anhydride</article-title><source>Bull. Chem. Soc. Jpn.</source><year>1987</year><volume>60</volume><fpage>1145</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1246/bcsj.60.1145</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-16-01174"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>Y.</given-names></name>
<name><surname>Habib</surname><given-names>M.S.</given-names></name>
<name><surname>Qureshi</surname><given-names>M.I.</given-names></name>
<name><surname>Faroogi</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Quinoxaline derivatives. XI. Reaction of quinoxaline 1,4-dioxide and some of its derivatives with acetyl chloride</article-title><source>J. Org. Chem.</source><year>1973</year><volume>38</volume><fpage>2176</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1021/jo00952a014</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-16-01174"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
<name><surname>Tsyrul&#x02019;nikova</surname><given-names>L.G.</given-names></name>
<name><surname>Musatova</surname><given-names>I.S.</given-names></name>
</person-group><article-title><italic toggle="yes">N</italic>-oxides of the quinoxaline series XVIII. Reactions of di-<italic toggle="yes">N</italic>-oxides of &#x003b1;-methyl derivatives of quinoxaline and pyrazine with <italic toggle="yes">p</italic>-nitrosodimethylaniline</article-title><source>Pharm. Chem. J.</source><year>1967</year><volume>1</volume><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1007/BF00766423</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-16-01174"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ley</surname><given-names>K.</given-names></name>
<name><surname>Seng</surname><given-names>F.</given-names></name>
<name><surname>Eholzer</surname><given-names>U.</given-names></name>
<name><surname>Nast</surname><given-names>R.</given-names></name>
<name><surname>Schubart</surname><given-names>R.</given-names></name>
</person-group><article-title>New syntheses of quinoxaline and phenazine di-<italic toggle="yes">N</italic>-oxides</article-title><source>Angew. Chem.</source><year>1969</year><volume>8</volume><fpage>596</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1002/anie.196905961</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-16-01174"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>K.M.</given-names></name>
<name><surname>Ismail</surname><given-names>M.M.F.</given-names></name>
<name><surname>Noaman</surname><given-names>E.</given-names></name>
<name><surname>Soliman</surname><given-names>D.H.</given-names></name>
<name><surname>Ammar</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>New quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides</article-title><source>Bioorg. Med. Chem.</source><year>2006</year><volume>14</volume><fpage>6917</fpage><lpage>6923</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.06.038</pub-id><pub-id pub-id-type="pmid">16843668</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-16-01174"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Said</surname><given-names>S.</given-names></name>
<name><surname>El-Ablack</surname><given-names>F.</given-names></name>
<name><surname>Elbeheiry</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Synthesis and characterization of newly fused 1,2-dihydropyrido [3,4-b], bridged oxadiazol-2-yl, 4-substituted-benzylidene hydrazide and arylidene 6-chloroquinoxaline 1,4-dioxides</article-title><source>J. Braz. Chem. Soc.</source><year>2018</year><volume>29</volume><fpage>2060</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.21577/0103-5053.20180081</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-16-01174"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quiliano</surname><given-names>M.</given-names></name>
<name><surname>Pab&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Ramirez-Calderon</surname><given-names>G.</given-names></name>
<name><surname>Barea</surname><given-names>C.</given-names></name>
<name><surname>Deharo</surname><given-names>E.</given-names></name>
<name><surname>Galiano</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
</person-group><article-title>New hydrazine and hydrazide quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives: <italic toggle="yes">In silico</italic> ADMET, antiplasmodial and antileishmanial activity</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2017</year><volume>27</volume><fpage>1820</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.02.049</pub-id><?supplied-pmid 28291694?><pub-id pub-id-type="pmid">28291694</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-16-01174"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>Barea</surname><given-names>C.</given-names></name>
<name><surname>Galiano</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
</person-group><article-title>New 1,4-di-<italic toggle="yes">N</italic>-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-<italic toggle="yes">Mycobacterium tuberculosis</italic> agents</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>3699</fpage><lpage>3703</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.04.072</pub-id><pub-id pub-id-type="pmid">21570839</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-16-01174"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Qu</surname><given-names>W.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Design, synthesis, and biological evaluation of novel thiazolidinone-containing quinoxaline-1,4-di-<italic toggle="yes">N</italic>-oxides as antimycobacterial and antifungal agents</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><fpage>598</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.00598</pub-id><?supplied-pmid 32850634?><pub-id pub-id-type="pmid">32850634</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-16-01174"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.K.</given-names></name>
<name><surname>Miller</surname><given-names>L.F.</given-names></name>
<name><surname>Bambury</surname><given-names>R.E.</given-names></name>
<name><surname>Ritter</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Nitrones. 7. alpha-Quinoxalinyl-<italic toggle="yes">N</italic>-substituted nitrone 1,4-dioxides</article-title><source>J. Med. Chem.</source><year>1977</year><volume>20</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1021/jm00214a019</pub-id><pub-id pub-id-type="pmid">557559</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-16-01174"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
</person-group><article-title>1,4-Dioxide nitrone derivatives quinoxalines and their biological action</article-title><source>Khim. Farm. Zh.</source><year>1967</year><volume>1</volume><fpage>69</fpage><lpage>73</lpage></element-citation></ref><ref id="B88-pharmaceuticals-16-01174"><label>88.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Michniak</surname><given-names>B.B.</given-names></name>
</person-group><article-title>Amines and amides as penetration enhancers</article-title><source>Percutaneous Penetration Enhancers</source><person-group person-group-type="editor">
<name><surname>Smith</surname><given-names>E.W.</given-names></name>
<name><surname>Maibach</surname><given-names>H.I.</given-names></name>
</person-group><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>1995</year><fpage>79</fpage><lpage>82</lpage><isbn>0-8493-2605-2</isbn></element-citation></ref><ref id="B89-pharmaceuticals-16-01174"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Dai</surname><given-names>M.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as antituberculosis agents</article-title><source>Bioorg. Med. Chem. Let.</source><year>2016</year><volume>26</volume><fpage>4146</fpage><lpage>4153</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.01.066</pub-id><?supplied-pmid 27426298?><pub-id pub-id-type="pmid">27426298</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-16-01174"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gil</surname><given-names>A.</given-names></name>
<name><surname>Pab&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Galiano</surname><given-names>S.</given-names></name>
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Deharo</surname><given-names>E.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
</person-group><article-title>Synthesis, biological evaluation and structure-activity relationships of new quinoxaline derivatives as anti-<italic toggle="yes">Plasmodium falciparum</italic> agents</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>2166</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.3390/molecules19022166</pub-id><?supplied-pmid 24552985?><pub-id pub-id-type="pmid">24552985</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-16-01174"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>Pontiki</surname><given-names>E.</given-names></name>
<name><surname>Hadjipavlou-Litina</surname><given-names>D.</given-names></name>
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Pe&#x000b4;rez</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and biological evaluation of new quinoxaline derivatives as antioxidant and anti-inflammatory agents</article-title><source>Chem. Biol. Drug Des.</source><year>2011</year><volume>77</volume><fpage>255</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2011.01076.x</pub-id><pub-id pub-id-type="pmid">21244639</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-16-01174"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>Pontiki</surname><given-names>E.</given-names></name>
<name><surname>Hadjipavlou-Litina</surname><given-names>D.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>Perez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-<italic toggle="yes">N</italic>-oxidequinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1<italic toggle="yes">H</italic>)-pyrazole an alogues</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2007</year><volume>17</volume><fpage>6439</fpage><lpage>6443</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2007.10.002</pub-id><pub-id pub-id-type="pmid">17942306</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-16-01174"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Ben&#x000ed;tez</surname><given-names>D.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Mar&#x000ed;n</surname><given-names>A.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-<italic toggle="yes">N</italic>-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs</article-title><source>Molecules</source><year>2009</year><volume>14</volume><fpage>2256</fpage><lpage>2272</lpage><pub-id pub-id-type="doi">10.3390/molecules14062256</pub-id><?supplied-pmid 19553897?><pub-id pub-id-type="pmid">19553897</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-16-01174"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez Crespo</surname><given-names>F.J.</given-names></name>
<name><surname>Palop</surname><given-names>J.A.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Narro</surname><given-names>S.</given-names></name>
<name><surname>Senador</surname><given-names>V.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Lopez De Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<name><surname>Barker</surname><given-names>A.J.</given-names></name>
</person-group><article-title>4-Cyano-2-oxo-1,2,4-oxadiazolo [2,3-a]quinoxaline 5-<italic toggle="yes">N</italic>-oxides. New synthetic method and reaction with alcohols. Potential cytotoxic activity</article-title><source>J. Heterocycl. Chem.</source><year>1996</year><volume>33</volume><fpage>1671</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570330620</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-16-01174"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdel-Sattar</surname><given-names>S.</given-names></name>
<name><surname>Elgazwy</surname><given-names>H.</given-names></name>
<name><surname>Soliman</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Design, synthesis and evaluation of 1,3,2-diazaphosphorin [4,5-b]quinoxaline-5,10-di-<italic toggle="yes">N</italic>-oxide derivatives as novel VEGFR-2 and SRC Kinase inhibitors in the treatment of prostate cancer</article-title><source>JPS Conf. Proc.</source><year>2013</year><volume>4</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.2174/2210289201304010077</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-16-01174"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urquiola</surname><given-names>C.</given-names></name>
<name><surname>Gambino</surname><given-names>D.</given-names></name>
<name><surname>Cabrera</surname><given-names>M.</given-names></name>
<name><surname>Lavaggi</surname><given-names>M.L.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonza&#x000b4;lez</surname><given-names>M.</given-names></name>
<name><surname>Lo&#x000b4;pez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Costa-Filho</surname><given-names>A.J.</given-names></name>
<name><surname>Torre</surname><given-names>M.H.</given-names></name>
</person-group><article-title>New copper-based complexes with quinoxaline <italic toggle="yes">N<sup>1</sup></italic>,<italic toggle="yes">N<sup>4</sup></italic>-dioxide derivatives, potential antitumoral agents</article-title><source>J. Inorg. Biochem.</source><year>2008</year><volume>102</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2007.07.028</pub-id><?supplied-pmid 17804074?><pub-id pub-id-type="pmid">17804074</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-16-01174"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stanila</surname><given-names>A.</given-names></name>
<name><surname>Marcu</surname><given-names>A.</given-names></name>
<name><surname>Rusu</surname><given-names>D.</given-names></name>
<name><surname>Rusu</surname><given-names>M.</given-names></name>
<name><surname>David</surname><given-names>L.</given-names></name>
</person-group><article-title>Spectroscopic studies of some copper(II) complexes with amino acids</article-title><source>J. Mol. Struct.</source><year>2007</year><volume>834&#x02013;836</volume><fpage>364</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2006.11.048</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-16-01174"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mar&#x00131;n-Hernandez</surname><given-names>A.</given-names></name>
<name><surname>Gracia-Morb</surname><given-names>I.</given-names></name>
<name><surname>Ruiz-Ram&#x00131;rez</surname><given-names>L.</given-names></name>
<name><surname>Moreno-Sanchez</surname><given-names>R.</given-names></name>
</person-group><article-title>Toxic effects of copper-based antineoplastic drugs (Casiopeinas 1) on mitochondrial functions</article-title><source>Biochem. Pharmacol.</source><year>2003</year><volume>65</volume><fpage>1979</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(03)00212-0</pub-id><?supplied-pmid 12787878?><pub-id pub-id-type="pmid">12787878</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-16-01174"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>K&#x000e1;llay</surname><given-names>C.</given-names></name>
<name><surname>V&#x000e1;rnagy</surname><given-names>K.</given-names></name>
<name><surname>Micera</surname><given-names>G.</given-names></name>
<name><surname>Sanna</surname><given-names>D.</given-names></name>
<name><surname>S&#x000f3;v&#x000e1;g&#x000f3;</surname><given-names>I.</given-names></name>
</person-group><article-title>Copper(II) complexes of oligopeptides containing aspartyl and glutamyl residues. Potentiometric and spectroscopic studies</article-title><source>J. Inorg. Biochem.</source><year>2005</year><volume>99</volume><fpage>1514</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2005.04.009</pub-id><pub-id pub-id-type="pmid">15927267</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-16-01174"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matera-Witkiewicz</surname><given-names>A.</given-names></name>
<name><surname>Brasu&#x00144;</surname><given-names>J.</given-names></name>
<name><surname>&#x0015a;wi&#x00105;tek-Koz&#x00142;owska</surname><given-names>J.</given-names></name>
<name><surname>Pratesi</surname><given-names>A.</given-names></name>
<name><surname>Ginanneschi</surname><given-names>M.</given-names></name>
<name><surname>Messori</surname><given-names>L.</given-names></name>
</person-group><article-title>Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities</article-title><source>J. Inorg. Biochem.</source><year>2009</year><volume>103</volume><fpage>678</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.01.001</pub-id><pub-id pub-id-type="pmid">19232735</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-16-01174"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pahontu</surname><given-names>E.</given-names></name>
<name><surname>Fala</surname><given-names>V.</given-names></name>
<name><surname>Gulea</surname><given-names>A.</given-names></name>
<name><surname>Poirier</surname><given-names>D.</given-names></name>
<name><surname>Tapcov</surname><given-names>V.</given-names></name>
<name><surname>Rosu</surname><given-names>T.</given-names></name>
</person-group><article-title>Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with salicylidene thiosemicarbazones: Antibacterial, antifungal and in vitro antileukemia activity</article-title><source>Molecules</source><year>2013</year><volume>18</volume><fpage>8812</fpage><lpage>8836</lpage><pub-id pub-id-type="doi">10.3390/molecules18088812</pub-id><pub-id pub-id-type="pmid">23887722</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-16-01174"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>S.</given-names></name>
<name><surname>Price</surname><given-names>K.A.</given-names></name>
<name><surname>Chong</surname><given-names>S.-F.</given-names></name>
<name><surname>Paterson</surname><given-names>B.M.</given-names></name>
<name><surname>Caragounis</surname><given-names>A.</given-names></name>
<name><surname>Barnham</surname><given-names>K.J.</given-names></name>
<name><surname>Crouch</surname><given-names>P.J.</given-names></name>
<name><surname>Peach</surname><given-names>J.M.</given-names></name>
<name><surname>Dilworth</surname><given-names>J.R.</given-names></name>
<name><surname>White</surname><given-names>A.R.</given-names></name>
<etal/>
</person-group><article-title>Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: Synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies</article-title><source>J. Biol. Inorg. Chem.</source><year>2009</year><volume>15</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s00775-009-0587-4</pub-id><pub-id pub-id-type="pmid">19771456</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-16-01174"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karayannis</surname><given-names>N.M.</given-names></name>
<name><surname>Speca</surname><given-names>A.N.</given-names></name>
<name><surname>Chasan</surname><given-names>D.E.</given-names></name>
<name><surname>Pytlewski</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Coordination complexes of the <italic toggle="yes">N</italic>-oxides of aromatic diimines and diazines</article-title><source>Coord. Chem. Rev.</source><year>1976</year><volume>20</volume><fpage>37</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0010-8545(00)80319-7</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-16-01174"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torre</surname><given-names>M.H.</given-names></name>
<name><surname>Gambino</surname><given-names>D.</given-names></name>
<name><surname>Araujo</surname><given-names>J.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Lavaggi</surname><given-names>M.L.</given-names></name>
<name><surname>Azqueta</surname><given-names>A.</given-names></name>
<name><surname>L&#x000f3;pez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Abra</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Novel Cu(II) quinoxaline <italic toggle="yes">N</italic><sup>1</sup>,<italic toggle="yes">N</italic><sup>4</sup>-dioxide complexes as selective hypoxic cytotoxins</article-title><source>Eur. J. Med. Chem.</source><year>2005</year><volume>40</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2004.11.012</pub-id><?supplied-pmid 15893021?><pub-id pub-id-type="pmid">15893021</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-16-01174"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noblia</surname><given-names>P.</given-names></name>
<name><surname>Vieites</surname><given-names>M.</given-names></name>
<name><surname>Torre</surname><given-names>M.H.</given-names></name>
<name><surname>Costa-Filho</surname><given-names>A.J.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Lavaggi</surname><given-names>M.L.</given-names></name>
<name><surname>Adachi</surname><given-names>Y.</given-names></name>
<name><surname>Sakurai</surname><given-names>H.</given-names></name>
<name><surname>Gambino</surname><given-names>D.</given-names></name>
</person-group><article-title>Novel vanadyl complexes with quinoxaline 1,4-dioxide derivatives as potent in vitro insulin-mimetic compounds</article-title><source>J. Inorg. Biochem.</source><year>2006</year><volume>100</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2005.11.012</pub-id><?supplied-pmid 16386797?><pub-id pub-id-type="pmid">16386797</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-16-01174"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Xia</surname><given-names>Q.</given-names></name>
<name><surname>Shangguan</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Sheng</surname><given-names>R.</given-names></name>
</person-group><article-title>Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as hypoxic selective anti-tumor agents</article-title><source>Molecules</source><year>2012</year><volume>17</volume><fpage>9683</fpage><lpage>9696</lpage><pub-id pub-id-type="doi">10.3390/molecules17089683</pub-id><?supplied-pmid 22890172?><pub-id pub-id-type="pmid">22890172</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-16-01174"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Morancho</surname><given-names>M.J.</given-names></name>
<name><surname>Martinez-Crespo</surname><given-names>F.J.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Montoya</surname><given-names>M.E.</given-names></name>
<name><surname>Lopez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>New quinoxalinecarbonitrile 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as hypoxic-cytotoxic agents</article-title><source>Eur. J. Med. Chem.</source><year>2000</year><volume>35</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0223-5234(00)00112-4</pub-id><pub-id pub-id-type="pmid">10733600</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-16-01174"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguirre</surname><given-names>G.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Di Maio</surname><given-names>R.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Alfaro</surname><given-names>M.E.M.</given-names></name>
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge-Vega</surname><given-names>A.</given-names></name>
</person-group><article-title>Quinoxaline <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02032;-dioxide derivatives and related compounds as growth inhibitors of <italic toggle="yes">Trypanosoma cruzi</italic>. Structure&#x02013;activity relationships</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2004</year><volume>14</volume><fpage>3835</fpage><lpage>3839</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.04.088</pub-id><pub-id pub-id-type="pmid">15203172</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-16-01174"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usta</surname><given-names>J.A.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Issidorides</surname><given-names>C.H.</given-names></name>
<name><surname>Jarrar</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Preparation of some functionalized quinoxaline 1,4-dioxides</article-title><source>J. Heterocycl. Chem.</source><year>1981</year><volume>18</volume><fpage>655</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570180401</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-16-01174"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vicente</surname><given-names>E.</given-names></name>
<name><surname>Villar</surname><given-names>R.</given-names></name>
<name><surname>Burguete</surname><given-names>A.</given-names></name>
<name><surname>Solano</surname><given-names>B.</given-names></name>
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>Perez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Substitutions of fluorine atoms and phenoxy groups in the synthesis of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>Molecules</source><year>2008</year><volume>13</volume><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.3390/molecules13010086</pub-id><?supplied-pmid 18259132?><pub-id pub-id-type="pmid">18259132</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-16-01174"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Martinez-Crespo</surname><given-names>F.J.</given-names></name>
<name><surname>Lopez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Palop</surname><given-names>J.A.</given-names></name>
<name><surname>Narro</surname><given-names>S.</given-names></name>
<name><surname>Senador</surname><given-names>V.</given-names></name>
<name><surname>Marin</surname><given-names>A.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-<italic toggle="yes">N</italic>-oxides</article-title><source>J. Med. Chem.</source><year>1995</year><volume>38</volume><fpage>4488</fpage><lpage>4494</lpage><pub-id pub-id-type="doi">10.1021/jm00022a014</pub-id><pub-id pub-id-type="pmid">7473576</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-16-01174"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Oporto</surname><given-names>P.</given-names></name>
<name><surname>Gimenez</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Deharo</surname><given-names>E.</given-names></name>
</person-group><article-title>Anti-malarial activity of some 7-chloro-2-quinoxalinecarbonitrile-1,4-di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>Pharmazie</source><year>2003</year><volume>58</volume><fpage>68</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">12622258</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-16-01174"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buravchenko</surname><given-names>G.I.</given-names></name>
<name><surname>Scherbakov</surname><given-names>A.M.</given-names></name>
<name><surname>Dezhenkova</surname><given-names>L.G.</given-names></name>
<name><surname>Bykov</surname><given-names>E.E.</given-names></name>
<name><surname>Solovieva</surname><given-names>S.E.</given-names></name>
<name><surname>Korlukov</surname><given-names>A.A.</given-names></name>
<name><surname>Sorokin</surname><given-names>D.N.</given-names></name>
<name><surname>Fidalgo</surname><given-names>L.M.</given-names></name>
<name><surname>Shchekotikhin</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: Novel, hypoxia-selective HIF-1&#x003b1; inhibitors with strong antiestrogenic potency</article-title><source>Bioorg. Chem.</source><year>2020</year><volume>104</volume><fpage>104324</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104324</pub-id><?supplied-pmid 33142432?><pub-id pub-id-type="pmid">33142432</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-16-01174"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Qu</surname><given-names>W.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-<italic toggle="yes">N</italic>-oxides as potent activator of autophagy in <italic toggle="yes">M. tb</italic>-infected macrophages</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>223</volume><fpage>113657</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113657</pub-id><?supplied-pmid 34217060?><pub-id pub-id-type="pmid">34217060</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-16-01174"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santiva&#x000f1;ez-Veliz</surname><given-names>M.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Moreno-Viguri</surname><given-names>E.</given-names></name>
</person-group><article-title>Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2016</year><volume>26</volume><fpage>2188</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.03.066</pub-id><?supplied-pmid 27025343?><pub-id pub-id-type="pmid">27025343</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-16-01174"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Arbillaga</surname><given-names>L.</given-names></name>
<name><surname>Varela</surname><given-names>J.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Azqueta</surname><given-names>A.</given-names></name>
<name><surname>Moreno-Viguri</surname><given-names>E.</given-names></name>
</person-group><article-title>Synthesis and biological evaluation of quinoxaline di-<italic toggle="yes">N</italic>-oxide derivatives with in vitro trypanocidal activity</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2016</year><volume>26</volume><fpage>903</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.070</pub-id><?supplied-pmid 26750255?><pub-id pub-id-type="pmid">26750255</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-16-01174"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Devarapally</surname><given-names>G.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Moreno-Viguri</surname><given-names>E.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Crawford</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Cyclic voltammetric study of some anti-chagas-active 1,4-dioxidoquinoxalin-2-ylketone derivatives</article-title><source>Helv. Chim. Acta</source><year>2013</year><volume>96</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1002/hlca.201200085</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-16-01174"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stumm</surname><given-names>G.</given-names></name>
<name><surname>Niclas</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>An improved and efficient synthesis of quinoxalinecarboxamide 1,4-dioxides from benzofuroxan and acetoacetamides in the presence of calcium salts</article-title><source>J. Prakt. Chem.</source><year>1989</year><volume>331</volume><fpage>736</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1002/prac.19893310506</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-16-01174"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabri</surname><given-names>S.S.</given-names></name>
<name><surname>El-Abadelah</surname><given-names>M.M.</given-names></name>
<name><surname>Al-Bitar</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Synthesis and spectroscopic studies on some new substituted 2-quinoxalinecarboxamides and their <italic toggle="yes">N</italic>-oxides</article-title><source>Heterocycles</source><year>1987</year><volume>26</volume><fpage>699</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.3987/R-1987-03-0699</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-16-01174"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>M.M.F.</given-names></name>
<name><surname>Amin</surname><given-names>K.M.</given-names></name>
<name><surname>Noaman</surname><given-names>E.</given-names></name>
<name><surname>Soliman</surname><given-names>D.H.</given-names></name>
<name><surname>Ammar</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>New quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides: Anticancer and hypoxia-selective therapeautic agents</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>2733</fpage><lpage>2738</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2010.02.052</pub-id><pub-id pub-id-type="pmid">20236735</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-16-01174"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>Z.Q.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
</person-group><article-title>Monooxygenase LaPhzX is involved in self-resistance mechanisms during the biosynthesis of <italic toggle="yes">N</italic>-oxide phenazine Myxin</article-title><source>J. Agric. Food Chem.</source><year>2021</year><volume>69</volume><fpage>13524</fpage><lpage>13532</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.1c05206</pub-id><pub-id pub-id-type="pmid">34735148</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-16-01174"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dutcher</surname><given-names>J.D.</given-names></name>
<name><surname>Wintersteiner</surname><given-names>O.</given-names></name>
</person-group><article-title>The Structure of aspergillic acid</article-title><source>J. Biol. Chem.</source><year>1944</year><volume>155</volume><fpage>359</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)43207-3</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-16-01174"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>K.</given-names></name>
<name><surname>Hotta</surname><given-names>K.</given-names></name>
<name><surname>Praseuth</surname><given-names>A.</given-names></name>
<name><surname>Koketsu</surname><given-names>K.</given-names></name>
<name><surname>Migita</surname><given-names>A.</given-names></name>
<name><surname>Boddy</surname><given-names>C.N.</given-names></name>
<name><surname>Wang</surname><given-names>C.C.C.</given-names></name>
<name><surname>Oguri</surname><given-names>H.</given-names></name>
<name><surname>Oikawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Total biosynthesis of antitumor nonribosomal peptides in <italic toggle="yes">Escherichia coli</italic></article-title><source>Nat. Chem. Biol.</source><year>2006</year><volume>2</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1038/nchembio803</pub-id><?supplied-pmid 16799553?><pub-id pub-id-type="pmid">16799553</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-16-01174"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clemo</surname><given-names>G.R.</given-names></name>
<name><surname>McIlwain</surname><given-names>H.</given-names></name>
</person-group><article-title>The Phenazine Series. Part VII. The Pigment of <italic toggle="yes">Chromobacterium iodinum</italic>; The phenazine di-<italic toggle="yes">N</italic>-oxides</article-title><source>J. Chem. Soc.</source><year>1938</year><volume>100</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1039/jr9380000479</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-16-01174"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suter</surname><given-names>W.</given-names></name>
<name><surname>Rosselet</surname><given-names>A.</given-names></name>
<name><surname>Knusel</surname><given-names>F.</given-names></name>
</person-group><article-title>Mode of action of quindoxin and substituted quinoxaline-di-<italic toggle="yes">N</italic>-oxides on <italic toggle="yes">Escherichia coli</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1978</year><volume>13</volume><fpage>770</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1128/AAC.13.5.770</pub-id><pub-id pub-id-type="pmid">352264</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-16-01174"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fadeeva</surname><given-names>N.I.</given-names></name>
<name><surname>Pade&#x0012d;skaia</surname><given-names>E.N.</given-names></name>
<name><surname>Degtiareva</surname><given-names>I.N.</given-names></name>
<name><surname>Pershin</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Effect of quinolaline di-<italic toggle="yes">N</italic>-oxide derivatives on the DNAse and plasmocoagulase of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Farmakol. Toksikol.</source><year>1978</year><volume>41</volume><fpage>613</fpage><lpage>617</lpage><?supplied-pmid 700089?><pub-id pub-id-type="pmid">700089</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-16-01174"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>X.-J.</given-names></name>
<name><surname>Zhang</surname><given-names>H.-H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>L.-L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.-Y.</given-names></name>
<name><surname>Yan</surname><given-names>C.-X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.-H.</given-names></name>
</person-group><article-title>ROS mediated cytotoxicity of porcine adrenocortical cells induced by QdNOs derivatives in vitro</article-title><source>Chem. Biol. Interact.</source><year>2010</year><volume>185</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2010.02.030</pub-id><pub-id pub-id-type="pmid">20188712</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-16-01174"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Peng</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Dai</surname><given-names>M.</given-names></name>
</person-group><article-title>Mechanisms of antibacterial action of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides against <italic toggle="yes">Clostridium perfringens</italic> and <italic toggle="yes">Brachyspira hyodysenteriae</italic></article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><fpage>1948</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2016.01948</pub-id><?supplied-pmid 28018297?><pub-id pub-id-type="pmid">28018297</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-16-01174"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azqueta</surname><given-names>A.</given-names></name>
<name><surname>Pachon</surname><given-names>G.</given-names></name>
<name><surname>Cascante</surname><given-names>M.</given-names></name>
<name><surname>Creppy</surname><given-names>E.E.</given-names></name>
<name><surname>de Cerain</surname><given-names>A.L.</given-names></name>
</person-group><article-title>DNA damage induced by a quinoxaline 1, 4-di-<italic toggle="yes">N</italic>-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay</article-title><source>Mutagenesis</source><year>2005</year><volume>20</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1093/mutage/gei023</pub-id><pub-id pub-id-type="pmid">15817574</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-16-01174"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popov</surname><given-names>D.A.</given-names></name>
<name><surname>Anuchina</surname><given-names>N.M.</given-names></name>
<name><surname>Terentyev</surname><given-names>A.A.</given-names></name>
<name><surname>Kostyuk</surname><given-names>G.V.</given-names></name>
<name><surname>Blatun</surname><given-names>L.A.</given-names></name>
<name><surname>Rusanova</surname><given-names>E.V.</given-names></name>
<name><surname>Aleksandrova</surname><given-names>I.A.</given-names></name>
<name><surname>Pkhakadze</surname><given-names>T.Y.</given-names></name>
<name><surname>Bogomolova</surname><given-names>N.S.</given-names></name>
<name><surname>Terekhova</surname><given-names>L.P.</given-names></name>
</person-group><article-title>Dioxidin: Antimicrobial activity and prospects of its clinical use at present</article-title><source>Antibiot. Chemother.</source><year>2013</year><volume>58</volume><fpage>37</fpage><lpage>42</lpage><comment>(In Russian)</comment></element-citation></ref><ref id="B131-pharmaceuticals-16-01174"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shabatina</surname><given-names>T.I.</given-names></name>
<name><surname>Morosov</surname><given-names>Y.N.</given-names></name>
<name><surname>Soloviev</surname><given-names>A.V.</given-names></name>
<name><surname>Shabatin</surname><given-names>A.V.</given-names></name>
<name><surname>Vernaya</surname><given-names>O.I.</given-names></name>
<name><surname>Melnikov</surname><given-names>M.Y.</given-names></name>
</person-group><article-title>Cryochemical production of drug nanoforms: Particle size and crystal phase control of the antibacterial medication 2,3-quinoxalinedimethanol-1,4-dioxide (Dioxidine)</article-title><source>Nanomaterials</source><year>2021</year><volume>11</volume><elocation-id>1588</elocation-id><pub-id pub-id-type="doi">10.3390/nano11061588</pub-id><?supplied-pmid 34204303?><pub-id pub-id-type="pmid">34204303</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-16-01174"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhuravleva</surname><given-names>M.</given-names></name>
<name><surname>Roshchina</surname><given-names>E.</given-names></name>
<name><surname>Loseva</surname><given-names>C.</given-names></name>
<name><surname>Gurov</surname><given-names>A.</given-names></name>
</person-group><article-title>Assessment of the toxicological profile of the new dioxidine dosage form (solution for topical and external use, 0.025%)</article-title><source>Antibiot. Chemother.</source><year>2022</year><volume>67</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.37489/0235-2990-2022-67-7-8-24-32</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-16-01174"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usai</surname><given-names>D.</given-names></name>
<name><surname>Sanna</surname><given-names>P.</given-names></name>
<name><surname>Sechi</surname><given-names>L.A.</given-names></name>
<name><surname>Carta</surname><given-names>A.</given-names></name>
<name><surname>Paglietti</surname><given-names>G.</given-names></name>
<name><surname>Zanettu</surname><given-names>S.</given-names></name>
</person-group><article-title>In vitro activity of quinoxaline 1, 4-dioxides derivatives against enterococci clinical strains</article-title><source>Ig. Mod.</source><year>2004</year><volume>121</volume><fpage>289</fpage><lpage>300</lpage></element-citation></ref><ref id="B134-pharmaceuticals-16-01174"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carta</surname><given-names>A.</given-names></name>
<name><surname>Paglietti</surname><given-names>G.</given-names></name>
<name><surname>Nikookar</surname><given-names>M.E.R.</given-names></name>
<name><surname>Sanna</surname><given-names>P.</given-names></name>
<name><surname>Sechi</surname><given-names>L.</given-names></name>
<name><surname>Zanetti</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity</article-title><source>Eur. J. Med. Chem.</source><year>2002</year><volume>37</volume><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/S0223-5234(02)01346-6</pub-id><pub-id pub-id-type="pmid">12008050</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-16-01174"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iland</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Effect of antibacterial analogues of vitamin K on <italic toggle="yes">M. tuberculosis</italic></article-title><source>Nature</source><year>1948</year><volume>161</volume><fpage>1010</fpage><pub-id pub-id-type="doi">10.1038/1611010a0</pub-id><?supplied-pmid 18865795?><pub-id pub-id-type="pmid">18865795</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-16-01174"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Ancizu</surname><given-names>S.</given-names></name>
<name><surname>P&#x000e9;rez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>4418</fpage><lpage>4426</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2010.06.036</pub-id><pub-id pub-id-type="pmid">20656380</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-16-01174"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Montoya</surname><given-names>M.E.</given-names></name>
<name><surname>Martinez-Crespo</surname><given-names>F.J.</given-names></name>
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Lopez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>New quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides for treatment of tuberculosis</article-title><source>Arzneim. Forsch. Drug Res.</source><year>1999</year><volume>49</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1300359</pub-id><pub-id pub-id-type="pmid">10028381</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-16-01174"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Montoya</surname><given-names>M.E.</given-names></name>
<name><surname>Lopez De Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-<italic toggle="yes">N</italic>-oxides</article-title><source>Pharmazie</source><year>1999</year><volume>54</volume><fpage>24</fpage><lpage>25</lpage><?supplied-pmid 9987794?><pub-id pub-id-type="pmid">9987794</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-16-01174"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montoya</surname><given-names>M.E.</given-names></name>
<name><surname>Sainz</surname><given-names>Y.</given-names></name>
<name><surname>Ortega</surname><given-names>M.A.</given-names></name>
<name><surname>Lopez De Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles</article-title><source>Farmaco</source><year>1998</year><volume>53</volume><fpage>570</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/S0014-827X(98)00067-6</pub-id><pub-id pub-id-type="pmid">10081819</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-16-01174"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-<italic toggle="yes">Mycobacterium tuberculosis</italic> agents</article-title><source>J. Med. Chem.</source><year>2005</year><volume>48</volume><fpage>2019</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.1021/jm049952w</pub-id><pub-id pub-id-type="pmid">15771444</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-16-01174"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as anti-<italic toggle="yes">Mycobacterium tuberculosis</italic> agents</article-title><source>Eur. J. Med. Chem.</source><year>2003</year><volume>38</volume><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/S0223-5234(03)00137-5</pub-id><pub-id pub-id-type="pmid">14561478</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-16-01174"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carta</surname><given-names>A.</given-names></name>
<name><surname>Loriga</surname><given-names>M.</given-names></name>
<name><surname>Paglietti</surname><given-names>G.</given-names></name>
<name><surname>Mattana</surname><given-names>A.</given-names></name>
<name><surname>Fiori</surname><given-names>P.L.</given-names></name>
<name><surname>Mollicotti</surname><given-names>P.</given-names></name>
<name><surname>Sechi</surname><given-names>L.</given-names></name>
<name><surname>Zanettic</surname><given-names>S.</given-names></name>
</person-group><article-title>Synthesis, antimycobacterial, antitrichomonas and anticandida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides</article-title><source>Eur. J. Med. Chem.</source><year>2004</year><volume>39</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2003.11.008</pub-id><pub-id pub-id-type="pmid">14987828</pub-id></element-citation></ref><ref id="B143-pharmaceuticals-16-01174"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zanetti</surname><given-names>S.</given-names></name>
<name><surname>Sechi</surname><given-names>L.A.</given-names></name>
<name><surname>Molicotti</surname><given-names>P.</given-names></name>
<name><surname>Cannas</surname><given-names>S.</given-names></name>
<name><surname>Bua</surname><given-names>A.</given-names></name>
<name><surname>Deriu</surname><given-names>A.</given-names></name>
<name><surname>Carta</surname><given-names>A.</given-names></name>
<name><surname>Paglietti</surname><given-names>G.</given-names></name>
</person-group><article-title><italic toggle="yes">In vitro</italic> activity of new quinoxaline 1,4-dioxide derivatives against strains of <italic toggle="yes">Mycobacterium tuberculosis</italic> and other mycobacteria</article-title><source>Int. J. Antimicrob. Agents</source><year>2005</year><volume>25</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.11.003</pub-id><?supplied-pmid 15664491?><pub-id pub-id-type="pmid">15664491</pub-id></element-citation></ref><ref id="B144-pharmaceuticals-16-01174"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noreen</surname><given-names>N.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Salman</surname><given-names>S.M.</given-names></name>
<name><surname>Mabkhot</surname><given-names>Y.</given-names></name>
<name><surname>Alsayari</surname><given-names>A.</given-names></name>
<name><surname>Badshah</surname><given-names>S.L.</given-names></name>
</person-group><article-title>New insights into the spread of resistance to artemisinin and its analogues</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2021</year><volume>27</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2021.09.001</pub-id><?supplied-pmid 34517141?><pub-id pub-id-type="pmid">34517141</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-16-01174"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Maurel</surname><given-names>S.</given-names></name>
<name><surname>Deharo</surname><given-names>E.</given-names></name>
<name><surname>Jullian</surname><given-names>V.</given-names></name>
<name><surname>Sauvain</surname><given-names>M.</given-names></name>
</person-group><article-title>Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives</article-title><source>Arzneim. Forsch./Drug Res.</source><year>2004</year><volume>55</volume><fpage>754</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1296926</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-16-01174"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarranz</surname><given-names>B.</given-names></name>
<name><surname>Jaso</surname><given-names>A.</given-names></name>
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Maurel</surname><given-names>S.</given-names></name>
<name><surname>Sauvain</surname><given-names>M.</given-names></name>
</person-group><article-title>Antiplasmodial activity of 3-trifluoromethyl-2-carbonylquinoxaline di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>Rev. Bras. Cienc. Farm.</source><year>2006</year><volume>42</volume><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1590/S1516-93322006000300005</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-16-01174"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brizuela</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>H.M.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Burgio</surname><given-names>G.</given-names></name>
<name><surname>Foote</surname><given-names>S.J.</given-names></name>
<name><surname>McMorran</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Treatment of erythrocytes with 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of <italic toggle="yes">Plasmodium falciparum</italic> and enhances parasite sensitivity to chloroquine oxides</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e92411</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092411</pub-id><pub-id pub-id-type="pmid">24699133</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-16-01174"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barea</surname><given-names>C.</given-names></name>
<name><surname>Pabon</surname><given-names>A.</given-names></name>
<name><surname>Galiano</surname><given-names>S.</given-names></name>
<name><surname>Perez-Silanes</surname><given-names>S.</given-names></name>
<name><surname>Gonzalez</surname><given-names>G.</given-names></name>
<name><surname>Deyssard</surname><given-names>C.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Deharo</surname><given-names>E.</given-names></name>
<name><surname>Aldana</surname><given-names>I.</given-names></name>
</person-group><article-title>Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido)quinoxaline 1,4-dioxide derivatives</article-title><source>Molecules</source><year>2012</year><volume>17</volume><fpage>9451</fpage><lpage>9461</lpage><pub-id pub-id-type="doi">10.3390/molecules17089451</pub-id><?supplied-pmid 22871647?><pub-id pub-id-type="pmid">22871647</pub-id></element-citation></ref><ref id="B149-pharmaceuticals-16-01174"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Villalobos-Rocha</surname><given-names>J.C.</given-names></name>
<name><surname>Sanchez-Torres</surname><given-names>L.</given-names></name>
<name><surname>Nogueda-Torres</surname><given-names>B.</given-names></name>
<name><surname>Segura-Cabrera</surname><given-names>A.</given-names></name>
<name><surname>Garcia-Perez</surname><given-names>C.A.</given-names></name>
<name><surname>Bocanegra-Garcia</surname><given-names>V.</given-names></name>
<name><surname>Palos</surname><given-names>I.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Rivera</surname><given-names>G.</given-names></name>
</person-group><article-title>Anti-<italic toggle="yes">Trypanosoma cruzi</italic> and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives</article-title><source>Parasitol. Res.</source><year>2014</year><volume>113</volume><fpage>2027</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1007/s00436-014-3850-8</pub-id><pub-id pub-id-type="pmid">24691716</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-16-01174"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chac&#x000f3;n-Vargas</surname><given-names>K.F.</given-names></name>
<name><surname>Andrade-Ochoa</surname><given-names>S.</given-names></name>
<name><surname>Nogueda-Torres</surname><given-names>B.</given-names></name>
<name><surname>Ju&#x000e1;rez-Ram&#x000ed;rez</surname><given-names>D.C.</given-names></name>
<name><surname>Lara-Ram&#x000ed;rez</surname><given-names>E.E.</given-names></name>
<name><surname>Mondrag&#x000f3;n-Flores</surname><given-names>R.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Rivera</surname><given-names>G.</given-names></name>
<name><surname>S&#x000e1;nchez-Torres</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Isopropyl quinoxaline-7-carboxylate 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives induce regulated necrosis like cell death on <italic toggle="yes">Leishmania</italic> (Leishmania) <italic toggle="yes">mexicana</italic></article-title><source>Parasitol. Res.</source><year>2017</year><volume>117</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s00436-017-5635-3</pub-id><pub-id pub-id-type="pmid">29159705</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-16-01174"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duque-Montano</surname><given-names>B.E.</given-names></name>
<name><surname>Gomez-Caro</surname><given-names>L.C.</given-names></name>
<name><surname>Sanchez-Sanchez</surname><given-names>M.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Hernandez-Baltazar</surname><given-names>E.</given-names></name>
<name><surname>Rivera</surname><given-names>G.</given-names></name>
<name><surname>Torres-Angeles</surname><given-names>O.</given-names></name>
</person-group><article-title>Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-<italic toggle="yes">N</italic>-oxide against <italic toggle="yes">Entamoeba histolytica</italic></article-title><source>Bioorg. Med. Chem.</source><year>2013</year><volume>21</volume><fpage>4550</fpage><lpage>4558</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.05.036</pub-id><pub-id pub-id-type="pmid">23787289</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-16-01174"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>W.R.</given-names></name>
<name><surname>Landquist</surname><given-names>J.K.</given-names></name>
<name><surname>Stewart</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Synthetic amoebicides. II. The anti-amoebic action of quinoxaline-1,4-dioxide and some derivatives</article-title><source>Br. J. Pharmacol. Chemother.</source><year>1953</year><volume>8</volume><fpage>286</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1953.tb00796.x</pub-id><pub-id pub-id-type="pmid">13093948</pub-id></element-citation></ref><ref id="B153-pharmaceuticals-16-01174"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glazer</surname><given-names>E.A.</given-names></name>
<name><surname>Chappel</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Pyridoquinoxaline <italic toggle="yes">N</italic>-oxides. A new class of antitrichomonal agents</article-title><source>J. Med. Chem.</source><year>1982</year><volume>25</volume><fpage>868</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1021/jm00349a021</pub-id><?supplied-pmid 7108904?><pub-id pub-id-type="pmid">7108904</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-16-01174"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torres</surname><given-names>E.</given-names></name>
<name><surname>Moreno-Viguri</surname><given-names>E.</given-names></name>
<name><surname>Galiano</surname><given-names>S.</given-names></name>
<name><surname>Devarapally</surname><given-names>G.</given-names></name>
<name><surname>Crawford</surname><given-names>P.W.</given-names></name>
<name><surname>Azqueta</surname><given-names>A.</given-names></name>
<name><surname>Arbillaga</surname><given-names>L.</given-names></name>
<name><surname>Varela</surname><given-names>J.</given-names></name>
<name><surname>Birriel</surname><given-names>E.</given-names></name>
<name><surname>Di Maio</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Novel quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as new potential antichagasic agents</article-title><source>Eur. J. Med. Chem.</source><year>2013</year><volume>66</volume><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.04.065</pub-id><pub-id pub-id-type="pmid">23811257</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-16-01174"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerpe</surname><given-names>A.</given-names></name>
<name><surname>Boiani</surname><given-names>L.</given-names></name>
<name><surname>Hernandez</surname><given-names>P.</given-names></name>
<name><surname>Sortino</surname><given-names>M.</given-names></name>
<name><surname>Zacchino</surname><given-names>S.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
</person-group><article-title>Naftifine-analogues as anti-<italic toggle="yes">Trypanosoma cruzi</italic> agents</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>2154</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2010.01.052</pub-id><?supplied-pmid 20163894?><pub-id pub-id-type="pmid">20163894</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-16-01174"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>E.</given-names></name>
<name><surname>Xia</surname><given-names>Q.</given-names></name>
<name><surname>Cella</surname><given-names>M.</given-names></name>
<name><surname>Nenninger</surname><given-names>A.</given-names></name>
<name><surname>Mruzik</surname><given-names>M.</given-names></name>
<name><surname>Brillos-Monia</surname><given-names>K.</given-names></name>
<name><surname>Hu</surname><given-names>Y.Z.</given-names></name>
<name><surname>Sheng</surname><given-names>R.</given-names></name>
<name><surname>Ragain</surname><given-names>C.M.</given-names></name>
<name><surname>Crawford</surname><given-names>P.</given-names></name>
</person-group><article-title>Voltammetric study of some 3-aryl-quinoxaline-2-carbonitrile 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives with anti-tumor activities</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1442</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22091442</pub-id><?supplied-pmid 28858261?><pub-id pub-id-type="pmid">28858261</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-16-01174"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>U.</given-names></name>
<name><surname>Pati</surname><given-names>H.N.</given-names></name>
<name><surname>Panda</surname><given-names>A.K.</given-names></name>
<name><surname>De Clercq</surname><given-names>E.</given-names></name>
<name><surname>Balzarini</surname><given-names>J.</given-names></name>
<name><surname>Molnar</surname><given-names>J.</given-names></name>
<name><surname>Barath</surname><given-names>Z.</given-names></name>
<name><surname>Ocsovszki</surname><given-names>I.</given-names></name>
<name><surname>Kawase</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: A novel cluster of tumor-specific cytotoxins which reverse multidrug resistance</article-title><source>Bioorg. Med. Chem.</source><year>2009</year><volume>17</volume><fpage>3909</fpage><lpage>3915</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2009.04.021</pub-id><pub-id pub-id-type="pmid">19427790</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-16-01174"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganley</surname><given-names>B.</given-names></name>
<name><surname>Chowdhury</surname><given-names>G.</given-names></name>
<name><surname>Bhansali</surname><given-names>J.</given-names></name>
<name><surname>Daniels</surname><given-names>J.S.</given-names></name>
<name><surname>Gates</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide</article-title><source>Bioorg. Med. Chem.</source><year>2001</year><volume>9</volume><fpage>2395</fpage><lpage>2401</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(01)00163-8</pub-id><pub-id pub-id-type="pmid">11553481</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-16-01174"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urquiola</surname><given-names>C.</given-names></name>
<name><surname>Vieites</surname><given-names>M.</given-names></name>
<name><surname>Torre</surname><given-names>M.H.</given-names></name>
<name><surname>Cabrera</surname><given-names>M.</given-names></name>
<name><surname>Lavaggi</surname><given-names>M.L.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>L&#x000f3;pez de Cerain</surname><given-names>A.</given-names></name>
<name><surname>Monge</surname><given-names>A.</given-names></name>
<name><surname>Smircich</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Cytotoxic palladium complexes of bioreductive quinoxaline <italic toggle="yes">N<sup>1</sup></italic>,<italic toggle="yes">N<sup>4</sup></italic>-dioxide prodrugs</article-title><source>Bioorg. Med. Chem.</source><year>2009</year><volume>17</volume><fpage>1623</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.12.064</pub-id><pub-id pub-id-type="pmid">19162490</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-16-01174"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gali-Muhtasib</surname><given-names>H.U.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Rahhal</surname><given-names>D.N.</given-names></name>
<name><surname>Younes</surname><given-names>I.H.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs</article-title><source>Oncol. Rep.</source><year>2001</year><volume>8</volume><fpage>679</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.3892/or.8.3.679</pub-id><pub-id pub-id-type="pmid">11295102</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-16-01174"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diab-Assef</surname><given-names>M.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Yared</surname><given-names>P.</given-names></name>
<name><surname>Assaad</surname><given-names>C.</given-names></name>
<name><surname>Gali-Muhtasib</surname><given-names>H.U.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxides: Hypoxia-selective therapeutic agents</article-title><source>Mol. Carcinog.</source><year>2002</year><volume>33</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1002/mc.10036</pub-id><pub-id pub-id-type="pmid">11933073</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-16-01174"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name>
<name><surname>Sidani</surname><given-names>M.</given-names></name>
<name><surname>Geara</surname><given-names>F.</given-names></name>
<name><surname>Mona</surname><given-names>A.-D.</given-names></name>
<name><surname>Al-Hmaira</surname><given-names>J.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Zaatari</surname><given-names>G.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation</article-title><source>Int. J. Oncol.</source><year>2004</year><volume>2</volume><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.3892/ijo.24.5.1121</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-16-01174"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gali-Muhtasib</surname><given-names>H.U.</given-names></name>
<name><surname>Diab-Assaf</surname><given-names>M.K.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells</article-title><source>Cancer Chemother. Pharmacol.</source><year>2005</year><volume>55</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s00280-004-0907-x</pub-id><pub-id pub-id-type="pmid">15538569</pub-id></element-citation></ref><ref id="B164-pharmaceuticals-16-01174"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weng</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Guo</surname><given-names>P.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
</person-group><article-title>Q39, a novel synthetic quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide compound with anti-cancer activity in hypoxia</article-title><source>Eur. J. Pharmacol.</source><year>2008</year><volume>581</volume><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.12.006</pub-id><?supplied-pmid 18215659?><pub-id pub-id-type="pmid">18215659</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-16-01174"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherbakov</surname><given-names>A.M.</given-names></name>
<name><surname>Borunov</surname><given-names>A.M.</given-names></name>
<name><surname>Buravchenko</surname><given-names>G.I.</given-names></name>
<name><surname>Andreeva</surname><given-names>O.E.</given-names></name>
<name><surname>Kudryavtsev</surname><given-names>I.A.</given-names></name>
<name><surname>Dezhenkova</surname><given-names>L.G.</given-names></name>
<name><surname>Shchekotikhin</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Novel quinoxaline-2-carbonitrile-1,4-dioxide derivatives suppress HIF1&#x003b1; activity and circumvent MDR in cancer cells</article-title><source>Cancer Investig.</source><year>2018</year><volume>36</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1080/07357907.2018.1453072</pub-id><?supplied-pmid 29624460?><pub-id pub-id-type="pmid">29624460</pub-id></element-citation></ref><ref id="B166-pharmaceuticals-16-01174"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Glaser</surname><given-names>R.</given-names></name>
<name><surname>Gates</surname><given-names>K.S.</given-names></name>
</person-group><article-title>On the reaction mechanism of tirapazamine reduction chemitry: Unimolecular N-OH homolysis, stepwise dehydration, or triazenering-opening</article-title><source>Chem. Res. Toxicol.</source><year>2012</year><volume>25</volume><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1021/tx200546u</pub-id><?supplied-pmid 22390168?><pub-id pub-id-type="pmid">22390168</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-16-01174"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Deoxidation rates play a critical role in DNA damage mediated by important synthetic drugs, quinoxaline 1,4-dioxides</article-title><source>Chem. Res. Toxicol.</source><year>2015</year><volume>28</volume><fpage>470</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1021/tx5004326</pub-id><pub-id pub-id-type="pmid">25626015</pub-id></element-citation></ref><ref id="B168-pharmaceuticals-16-01174"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Zhan</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zeng</surname><given-names>Q.</given-names></name>
<name><surname>Liang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Hypoxia-activated prodrugs and redox-responsive nanocarriers</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>6551</fpage><lpage>6574</lpage><pub-id pub-id-type="doi">10.2147/IJN.S173431</pub-id></element-citation></ref><ref id="B169-pharmaceuticals-16-01174"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sibiya</surname><given-names>M.A.</given-names></name>
<name><surname>Raphoko</surname><given-names>L.</given-names></name>
<name><surname>Mangokoana</surname><given-names>D.</given-names></name>
<name><surname>Makola</surname><given-names>R.</given-names></name>
<name><surname>Nxumalo</surname><given-names>W.</given-names></name>
<name><surname>Matsebatlela</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Induction of cell death in human A549 cells using 3-(quinoxaline-3-yl)prop-2-ynyl methanosulphonate and 3-(quinoxaline-3-yl)prop-2-yn-1-ol</article-title><source>Molecules</source><year>2019</year><volume>24</volume><fpage>407</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.3390/molecules24030407</pub-id><pub-id pub-id-type="pmid">30678061</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-16-01174"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamudio-Vazquez</surname><given-names>R.</given-names></name>
<name><surname>Ivanova</surname><given-names>S.</given-names></name>
<name><surname>Moreno</surname><given-names>M.</given-names></name>
<name><surname>Hernandez-Alvarez</surname><given-names>M.I.</given-names></name>
<name><surname>Giralt</surname><given-names>E.</given-names></name>
<name><surname>Bidon-Chanal</surname><given-names>A.</given-names></name>
<name><surname>Zorzano</surname><given-names>A.</given-names></name>
<name><surname>Albericio</surname><given-names>F.</given-names></name>
<name><surname>Tulla-Puche</surname><given-names>J.</given-names></name>
</person-group><article-title>A new quinoxaline-containing peptide induces apoptosis in cancer cells by autophagy modulation</article-title><source>Chem. Sci.</source><year>2015</year><volume>6</volume><fpage>4537</fpage><lpage>4549</lpage><pub-id pub-id-type="doi">10.1039/C5SC00125K</pub-id><pub-id pub-id-type="pmid">29142702</pub-id></element-citation></ref><ref id="B171-pharmaceuticals-16-01174"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Khatib</surname><given-names>M.</given-names></name>
<name><surname>Geara</surname><given-names>F.</given-names></name>
<name><surname>Haddadin</surname><given-names>M.J.</given-names></name>
<name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name>
</person-group><article-title>Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21</article-title><source>Radiat. Oncol.</source><year>2010</year><volume>5</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/1748-717X-5-107</pub-id><pub-id pub-id-type="pmid">21078189</pub-id></element-citation></ref><ref id="B172-pharmaceuticals-16-01174"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Dai</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Xiao</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>S.</given-names></name>
</person-group><article-title>GADD45a regulates olaquindox-induced DNA damage and S-phase arrest in human hepatoma G2 cells via JNK/p38 pathways</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>124</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22010124</pub-id><pub-id pub-id-type="pmid">28098804</pub-id></element-citation></ref><ref id="B173-pharmaceuticals-16-01174"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chac&#x000f3;n-Vargas</surname><given-names>K.</given-names></name>
<name><surname>Nogueda-Torres</surname><given-names>B.</given-names></name>
<name><surname>S&#x000e1;nchez-Torres</surname><given-names>L.</given-names></name>
<name><surname>Suarez-Contreras</surname><given-names>E.</given-names></name>
<name><surname>Villalobos-Rocha</surname><given-names>J.</given-names></name>
<name><surname>Torres-Martinez</surname><given-names>Y.</given-names></name>
<name><surname>Lara-Ramirez</surname><given-names>E.E.</given-names></name>
<name><surname>Fiorani</surname><given-names>G.</given-names></name>
<name><surname>Krauth-Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Bolognesi</surname><given-names>M.L.</given-names></name>
<etal/>
</person-group><article-title>Trypanocidal activity of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide derivatives as Trypanothione reductase inhibitors</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22020220</pub-id><?supplied-pmid 28157150?><pub-id pub-id-type="pmid">28157150</pub-id></element-citation></ref><ref id="B174-pharmaceuticals-16-01174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soto-S&#x000e1;nchez</surname><given-names>J.</given-names></name>
<name><surname>Caro-G&#x000f3;mez</surname><given-names>L.A.</given-names></name>
<name><surname>Paz-Gonz&#x000e1;lez</surname><given-names>A.D.</given-names></name>
<name><surname>Marchat</surname><given-names>L.A.</given-names></name>
<name><surname>Rivera</surname><given-names>G.</given-names></name>
<name><surname>Moo-Puc</surname><given-names>R.</given-names></name>
<name><surname>Arias</surname><given-names>D.G.</given-names></name>
<name><surname>Ram&#x000ed;rez-Moreno</surname><given-names>E.</given-names></name>
</person-group><article-title>Biological activity of esters of quinoxaline-7-carboxylate 1,4-di-<italic toggle="yes">N</italic>-oxide against <italic toggle="yes">E. histolytica</italic> and their analysis as potential thioredoxin reductase inhibitors</article-title><source>Parasitol. Res.</source><year>2020</year><volume>119</volume><fpage>695</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1007/s00436-019-06580-8</pub-id><?supplied-pmid 31907668?><pub-id pub-id-type="pmid">31907668</pub-id></element-citation></ref><ref id="B175-pharmaceuticals-16-01174"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Norris</surname><given-names>L.C.</given-names></name>
</person-group><article-title>The significant advances of the past fifty years in poultry nutrition</article-title><source>Poult. Sci.</source><year>1958</year><volume>37</volume><fpage>256</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.3382/ps.0370256</pub-id></element-citation></ref><ref id="B176-pharmaceuticals-16-01174"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Weng</surname><given-names>Z.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Dai</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Systematic and molecular basis of the antibacterial action of quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxides against <italic toggle="yes">Escherichia coli</italic></article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0136450</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0136450</pub-id><?supplied-pmid 26296207?><pub-id pub-id-type="pmid">26296207</pub-id></element-citation></ref><ref id="B177-pharmaceuticals-16-01174"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>D.-J.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.-F.</given-names></name>
<name><surname>Huang</surname><given-names>X.-J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Ihsan</surname><given-names>A.</given-names></name>
</person-group><article-title>Potential benefits of quinoxaline 1,4-dioxides in aldosterone dysmetabolism disease&#x02014;A medical hypothesis</article-title><source>J. Anim. Sci.</source><year>2011</year><volume>1</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.4236/ojas.2011.13016</pub-id></element-citation></ref><ref id="B178-pharmaceuticals-16-01174"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butaye</surname><given-names>P.</given-names></name>
<name><surname>Devriese</surname><given-names>L.A.</given-names></name>
<name><surname>Haesebrouck</surname><given-names>F.</given-names></name>
</person-group><article-title>Antimicrobial growth promoters used in animal feed: Effects of less well known antibiotics on Gram-positive bacteria</article-title><source>Clin. Microbiol. Rev.</source><year>2003</year><volume>16</volume><fpage>175</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.2.175-188.2003</pub-id><pub-id pub-id-type="pmid">12692092</pub-id></element-citation></ref><ref id="B179-pharmaceuticals-16-01174"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>J.T.</given-names></name>
<name><surname>Nienaber</surname><given-names>J.A.</given-names></name>
<name><surname>Pond</surname><given-names>W.G.</given-names></name>
<name><surname>Varel</surname><given-names>V.H.</given-names></name>
</person-group><article-title>Effect of carbadox on growth, fasting metabolism, thyroid function and gastrointestinal tract in young pigs</article-title><source>J. Nutr.</source><year>1985</year><volume>115</volume><fpage>970</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1093/jn/115.8.970</pub-id><pub-id pub-id-type="pmid">3926967</pub-id></element-citation></ref><ref id="B180-pharmaceuticals-16-01174"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>J.T.</given-names></name>
<name><surname>Pond</surname><given-names>W.G.</given-names></name>
</person-group><article-title>Effects of carbadox, copper, or <italic toggle="yes">Yucca shidigera</italic> extract on growth performance and visceral weight of young pigs</article-title><source>J. Anim. Sci.</source><year>1993</year><volume>71</volume><fpage>2140</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.2527/1993.7182140x</pub-id><pub-id pub-id-type="pmid">8376238</pub-id></element-citation></ref><ref id="B181-pharmaceuticals-16-01174"><label>181.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Constable</surname><given-names>P.</given-names></name>
<name><surname>Hinchcliff</surname><given-names>K.W.</given-names></name>
<name><surname>Done</surname><given-names>S.</given-names></name>
<name><surname>Gruenberg</surname><given-names>W.</given-names></name>
</person-group><source>Practical Antimicrobial Therapeutics</source><edition>11th ed.</edition><publisher-name>Saunders Ltd.</publisher-name><publisher-loc>Nottingham, UK</publisher-loc><year>2017</year><fpage>153</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/b978-0-7020-5246-0.00006-1</pub-id></element-citation></ref><ref id="B182-pharmaceuticals-16-01174"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Fang</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Residue depletion and tissue-plasma correlation of methyl-3-quinoxaline-2-carboxylic acid after dietary administration of Olaquindox in pigs</article-title><source>J. Agric. Food Chem.</source><year>2010</year><volume>58</volume><fpage>937</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1021/jf902418k</pub-id><pub-id pub-id-type="pmid">20039635</pub-id></element-citation></ref><ref id="B183-pharmaceuticals-16-01174"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x0010c;ih&#x000e1;k</surname><given-names>R.</given-names></name>
<name><surname>Vontorkov&#x000e1;</surname><given-names>M.</given-names></name>
</person-group><article-title>Cytogenetic effects of quinoxaline-1,4-dioxide-type growth-promoting agents</article-title><source>Mutat. Res. Genet. Toxicol. Environ. Mutagen.</source><year>1983</year><volume>117</volume><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/0165-1218(83)90130-1</pub-id></element-citation></ref><ref id="B184-pharmaceuticals-16-01174"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>F.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wan</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Metabolism, distribution, and elimination of mequindox in pigs, chickens, and rats</article-title><source>J. Agric. Food Chem.</source><year>2015</year><volume>63</volume><fpage>9839</fpage><lpage>9849</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.5b02780</pub-id><pub-id pub-id-type="pmid">26376954</pub-id></element-citation></ref><ref id="B185-pharmaceuticals-16-01174"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.S.</given-names></name>
<name><surname>Zhao</surname><given-names>R.C.</given-names></name>
<name><surname>Lu</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Quincetone growth promoter in fat chicklings</article-title><source>Ind. Vet. J.</source><year>2005</year><volume>82</volume><fpage>1149</fpage><lpage>1151</lpage></element-citation></ref><ref id="B186-pharmaceuticals-16-01174"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Iqbal</surname><given-names>Z.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Peng</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Impact of cyadox on human colonic microflora in chemostat models</article-title><source>Regul. Toxicol. Pharmacol.</source><year>2013</year><volume>67</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2013.08.011</pub-id><?supplied-pmid 23973379?><pub-id pub-id-type="pmid">23973379</pub-id></element-citation></ref><ref id="B187-pharmaceuticals-16-01174"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Dias</surname><given-names>E.</given-names></name>
<name><surname>Di Maio</surname><given-names>R.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.</given-names></name>
<name><surname>Pacce</surname><given-names>S.</given-names></name>
<name><surname>Saenz</surname><given-names>P.</given-names></name>
<name><surname>Seoane</surname><given-names>G.</given-names></name>
<name><surname>Suescun</surname><given-names>L.</given-names></name>
<name><surname>Mombru</surname><given-names>A.</given-names></name>
<name><surname>Fernandez</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and herbicidal activity of <italic toggle="yes">N</italic>-oxide derivatives</article-title><source>J. Agric. Food Chem.</source><year>2000</year><volume>48</volume><fpage>2995</fpage><lpage>3002</lpage><pub-id pub-id-type="doi">10.1021/jf9904766</pub-id><?supplied-pmid 10898655?><pub-id pub-id-type="pmid">10898655</pub-id></element-citation></ref><ref id="B188-pharmaceuticals-16-01174"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Negishi</surname><given-names>T.</given-names></name>
<name><surname>Tanaka</surname><given-names>K.</given-names></name>
<name><surname>Hayatsu</surname><given-names>H.</given-names></name>
</person-group><article-title>Mutagenicity of carbadox and several quinoxaline 1,4-dioxide derivatives</article-title><source>Chem. Pharm. Bull.</source><year>1980</year><volume>28</volume><fpage>1347</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1248/cpb.28.1347</pub-id><?supplied-pmid 6998586?><pub-id pub-id-type="pmid">6998586</pub-id></element-citation></ref><ref id="B189-pharmaceuticals-16-01174"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cihak</surname><given-names>R.</given-names></name>
<name><surname>Srb</surname><given-names>V.</given-names></name>
</person-group><article-title>Cytogenetic effects of quinoxaline-1,4-dioxide-type growth-promoting agents: I. Micronucleus test in rats</article-title><source>Mutat. Res. Genet. Toxicol.</source><year>1983</year><volume>116</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/0165-1218(83)90103-9</pub-id></element-citation></ref><ref id="B190-pharmaceuticals-16-01174"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshimura</surname><given-names>H.</given-names></name>
</person-group><article-title>Teratogenic assessment of carbadox in rats</article-title><source>Toxicol. Lett.</source><year>2002</year><volume>129</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0378-4274(01)00522-7</pub-id><?supplied-pmid 11879981?><pub-id pub-id-type="pmid">11879981</pub-id></element-citation></ref><ref id="B191-pharmaceuticals-16-01174"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fonshte&#x0012d;n</surname><given-names>L.M.</given-names></name>
<name><surname>Revazova</surname><given-names>I.A.</given-names></name>
<name><surname>Zolotareva</surname><given-names>G.N.</given-names></name>
<name><surname>Abilev</surname><given-names>S.K.</given-names></name>
<name><surname>Akin&#x02019;shina</surname><given-names>L.N.</given-names></name>
</person-group><article-title>Mutagenic activity of dioxydine</article-title><source>Genetika</source><year>1978</year><volume>14</volume><fpage>900</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">352806</pub-id></element-citation></ref><ref id="B192-pharmaceuticals-16-01174"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elina</surname><given-names>A.S.</given-names></name>
<name><surname>Musatova</surname><given-names>I.S.</given-names></name>
<name><surname>Padeiskaya</surname><given-names>E.N.</given-names></name>
<name><surname>Shvarts</surname><given-names>Y.G.</given-names></name>
</person-group><article-title>Esters of 2,3-bis(hydroxymethyl)quinoxaline 1,4-di-<italic toggle="yes">N</italic>-oxide and their biological action</article-title><source>Pharm. Chem. J.</source><year>1977</year><volume>11</volume><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1007/BF00779294</pub-id></element-citation></ref><ref id="B193-pharmaceuticals-16-01174"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>T.</given-names></name>
<name><surname>Gates</surname><given-names>K.S.</given-names></name>
<name><surname>Hwang</surname><given-names>J.T.</given-names></name>
<name><surname>Greenberg</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Photosensitization of guanine-specific DNA damage by a cyano-substituted quinoxaline di-<italic toggle="yes">N</italic>-oxide</article-title><source>Chem. Res. Toxicol.</source><year>1999</year><volume>12</volume><fpage>1190</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1021/tx990149s</pub-id><pub-id pub-id-type="pmid">10604868</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Schemes</title><fig position="float" id="pharmaceuticals-16-01174-f001"><label>Figure 1</label><caption><p>Examples of heterocyclic <italic toggle="yes">N</italic>-oxides of natural origin.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f002"><label>Figure 2</label><caption><p>Antibacterial drugs based on quinoxaline 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f003"><label>Figure 3</label><caption><p>Derivatives of quinoxaline 1,4-dioxide with miscellaneous biological activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f004"><label>Figure 4</label><caption><p>The main approaches for the synthesis of quinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch001"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of quinoxaline 1,4-dioxides via oxidation reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch002"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Synthesis of 2,3-substituted quinoxaline 1,4-dioxides from <italic toggle="yes">o</italic>-benzoquinone.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch002" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch003"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>Examples of quinoxaline 1,4-dioxides obtained from benzofuroxan by the Beirut reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch003" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f005"><label>Figure 5</label><caption><p>Proposed mechanism of the Beirut reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch004"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch004_Scheme 4</object-id><label>Scheme 4</label><caption><p>Synthesis of 3-amino- and 3-hydroxyquinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch004" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch005"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch005_Scheme 5</object-id><label>Scheme 5</label><caption><p>Method of preparation of 2-acylquinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch005" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch006"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch006_Scheme 6</object-id><label>Scheme 6</label><caption><p>Example of the synthesis of 6- and 7-regioisomeric quinoxaline 1,4-dioxides from monosubstituted benzofuroxans.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch006" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch007"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch007_Scheme 7</object-id><label>Scheme 7</label><caption><p>Synthesis of derivatives of 7-aminoquinoxaline 1,4-dioxides by the Beirut reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch007" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch008"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch008_Scheme 8</object-id><label>Scheme 8</label><caption><p>Photoinduced rearrangement of 2-substituted quinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch008" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch009"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch009_Scheme 9</object-id><label>Scheme 9</label><caption><p>Synthetic route for the preparation of quinoxidine (<bold>3</bold>) and dioxidine (<bold>4</bold>).</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch009" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch010"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch010_Scheme 10</object-id><label>Scheme 10</label><caption><p>Transformation of the 2-methyl group of quinoxaline 1,4-dioxides <bold>32a</bold>,<bold>b</bold> into enamines.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch010" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch011"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch011_Scheme 11</object-id><label>Scheme 11</label><caption><p>Transamination reactions of the enamine-derived quinoxaline 1,4-dioxide <bold>34</bold>.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch011" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch012"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch012_Scheme 12</object-id><label>Scheme 12</label><caption><p>Synthesis of antimycobacterial derivatives based on molecular hybridization of arylhydrazides with a quinoxaline scaffold.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch012" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch013"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch013_Scheme 13</object-id><label>Scheme 13</label><caption><p>Synthesis of antimycobacterial derivatives based on conjugates of quinoxaline and thiazolidinone.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch013" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch014"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch014_Scheme 14</object-id><label>Scheme 14</label><caption><p>Synthesis of nitrones by the condensation of 2-formylquinoxaline 1,4-dioxide <bold>37a</bold> with hydroxylamines.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch014" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch015"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch015_Scheme 15</object-id><label>Scheme 15</label><caption><p>Example of the synthesis of nitrone from 2-methylquinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch015" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch016"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch016_Scheme 16</object-id><label>Scheme 16</label><caption><p>Synthesis of quinoxaline-2-carbonitrile 1,4-dioxide by transformation of an aldehyde group.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch016" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch017"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch017_Scheme 17</object-id><label>Scheme 17</label><caption><p>Synthesis of some quinoxaline 1,4-dioxides by transformation of acetyl group.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch017" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch018"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch018_Scheme 18</object-id><label>Scheme 18</label><caption><p>Modification of quinoxaline-derived chalcones into thiopyrimidino- and pyrazoloquinoxaline heterocyclic hybrids.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch018" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch019"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch019_Scheme 19</object-id><label>Scheme 19</label><caption><p>Synthesis of quinoxaline-derived chalcones by the Wittig reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch019" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch020"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch020_Scheme 20</object-id><label>Scheme 20</label><caption><p>Cyclopropanation of chalcone based on quinoxaline 1,4-dioxide by the Corey-Tchaikovsky reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch020" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch021"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch021_Scheme 21</object-id><label>Scheme 21</label><caption><p>Acylation reactions of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch021" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch022"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch022_Scheme 22</object-id><label>Scheme 22</label><caption><p>Transformation of 3-amino group of quinoxaline-2-caronitrile 1,4-dioxides into alkylcarbamates.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch022" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch023"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch023_Scheme 23</object-id><label>Scheme 23</label><caption><p>Modification of 3-aminoquinoxaline-2-carboxamide (2-carbonirile) 1,4-dioxides using P<sub>2</sub>S<sub>5</sub>.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch023" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch024"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch024_Scheme 24</object-id><label>Scheme 24</label><caption><p>Preparation of metal complexes of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch024" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch025"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch025_Scheme 25</object-id><label>Scheme 25</label><caption><p>Synthetic route for the synthesis of 3-aminoquinoxaline 1,4-dioxides via 2-chloro derivatives.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch025" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch026"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch026_Scheme 26</object-id><label>Scheme 26</label><caption><p>Synthesis of 6(7)-aminoquinoxaline-2-carbonitrile 1,4-dioxides by nucleophilic substitution of halogens.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch026" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch027"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch027_Scheme 27</object-id><label>Scheme 27</label><caption><p>Synthesis of 3-acyl-6-aminoquinoxaline 1,4-dioxides.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch027" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch028"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch028_Scheme 28</object-id><label>Scheme 28</label><caption><p>Variations of the synthesis of 7-amino-3-trifluoromethylquinoxaline 1,4-dioxides via substitution reaction.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch028" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch029"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch029_Scheme 29</object-id><label>Scheme 29</label><caption><p>Decarboxylation of quinoxaline-2-carboxylic acid 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch029" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch030"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch030_Scheme 30</object-id><label>Scheme 30</label><caption><p>CaCl<sub>2</sub>-Catalyzed hydrolysis of 2-ethoxycarbonyl derivative of quinoxaline 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch030" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch031"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch031_Scheme 31</object-id><label>Scheme 31</label><caption><p>Example of alkaline hydrolysis of 2-ethoxycarbonyl derivative of quinoxaline 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch031" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch032"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch032_Scheme 32</object-id><label>Scheme 32</label><caption><p>Transformation of quinoxaline-2-carboxilic acid 1,4-dioxide into amides using DPPA.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch032" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch033"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch033_Scheme 33</object-id><label>Scheme 33</label><caption><p>Synthesis of substituted ureas on quinoxaline scaffold via Curtius rearrangement.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch033" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch034"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch034_Scheme 34</object-id><label>Scheme 34</label><caption><p>Example of transformations of hydrazide of quinoxaline-2-carboxilic acid 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch034" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-sch035"><object-id pub-id-type="pii">pharmaceuticals-16-01174-sch035_Scheme 35</object-id><label>Scheme 35</label><caption><p>One-electron intracellular reduction of quinoxaline 1,4-dioxide by reductases.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-sch035" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f006"><label>Figure 6</label><caption><p>Examples of the structures of quinoxaline 1,4-dioxides with antibacterial and antifungal activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f007"><label>Figure 7</label><caption><p>Derivatives of quinoxaline-2-carbonitrile 1,4-dioxide with antimycobacterial activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f008"><label>Figure 8</label><caption><p>Examples of derivatives with antimycobacterial activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g008" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f009"><label>Figure 9</label><caption><p>Examples of quinoxaline 1,4-dioxides active against <italic toggle="yes">P. falciparum</italic>.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g009" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f010"><label>Figure 10</label><caption><p>Quinoxaline 1,4-dioxides inhibit the growth of <italic toggle="yes">Leishmania</italic> spp.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g010" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f011"><label>Figure 11</label><caption><p>Derivatives of quinoxaline 1,4-dioxide with promising activity against <italic toggle="yes">E. histolytica</italic>.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g011" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f012"><label>Figure 12</label><caption><p>Quinoxaline 1,4-dioxides inhibit the growth of <italic toggle="yes">T. vaginalis</italic>.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g012" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f013"><label>Figure 13</label><caption><p>Quinoxaline 1,4-dioxides with antitrypanosomal activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g013" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f014"><label>Figure 14</label><caption><p>Hypoxia-selective anticancer cytotoxins based on quinoxaline 1,4-dioxide scaffold.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g014" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f015"><label>Figure 15</label><caption><p>Quinoxaline 1,4-dioxide derivatives with promising antiproliferative activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g015" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f016"><label>Figure 16</label><caption><p>Cytotoxic derivatives of quinoxaline 1,4-dioxide.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g016" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f017"><label>Figure 17</label><caption><p>Animal growth promoters based on the quinoxaline 1,4-dioxide scaffold: carbadox (<bold>101</bold>), olaquindox (<bold>102</bold>), mequindox (<bold>21b</bold>), quincetone (<bold>103</bold>), and cyadox (<bold>104</bold>).</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g017" position="float"/></fig><fig position="float" id="pharmaceuticals-16-01174-f018"><label>Figure 18</label><caption><p>Quinoxaline 1,4-dioxides with herbicidal activity.</p></caption><graphic xlink:href="pharmaceuticals-16-01174-g018" position="float"/></fig></sec></back></article>